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ABSTRACT 
Molecular and Cellular Mechanisms of Peroxisomal Fusion and Aging in Yeast 
Tatiana Boukh-Viner, Ph.D. 
Concordia University, 2009 
Peroxisomes are organelles best known for their essential roles in lipid metabolism 
and hydrogen peroxide detoxification. Peroxisomal biogenesis in the yeast Yarrowia 
lipolytica is a multi-step process of temporally ordered sequential conversion of five 
distinct peroxisomal subforms, termed PI to P5, into a mature peroxisomal sub form P6 
carrying the complete set of matrix and membrane proteins. 
In the first part of my thesis, I investigate the effect of lateral heterogeneity of the 
peroxisomal membrane bilayer on the efficiency of the fusion between P1 and P2 in the 
yeast Y. lipolytica. My findings provide a unique view of the multistep remodeling of the 
protein repertoire of ergosterol- and ceramide-rich (ECR) domains found in the 
peroxisomal membrane during fusion of PI and P2, and define the hierarchy of individual 
steps during the spatial and temporal reorganization of the peroxisome fusion machinery 
that only transiently associates with ECR domains. 
In the second part of my thesis, I described the use of mass spectrometry-based 
proteomics for examining the contribution of peroxisomal proteins to longevity 
regulation in the yeast Saccharomyces cerevisiae grown under calorie restriction (CR) 
conditions. My proteomic analysis and experimental results from Dr. Titorenko's 
laboratory show that CR yeast are able to meet their metabolic requirements by 
remodeling their carbohydrate and lipid metabolism, which relies on functional lipid 
iii 
metabolic pathways in the peroxisome. These findings suggest that peroxisomal P-
oxidation of fatty acids significantly affects the rate of chronological aging in CR yeast 
by defining the rate of ATP production in their mitochondria but not by making ROS. 
I also present my research findings on longevity regulation in S. cerevisiae by a novel 
anti-aging molecule "LA" identified recently in Dr. Titorenko's laboratory. 
Comprehensive analysis of the proteome remodeling in yeast placed on a CR diet and 
exposed to LA, along with experimental data obtained through various metabolomic and 
functional studies in Dr. Titorenko's laboratory, demonstrate that LA extends yeast 
chronological lifespan by maintaining the mitochondrial production of ROS at an optimal 
level that does not excessively damage cellular macromolecules but triggers a potent 
cellular stress response. 
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1 Introduction 
1.1 Peroxisome function and pathology 
Found in almost all eukaryotic cells, peroxisomes are single membrane-bound organelles 
known for their essential roles in lipid metabolism and detoxification of hydrogen 
peroxide [1-3]. Peroxisomes constitute a highly dynamic organelle population; their 
number, size, morphology, protein composition and biochemical functions change in 
response to altered cellular demands and environmental cues [4-6]. Peroxisomes 
compartmentalize a number of metabolic pathways such as a- and p-oxidation of fatty 
acids, catabolism of purines and amino acids, and the degradation of polyamines and 
prostaglandins [4-6]. Catalase housed in the peroxisome detoxifies hydrogen peroxide, a 
reactive oxygen species (ROS) generated in several metabolic processes confined to the 
peroxisome, by converting it to water and oxygen [7, 8]. The molecular oxygen generated 
in the catalase reaction is then used by several peroxisomal oxidases to oxidize various 
compounds such as ethanol, methanol, formic acid, fatty acids, L- and D-amino acids, 
quinines and polyamines [7-10]. Peroxisomes generate a number of important structural 
and signaling lipids such as plasmalogens, polyunsaturated fatty acids, bile acids and 
cholesterol [4-6]. Recent evidence suggests that, by modulating intracellular levels of the 
signaling lipids retinoic acid, phytanic acid and long-chain fatty acids, peroxisomes 
regulate a number of developmental processes [11-17]. 
Peroxisomes lack DNA and thus rely on selective post-translational import of 
proteins required for peroxisome assembly, division and inheritance [1-3, 18-21]. All 
known peroxisomal proteins are encoded by nuclear genes. Many of these proteins are 
initially synthesized on free polysomes in the cytosol and then imported into pre-existing 
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peroxisomal vesicles, which recently have been shown to originate from the endoplasmic 
reticulum (ER) [21-28]. Some of the peroxisomal membrane proteins are initially 
targeted, co- or post-translationally, to the ER template for peroxisome formation [21-
28]. At least 32 proteins known as peroxins drive the ATP-driven import of many 
proteins bearing the PTS1 or PTS2 peroxisomal targeting signals to the matrix of the 
peroxisome [21-28]. 
Mutations in the peroxin-encoding PEX genes result in peroxisomal biogenesis 
disorders (PBDs), which affect multiple peroxisomal metabolic pathways and lead to 
progressive neurological and physiological deficits [29-35]. The most severe form of 
PBDs is known as the Zellweger syndrome (ZS). Patients suffering of this PBD exhibit 
global developmental delay due to incomplete migration and differentiation of 
neuroblasts during psychomotor development as well as defects in white matter 
development and increased apoptosis of neurons [29-35]. ZS patients die in infancy, 
illustrating how indispensable peroxisomes are for normal human development and 
physiology, and how vital the research of peroxisomal biogenesis is for designing 
effective methods of PBDs treatment and prevention. To gain greater insight into the 
mechanisms responsible for the pathology of PBDs, current research strategies focus on 
defining peroxisomal contribution to the development and differentiation pathways in 
evolutionarily distant organisms [16, 18, 30, 36]. 
1.2 Peroxisome biogenesis 
Until recently, peroxisomes were thought of as a static and homogeneous organelle 
population, where structurally and functionally identical peroxisomes increase in size by 
the bulk import of peroxisomal proteins and then divided to form new ones [1-3, 32-34]. 
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According to this classical "growth and division" model, peroxisome biogenesis does not 
involve inter-compartmental vesicular trafficking or membrane fusion. In this model, the 
contribution of the ER was viewed solely as that of source of lipids for the peroxisomal 
membrane [1-3, 37-39]. However, a body of evidence accumulated over the last decade 
from studies in evolutionarily diverse organisms strongly suggests that peroxisomal 
population in a cell constitutes a dynamic, multi-cornpartmental endomembrane system, 
which originates from the ER and involves inter-compartmental vesicular trafficking and 
fusion events similar to those seen in the secretory system [26, 28, 40-53]. Furthermore, 
studies in the yeast Yarrowia lipolytica and mouse dendritic cells provided evidence that 
peroxisomes exist as a dynamic organelle population that consists of structurally distinct 
compartments having different import capacities for various proteins and lipids [18, 54-
56]. In fact, individual compartments of Y. lipolytica peroxisomal endomembrane system 
appear to undergo a multi-step remodeling process of peroxisome maturation (Figure 
1.1). This process is initiated by the fusion of the ER-derived pre-peroxisomal vesicles 
and then progresses through several consecutive steps, each involving the import of a 
distinct set of peroxisomal matrix proteins and transfer of certain lipid species to the 
peroxisomal membrane [26, 28, 40-47]. In the peroxisome biogenesis model for Y. 
lipolytica, early peroxisomal intermediates PI and P2 are converted into a mature 
peroxisome P6 through multiple rounds of import of specific peroxisomal proteins and 
lipids (Figure 1.1) [18, 36, 40-42, 47, 61, 62]. All six peroxisomal subforms (termed PI 
to P6) assembled through the multistep pathway depicted in Figure 1.1 have been purified 
and characterized biochemically and morphologically [18, 41, 62]. The P6 subform is a 
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mature, fully functional peroxisome that contains a complete set of matrix and membrane 
proteins [18,41, 62]. 
Figure 1.1. A model for peroxisome biogenesis in the yeast Yarrowia lipolytica. 
In contrast, the earliest intermediates in the pathway, PI and P2, contain mostly 
peroxisomal membrane proteins and lack the majority of matrix proteins [18, 42, 62]. 
Different intermediates in the peroxisome assembly pathway operating in Y. lipolytica 
differ in their import capacity for various matrix proteins [18, 28, 36, 47]. For instance, 
only the early peroxisomal intermediates PI and P2 can import malate synthase, a 
peroxisomal matrix protein that is targeted to PI and P2 by a PTS1 peroxisomal targeting 
signal [47]. Furthermore, only P2 can import the PTS3-containing acyl-CoA oxidase and 
the PTS2-targeted thiolase directly from the cytosol to the peroxisome matrix [47]. 
Moreover, the PTS 1-containing 62-kDa protein can only be imported into P3, whereas 
the PTSl-bearing isocitrate lyase can only be imported into P4 [47]. Taken together, 
these findings convincingly demonstrated that the assembly of the import machines 
specific for different peroxisomal matrix proteins occurs in distinct intermediates of the 
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peroxisome assembly pathway in a time-ordered fashion [18, 28, 36,47]. The peroxisome 
biogenesis model based on studies in Y. lipolytica has been supported by growing 
evidence from other model systems such as the yeast Pichia pastoris, mouse dendritic 
cells and human fibroblasts, all of which have been shown to carry out a similar multi-
step peroxisome assembly pathway [21, 23, 30, 49, 54, 64-68]. 
In mouse dendritic cells, pre-peroxisomal vesicles are formed by protrusions of the 
lamellar ER extensions that detach from the ER as tubular or sac-shaped carriers of 
various sizes [54]. After budding off from the ER, these pre-peroxisomal carriers recruit a 
transporter protein PMP70, possibly along with the membrane components of the import 
machinery for peroxisomal matrix proteins, to form the so-called "peroxisomal 
reticulum". Only this peroxisomal reticulum is capable of importing post-translationally 
the essential peroxisomal matrix proteins thiolase and catalase [49, 54]. During the final 
step of the peroxisome maturation pathway operating in mouse dendritic cells, the 
peroxisomal reticulum serves as a template for the formation of mature globular 
peroxisomes [49, 54]. It is presently unknown if peroxisomal matrix proteins other than 
thiolase and catalase are imported to the peroxisomal reticulum or to the mature 
peroxisome [28]. Also, in contrast to yeast cells, no evidence exists so far in mammalian 
cells to suggest that their early intermediates of the peroxisome assembly pathway 
undergo fusion [18, 36]. Future research will show if, similar to their stepwise assembly 
during multi-step peroxisome maturation in yeast, the import machineries specific for 
different peroxisomal matrix proteins in mammalian cells also assemble in a multi-step 
fashion in different intermediates of the peroxisome assembly pathway [18, 28, 36]. 
Taken together, these findings suggest that yeast and higher eukaryotes evolved different 
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strategies for the formation and maintenance of their ER-derived peroxisomal 
endomembrane systems [28]. 
1.3 The ER plays an essential role in peroxisomal biogenesis 
Until recently, the contribution of the ER to peroxisome biogenesis was a highly debated 
and controversial issue due to the conflicting evidence based on studies in different 
model organisms. It has been initially postulated that all peroxisomal proteins are first 
synthesized in the ER and only then sorted to the peroxisomal vesicles exiting their ER 
template [57]. This view was then challenged by the discovery that many peroxisomal 
proteins are, in fact, synthesized on free polysomes in the cytosol. As a result, the so-
called "growth and division" model of peroxisomal biogenesis became widely accepted 
[1-3, 38]. However, emerging evidence from studies in evolutionarily distant organisms 
strongly suggests that a distinct subset of peroxisomal membrane proteins, known as 
group I PMPs, indeed undergoes initial sorting in the ER prior to its targeting to the 
peroxisome [36]. Specifically, studies in the yeast Y. lipolytica and mouse dendritic cells 
revealed that the targeting of specific PMPs to the membranes of ER-derived peroxisomal 
precursors is an event that precedes and is necessary for the subsequent import of various 
peroxisomal proteins into different intermediates of the multi-step peroxisome assembly 
pathway [18, 28, 36, 49, 54]. In Y. lipolytica, the formation of pre-peroxisomal vesicles 
from the ER is initiated by the post-translational import of group I PMPs into the ER, 
their 7V-glycosylation in the ER lumen, and their subsequent sorting to a distinct domain 
of the ER called the pre-peroxisomal template [36, 40-42]. Pre-peroxisomal vesicles 
PPV1 and PPV2 that carry the group I PMPs Pex2p and Pexl6p then exit ER by budding 
off from the pre-peroxisomal template, which is different from the ER domain that serves 
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as a template for the formation of secretory vesicles [32, 40-42]. The subsequent post-
translational targeting of two partially overlapping sets of group II PMPs to the ER-
derived pre-peroxisomal vesicles PPV1 and PPV2 leads to the formation of immature 
peroxisomal vesicles PI and P2 [18, 36, 47, 61]. The co- or post-translational import of 
group I PMPs to the ER and their subsequent exit from the ER via PPV1 and PPV2 are 
regulated by two independent mechanisms [47, 58-60]. Presently, it is unknown what 
structural features of group I PMPs are responsible for their targeting to, sorting within 
and exit from the ER. 
In the yeast Y. lipolytica, the transfer of lipids to the peroxisomal membrane is 
initiated in the ER, when a subset of lipids synthesized in the ER membrane is segregated 
into the pre-peroxisomal template that also carries group I PMPs [26, 41, 42, 45, 46]. 
Distinct lipid domains of the ER membrane that are enriched in ergosterol and ceramide 
(ECR domains) have been implicated in the segregation of group I PMPs from the 
resident ER, secretory and plasma membrane proteins [28]. The availability of an in vitro 
assay for the ER-dependent formation of distinct proteolipid carriers would greatly 
facilitate the elucidation of the molecular mechanisms underlying protein and lipid 
sorting into either pre-peroxisomal or secretory vesicles [70-73]. Such assay would 
provide a valuable experimental approach for establishing the mechanisms through which 
ECR domains in the ER membrane govern this process [70-73]. 
1.4 Interplay between peroxisome assembly and division 
A growing body of evidence strongly suggests that, in addition to the ER-dependent 
formation of pre-peroxisomal vesicles and their stepwise maturation into individual 
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compartments of the peroxisomal endomembrane system, the process of peroxisome 
biogenesis involves the division of at least some of these compartments [28]. Although 
the exact mechanism responsible for coordinating peroxisome assembly and division 
remains to be established, two models have been proposed to explain the interplay 
between the processes of peroxisome assembly and division [18, 28, 36, 47, 74]. 
According to the first model, only mature peroxisomes can undergo division, suggesting 
that the complete assembly of mature peroxisomes is mandatory for their subsequent 
proliferation by fission [18, 28, 36]. The second model predicts that the proliferation of 
ER-derived immature pre-peroxisomal vesicles precedes their maturation leading to the 
assembly of mature, fully functional peroxisomes [18, 28, 36, 47, 74]. Recent advances in 
live-cell imaging, including the development of novel fluorescent probes, provide 
powerful tools for testing the validity of these two models in evolutionarily distant 
organisms [28, 47]. 
Similar to the division of mitochondria and chloroplasts, peroxisome division is 
uncoupled from the cell division and requires dynamin-related GTPases [76-83]. 
Numerous data suggest that in yeast and human cells peroxisomes do not simultaneously 
grow and divide [28, 30, 74, 84, 85]. In the yeast Y. lipolytica, only mature, fully formed 
peroxisomes can undergo division, which is regulated by a mechanism that controls 
membrane scission in response to a signal transmitted from the matrix of the peroxisome 
[84]. In fact, once the total mass of proteins within the peroxisome exceeds a certain 
critical level, the first enzyme of fatty acid oxidation acyl-CoA oxidase (Aox) relocates 
from the peroxisomal matrix to the membrane [84]. Such redistribution of Aox occurs 
only in the mature peroxisome, where the mass of matrix proteins is at its highest. 
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Following its relocation from the matrix to the membrane, Aox binds to and sequesters 
Pexl6p, a membrane-associated peroxin that prevents the proliferation of immature 
peroxisomes by inhibiting the scission of their membrane [84, 86]. Aox-mediated 
sequestering of Pexl6p at the peroxisomal membrane abolishes the ability of this peroxin 
to inhibit membrane scission, thereby promoting division of mature peroxisomes [71]. 
Similar to other membrane scission events, peroxisomal membrane scission occurs after 
membrane bending, which is achieved through the destabilization of the membrane 
bilayer [88, 89, 90-101]. As energetically unfavorable processes, both scission and 
bending of mitochondrial, chloroplast and Golgi membranes in yeast, plant and 
mammalian cells are mediated by an evolutionarily conserved proteolipid machine, 
which includes such membrane lipids as phosphatidic acid (PA), diacylglycerol (DAG) 
and certain phosphoinositides [88, 89, 90-106]. The cone-shaped structure of both PA 
and DAG strongly induces negative membrane curvature and thus promotes membrane 
bending [88, 90, 102-104, 107-110]. The molecular mechanism underlying the ability of 
the Pex 16p/Aox-dependent intraperoxisomal signaling pathway to induce the membrane 
scission event needed for peroxisome division in Y. lipolytica remains to be defined. The 
establishment of the contributions of various membrane lipid species and lipid domains to 
the processes of membrane destabilization, bending, scission and fission during 
peroxisome division could provide valuable information for understanding such 
mechanism. 
Peroxisome division is also regulated by the metabolic activity of the peroxisome 
[111-114]. Growing evidence suggests that defects in intraperoxisomal P-oxidation 
pathways significantly affect peroxisomal abundance and size. For instance, the loss of 
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enzymatic activities of Aox, fatty acyl-CoA synthetase, multifunctional enzyme type 2 
and/or 2-enoyl-CoA hydratase has been shown to alter both peroxisome size and number 
[111, 112, 115]. Although the mechanisms underlying this so-called metabolic control on 
peroxisomal division are yet to be established, the observed change in peroxisomal size 
and number in response to inactivation of Aox and 2-enoyl-CoA hydratase could be due 
to the resulting overproduction of other enzymes involved in peroxisomal P-oxidation of 
fatty acids [111,112, 115]. 
1.5 Peroxisomes play an essential role in longevity regulation in yeast 
Programmed cell death, also known as apoptosis, controls the pace of aging in eukaryotic 
organisms [189-192]. Recent unpublished data from Dr. Titorenko's laboratory imply 
that the mitochondria-dependent apoptotic death in the yeast Saccharomyces cerevisiae is 
regulated, in part, by the fi-oxidation of free fatty acids in peroxisomes. Specifically, it 
appears that, in addition to playing an essential role in peroxisomal biogenesis, the 
cytosolic shuttling receptor Pex5p for PTS1 -containing peroxisomal matrix proteins links 
the intrinsic, mitochondria-dependent apoptotic cell death to longevity regulation in 
chronologically aging yeast. Lack of Pex5p shortens the chronological life span of yeast 
by impairing peroxisomal fatty acid oxidation, thereby causing the accumulation of 
excessive, cytotoxic quantities of free fatty acids. Furthermore, under calorie-restriction 
(CR) conditions, various mutational blocks of peroxisomal fatty acid oxidation and the 
resulting decrease in peroxisomal production of acetyl-CoA impair essential oxidation-
reduction processes in mitochondria, promote fragmentation of the mitochondrial tubular 
network and trigger activation of mitochondrial pro-apoptotic signaling pathways, 
thereby shortening chronological life span [unpublished data from Dr. Titorenko's lab]. 
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Moreover, recent findings from Dr. Titorenko's laboratory provide evidence that the 
peroxins Pexlp and Pex6p, two AAA ATPases required for peroxisome biogenesis and 
peroxisomal protein import, also modulate the ability of mitochondria to generate 
reactive oxygen species (ROS) known to accelerate organismal aging through oxidative 
damage of DNA, proteins and lipids [183-186]. 
Taken together, findings from Dr. Titorenko's laboratory suggest that fatty acid 
oxidation in yeast peroxisomes plays an essential role in regulating the age-related, 
mitochondria-controlled apoptotic cell death, thereby indirectly controlling the rate of 
chronological aging. The mechanisms underlying such essential role of peroxisomes in 
longevity regulation are addressed in chapters 10-14 of this thesis. 
1.6 Molecular mechanisms underlying aging 
The circle of life has been a mystery for the human kind for as long as it existed, and 
generations have been plagued by thirst for eternal life potions and fountains of youth. 
Not much have changed over the centuries, albeit the aging research field had evolved 
from the feared wizardry and witchcraft domain to the slightly less mystifying one of a 
laboratory bench top. Aging is defined as the progressive decline in the ability of an 
organism to resist stress, repair damage and battle disease [172-175]. In light of these 
detrimental effects, the purpose of aging as a biological process remains rather elusive. 
Currently, there are two contradictory models for aging as a biological process. One of 
them defines aging as a final stage of a developmental program, which is regulated by a 
distinct set of evolutionarily conserved signaling networks [176-179]. The other, more 
widely accepted model of aging proposes that this irreversible process is caused by the 
random accumulation of unrepaired cellular and molecular damage, which is primarily 
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due to harmful effects of ROS generated as by-products of the metabolic reactions taking 
place consistently throughout life [172, 180-182]. In fact, evidence from various model 
systems implicates ROS as negative regulators of life span based on the observed aging-
related increase of oxidative damage to nucleic acids, proteins and lipids [183-186]. 
Studies in chronologically aging yeast and Drosophila flies further support this model of 
aging by showing that decreasing the amount of ROS through the over-expression of 
ROS-scavenging enzyme superoxide dismutase (SOD) can dramatically extend life span 
[187, 188]. 
Multiple cellular compartments generate ROS as side-products of various 
enzymatic reactions routinely taking place throughout life span. The contribution of 
mitochondria to the production of ROS is the most significant, with ATP synthesis by 
mitochondrial respiration accounting for as much as 90% of the overall ROS generated 
within a cell [189-193]. However, to a lesser extent, ROS are also made in the plasma 
membrane by NADPH oxidases, in the cytosol by cyclooxygenases catalyzing several 
oxidative reactions, and in the peroxisome during fatty acid P-oxidation [14, 31, 189-
193]. Major targets of the ROS-induced oxidative damage are mitochondrial proteins, 
including 1) aconitase (Acolp), an [4Fe-4S] cluster enzyme of the TCA cycle with 
another essential function in the maintenance of the mitochondrial genome; 2) 
homoaconitase (Lys4p), another [4Fe-4S] cluster enzyme involved in lysine biosynthesis 
in the mitochondrion; 3) succinate dehydrogenase, a dual function enzyme involved not 
only in the TCA cycle but also in the mitochondrial electron transfer chain (ETC) as 
respiratory complex II; 4) cytochrome c, a heme-containing mobile component of the 
mitochondrial ETC; and 5) cytochrome c oxidase, a heme-containing complex IV of the 
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mitochondrial ETC [189-192]. In addition, the mitochondrial DNA (mtDNA) nucleoid 
and the saturated fatty acids of membrane lipids are also highly susceptible to oxidative 
damage by ROS [189-192]. 
Several antioxidant scavenging pathways protect cellular components against 
oxidative damage by ROS. Two subforms of superoxide dismutase, one found in the 
cytosol (Sodlp) and another in the mitochondria (Sod2p), convert superoxide radicals to 
more stable and less toxic hydrogen peroxide [189-192]. Hydrogen peroxide is then 
further detoxified through various enzymatic reactions catalyzed by glutathione 
peroxidases, catalases and peroxiredoxins present in the cytosol, mitochondria and 
peroxisomes. 
At any given time, the steady-state level of ROS is defined by the relative rates of 
ROS formation and detoxification in various cellular locations. While high levels of ROS 
have been linked to increased oxidative damage to various cellular and organellar 
constituents, low levels of these reactive compounds, in fact, protect cellular 
macromolecules against oxidative damage by activating several stress-response and 
damage-repair pathways [189-192]. Low intracellular and intraorganellar concentrations 
of ROS have been shown to prevent cells from undergoing apoptosis, a process of 
programmed cell suicide [189-192, 194]. Apoptotic cell death is known to occur in 
numerous multicellular organisms and mammals, including humans, where it plays a 
pivotal role in normal development and physiology [194, 195]. Recent studies show that 
even unicellular eukaryotic organisms, such as aging yeast cells, also die exhibiting 
characteristic markers of apoptosis such as DNA cleavage, chromatin condensation, 
externalization of phosphatidylserine in the plasma membrane, and release of cytochrome 
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c from mitochondria [196-198]. This emerging evidence strongly suggests that apoptotic 
cell death plays a major role in the aging process of yeast cells. In addition, several 
mammalian regulators of apoptosis have orthologues in yeast, providing further evidence 
that the apoptotic cell death of yeast and metazoan is an evolutionarily conserved 
mechanism. In yeast, these key regulators of apoptosis include metacaspase Ycalp, an 
HtrA2/Omi-like apoptotic serine protease Nmal 1 lp, the apoptosis inducing factor Aiflp, 
the histone chaperone Asflp, and the mitochondrial fission protein Drplp [201-204]. 
Moreover, similar to the metazoan organisms, apoptotic pathways in yeast are also 
regulated primarily by ROS [200]. 
Several ROS-sensing protein machines exist in the mitochondrion (protein kinases 
PKD1, PKC6, Src, Abl, PI3 and Akt), plasma membrane (Ras), and cytosol (PNC1) [189-
192]. There is strong evidence that low levels of ROS stimulate the interaction of the 
ROS-sensing proteins with some of the cytosol-to-nucleus and mitochondrion-to-nucleus 
shuttling proteins, such as p32 and Hsp27p, promoting their import into the nucleus, 
where they activate transcriptional factors and co-factors (SIRT1, FOX03, p53, NF-KB, 
DET1 and COP1) responsible for the expression of genes encoding stress-response and 
anti-apoptotic proteins [189-192]. In addition, the inactivation of the mitochondrial pro-
apoptotic factors Bad and INK by some of the ROS sensors in the cytosol and 
mitochondrion in response to low ROS levels have been shown to delay apoptotic 
pathways that are activated intrinsically through mitochondria [189-192]. In fact, 
numerous findings suggest that aging of evolutionarily distant organisms is regulated, in 
part, through an intrinsic, mitochondria-dependent apoptotic cell death mechanism [190, 
191, 205-208]. According to unpublished data from Dr. Titorenko's laboratory, the age-
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related, mitochondria-controlled apoptotic death in yeast is regulated, in part, by the 
oxidation of free fatty acids in peroxisomes. In particular, recent evidence from Dr. 
Titorenko's laboratory implicates peroxisomal proteins Pexlp, Pex5p and Pex6p as the 
key factors controlling the rate of chronological aging in yeast by modulating the 
intrinsic, mitochondria-dependent apoptotic cell death. 
1.7 Calorie-restricted yeast as a model system for aging research 
A growing body of evidence suggests that fundamental mechanisms of aging are 
conserved across phyla [209-212, 238]. Our laboratory uses the yeast S. cerevisiae, a 
unicellular eukaryotic organism, to study the molecular and cellular mechanisms 
governing the aging process. The availability of a completely sequenced genome as well 
as easy genetic and biochemical manipulations make yeast a valuable model for unveiling 
the mechanisms of aging in multicellular eukaryotes [216, 217]. Two different methods 
for studying aging in S. cerevisiae measure either replicative or chronological life span. 
The replicative life span of S. cerevisiae, which represents the maximum replicative 
potential of a yeast cell, is measured by the number of daughter cells produced before 
senescence and can be used as a model for aging of the dividing (i.e., mitotically active) 
mammalian cells [218]. The chronological life span of the yeast S. cerevisiae reflects the 
viability of yeast cells in a non-dividing state and has been extensively used as model for 
studying the aging of non-dividing (i.e., post-mitotic) mammalian cells [219]. Both the 
replicative and the chronological life spans of yeast can be extended by a diet known as 
calorie-restriction (CR). This diet decreases the intake of calories derived from 
carbohydrates, proteins and fat by 25% - 60% without compromising the supply of 
essential nutrients [208, 220, 222-224]. The CR diet significantly extends life span of a 
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wide variety of organisms, ranging from yeast to non-human primates and does not cause 
irreversible reproductive and/or developmental defects that are often observed in 
genetically-modified long-lived mutants of yeast, flies and mice [208, 220, 222-227]. 
Furthermore, the CR diet delays the onset of several age-related diseases, such as 
atherosclerosis, cancer, and type II diabetes [228]. The CR dietary regimen has been also 
shown to decelerate neuronal degeneration in mouse models of age-related disorders like 
Parkinson's or Alzheimer's diseases [229, 230]. In fact, the aging-associated decline of 
spatial and psychomotor memory functions, as well as deterioration of learning 
capabilities due to dendritic loss, can be delayed by CR [231, 232]. In addition, the CR 
diet has been linked to the improved plasticity and self-repair of the brain [233]. 
Despite the available extensive knowledge of the beneficial effects of CR, the 
mechanisms underlying the CR-dependent life span extension have not been defined yet. 
The challenge lays in the overall complexity of the multiple effects of the CR diet on the 
organism's metabolic, apoptotic, and neuroendocrine functions, among possible others. 
Furthermore, functional changes induced by the CR diet are organ-specific and exhibit 
various intensities in different organ systems [233]. 
As a model system to study the mechanisms of aging under CR conditions, Dr. 
Titorenko's laboratory uses the strain BY4742 of S. cerevisiae. This particular strain was 
chosen based on its relatively short life span, which facilitates the research of its 
chronological aging, as well as due to the availability of a collection of its knock-out 
mutants from Open Biosystems [235]. In Dr. Titorenko's laboratory, the experimental 
set-up of a traditional CR dietary regimen is achieved by growing yeast cells in the 
YEPD medium with the glucose concentration in the medium lowered from 2% (non-CR 
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conditions) to 0.5% or 0.2% [236, 237]. The use of nutrient-rich YEPD medium with 
decreased glucose content does not compromise the supply of essential nutrients and 
vitamins, which maintains yeast cells viable as glucose is consumed, a requirement that 
cannot be achieved under other CR protocols that limit availability of amino acids or 
essential nutrients by using nutrient-limited media [219, 238]. In fact, evidence from Dr. 
Titorenko's laboratory indicates that the kinetics of growth rate and glucose consumption 
observed in yeast cells placed on the CR diet are similar to those seen under non-CR 
conditions (Figure 1.2). 






r-^vS, *—-,.- -. 
' " " " X " - - " " X ~ " ~ - ~ " ~ " ~ " " 
--ZZ-L ; : : n: z z z _:::_ 
::± : ± . ; _z::_ 
_. -- + - - -T -- - - -" : . 
• - - - J I S i 14 M h o 4 >= i 4 H 1= = = =
 3 c = = = 4 r 
a ! — - - - - • - Y b r + u./To glucose 
X _^ _ YEP + 0 5% alucose 
i f - - I I _ , -* -Tcr + i.uk glucose 
J E " ~ - - - " ••-YEP +2.0% glucose : m- i i i i i i i i r n i i i m i 
L = log phase 
D = diauxic phase 
PD = post-diauxic phase 
ST = stationary phase 
=
 1 
5 10 15 20 25 30 O 
Days in culture 
Data from Alex Goldberg, Chris Gregg 
& Simon Bourque 
1.0 0.50 
QM 0.25 
0 J 0J 0 J 0 
6 12 18 24 30 36 
Hours in culture 
Figure 1.2. Kinetics of growth and glucose consumption for the wild-type 5. cerevisiae 
strain BY4742 grown in media initially containing different concentrations of glucose. 
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Furthermore, the rate of aging and the degree of calorie restriction appear to be in a dose-
response relationship, with the maximal life span extension of wild-type strain being 
achieved under CR conditions at 0.5% glucose concentration (Figure 1.3). 
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Figure 1.3. A dose-response relationship between the rate of aging and the degree of 
calorie restriction in the wild-type S. cerevisiae strain BY4742. 
Moreover, the intracellular levels of ATP and the dynamics of their changes observed 
during chronological aging of CR yeast are very similar to those seen in the non-CR 
yeast, indicating that yeast growing under CR are not starving (Figure 1.4). 
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Figure 1.4. Intracellular levels of ATP and the dynamics of their change during 
chronological aging are very similar in CR and non-CR yeast. 
Taken together, these findings imply that CR yeast must somehow remodel their 
metabolism to generate sufficient amounts of ATP, matching those observed in non-CR 
yeast, and that this CR-induced metabolic remodeling could lead to the observed life span 
extension. 
The next section provides a detailed description on the experimental approaches 
used in Dr. Titorenko's laboratory to determine how yeast remodel their metabolism 
under CR conditions and how such remodeling modulates the age-dependent dynamics of 
longevity-related processes in yeast, including lipid and carbohydrate metabolism, ROS 
homeostasis, stability of nuclear and mitochondrial genomes, stress resistance, and 
apoptosis induced by stress and aging. 
19 
1.8 Using mass spectrometry-based proteomics for elucidating the mechanisms 
of longevity regulation in chronologically aging yeast 
To define the metabolic remodeling responsible for the anti-aging effect of CR and to 
elucidate its regulatory mechanisms, Dr. Titorenko's laboratory employs various 
biochemical methods to compare CR and non-CR yeast recovered at different times of 
their chronological life span, in terms of their cellular and organellar proteomes, cellular 
and organellar lipidomes, cellular metabolomes, production of ROS, stability of nuclear 
and mitochondrial genomes, mitochondrial morphology, oxidation-reduction reactions in 
mitochondria, resistance to acute stress, age- and stress-induced apoptosis, and cell 
ultrastructure. 
The goal of my graduate research was to use the yeast S. cerevisiae as a model 
system for identifying the key proteins controlling the rate of chronological aging. Using 
mass spectrometry, I compared the age-dependent dynamics of changes in cellular and 
organellar proteomes in CR and non-CR yeast recovered at different stages of their 
chronological aging. I then characterized the age-dependent dynamics of changes in 
cellular and organellar proteomes of the short-lived pex5A mutant strain grown under CR 
conditions to study the effect of peroxisomal fatty acid oxidation on age-related processes 
in chronologically aging yeast. I have identified numerous proteins that are enriched or 
depleted in total cell lysates as well as in purified mitochondria, lipid bodies and ER of 
pex5A, as compared to the wild-type strain of S. cerevisiae grown under CR conditions. 
In addition, I used mass spectrometry-based proteomics to monitor the effect of a novel 
anti-aging molecule recently identified in Dr. Titorenko's laboratory on the age-
dependent dynamics of changes in cellular proteomes of chronologically aging yeast. The 
results of these studies, which are described and discussed in chapters 10 to 14 of the 
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thesis, strongly suggest that the chronological aging of yeast is a developmental program 
that integrates a distinct set of protein machines into what I call a modular longevity 
network. 
1.9 Thesis outline and contributions of colleagues 
I was able to define the molecular mechanisms regulating the fusion between PI and P2 
peroxisomes during the first post-ER step of the peroxisome biogenesis process in the 
yeast Y. lipolytica. A detailed description of my research findings on this topic has been 
published in The Journal of Cell Biology [116] and is presented in chapters 2 to 9 of this 
thesis with the Journal's permission. I contributed approximately 80% of all of the work 
described in this publication and prepared the first draft of the manuscript, while Dr. V. 
Titorenko provided intellectual leadership of this project and edited the manuscript. The 
numbering of figures and tables, as well as the format of abbreviations and citations 
presented in the paper have been changed to fit this thesis. 
In chapters 10 to 14 of this thesis, I describe and discuss my findings on the 
molecular mechanisms regulating longevity in the yeast S. cerevisiae. Some of these 
findings are presented in two research articles that have been recently accepted for 
publication in Biochemical Society Transactions and Experimental Gerontology, whereas 
the other findings constitute an integral part of a manuscript that is currently in 
preparation for submission to the PNAS USA. I contributed approximately 50% of all of 
the work described in these three publications and am an equally contributed first co-
author on all of them. 
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2 Pharmacological analysis of peroxisomal fusion 
2.1 Introduction 
Membrane fusion is an essential process required for the proper division of eukaryotic 
cells, their communication with the environment by hormones and neurotransmitters, 
their integration into multicellular organisms, and their invasion by enveloped viruses 
[125]. In addition, membrane fusion reactions are necessary for maintaining the structural 
integrity of organelles during mitosis and the vesicular flow between the organellar 
compartments of the secretory and endocytic pathways [126]. All membrane fusion 
reactions inside the secretory and endocytic systems are regulated by very similar 
mechanisms that require a common set of core proteins such as SNAREs [125]. 
However, the fusion of mitochondria and peroxisomes [36, 127] do not require 
intracellular fusion machines that function in the secretory and endocytic pathways and 
may therefore involve unique, yet unknown, mechanisms [125, 126]. 
In the yeast Y. lipolytica, the fusion of immature peroxisomal sub forms P1 and P2 
initiates the multi-step peroxisomal maturation process (Figure 1.1). It is driven by ATP 
hydrolysis, requires cytosolic proteins, and depends on the peroxins Pexlp and Pex6p, 
two AAA ATPases essential for peroxisome biogenesis [3, 18, 21, 23, 36, 40-42, 47, 61-
63]. This fusion event is a multi-step process consisting of priming, docking and fusion 
stages (Figure 2.1) [62]. 
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Figure 2.1. A model for the fusion of the peroxisomal subforms PI and P2 in the yeast Y. 
lipolytica. This fusion is a multi-step process consisting of priming, docking and fusion 
events. 
Before priming, Pexlp and Pex6p are bound to the outer face of both peroxisomal fusion 
partners [63]. The priming of PI and P2 is driven by asymmetrical dissociation of these 
two ATPases from the surfaces of PI and P2, which requires ATP hydrolysis and 
cytosolic proteins [63]. The subsequent release of Pexlp and Pex6p to the cytosol 
promotes the docking of primed peroxisomal fusion partners. During docking of primed 
PI and P2, Pexlp is released from the surface of P2 in an ATP hydrolysis- and cytosol-
dependent fashion [63]. Following the formation of a stable docking complex, PI and P2 
fuse to generate the peroxisomal subform P3. Fusion of docked PI and P2 does not 
require ATP hydrolysis or cytosol [63]. P3 formed by the fusion between PI and P2 
undergoes a multi-step maturation into a fully functional peroxisome P6 through a multi-
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step peroxisomal assembly pathway, as described previously (Figure 1.1) [18, 36, 40, 41, 
42,47,61,62]. 
The fusion of PI and P2 has been reconstituted in vitro using an assay (Figure 2.1; 
see insert) that evaluates fusion efficiency by measuring the % conversion of thiolase, a 
peroxisomal matrix protein, from its precursor form (which is present only in P2) to its 
mature form by its proteolytic processing enzyme (which is present only in PI) [62, 63]. 
The availability of this rapid and quantitative in vitro fusion assay allowed me to identify 
several key protein and lipid compounds that are required for the fusion of P1 and P2 
peroxisomes [63]. 
2.2 Materials and methods 
Strains and growth media 
The Y. lipolytica wild-type strain POld {MatA ura3-302 leu2-270 xpr2-302) and mutant 
strainpex5KO {MATA, ura3-302, leu2-270, lys8-ll, pex5::LEU2)[\\l] were grown in 
YPD media (2% glucose, 2% peptone, 1% yeast extract) to OD600 value of ~1.5 and then 
switched to YPBO media (1% oleic acid, 0.3% yeast extract, 0.5% peptone, 0.5% 
K2HPO4, 0.5% KH2PO4, 1 % Brij-35) in order to induce peroxisome proliferation [118]. 
Subcellular fractionation of yeast cells 
Subcellular compartments of YPBO-grown yeast cells were fractionated by differential 
centrifugation of lysed and homogenized cell spheroplasts at 1,000 x g for 8 min at 4°C 
using a Beckman JS13.1 rotor. The postnuclear supernatant (PNS) fraction was 
centrifuged further at 20,000 x g for 30 min at 4°C in a Beckman JS13.1 rotor, producing 
the pellet (20KgP) and supernatant (20KgS) fractions. The 20KgS fraction was 
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centrifuged at 200,000 x g for 1 h at 4°C using a TLA 120.2 Beckman rotor yielding the 
pellet (200KgP) fraction, which contained immature peroxisomal subforms PI to P5, and 
the supernatant (200KgS) fraction, which contained mature peroxisomal subform P6 [63]. 
Purification of PI and P2 peroxisomal subforms 
Immature peroxisomal subforms PI through P5 were purified by centrifugation of the 
200KgP fraction on a discontinuous sucrose gradient (18, 25, 30, 35, 40, and 53% 
sucrose, wt/wt) at 120,000 x g for 18 h at 4°C using a Beckman SW28 rotor. Thirty six 
fractions of 1 ml each were collected. Fractions containing different peroxisomal 
subforms were supplemented with 4 volumes of 0.5 M sucrose in buffer H (5 mM MES, 
pH 5.5; ImM KC1; 0.5mM EDTA; 0.1% ethanol; protease inhibitors) [119]. Immature 
peroxisomes were pelleted onto a 150-ul layer of 2 M sucrose in buffer H by 
centrifugation at 200,000 x g for 20 min at 4°C using a Beckman TLA120.2 rotor. Pellets 
containing immature peroxisomal subforms PI and P2 were resuspended in 3 ml of 50% 
(wt/wt) sucrose in buffer H, overlaid with 30%, 28%, 26%, 24%, 22%, and 10% (all 
wt/wt) sucrose in buffer H and centrifuged at 120,000 x g for 18 h at 4°C using a 
Beckman SW28 rotor. Eighteen fractions of 2 ml each were collected. Peroxisomes PI 
and P2 were pelleted, resuspended and then centrifuged through the same multistep 
sucrose density gradient. Gradient fractions of 2 ml each were collected and peroxisomes 
PI and P2 were pelleted, resuspended in T99 buffer (15 mM MES, pH 6.0; 100 mM KC1; 
50 mM KOAc; 3 mM MgCl2; 2 mM MgOAc) containing 250 mM sorbitol, washed twice 
in the same buffer and centrifuged as described above. Final suspensions of P1 and P2 in 
T99 buffer containing 250 mM sorbitol were used for the fusion assay [63]. 
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In vitro peroxisome fusion assay 
PI peroxisomes were purified from unlabeled wild-type or pex5KO Y. lipolytica cells, 
whereas P2 peroxisomes were isolated from pex5KO Y. lipolytica cells labeled with L-
[35S] methionine for 30 min [118, 41]. Isolated peroxisomes PI and P2 were individually 
incubated in PF buffer (T99 buffer containing 250 mM sorbitol; 1 mg cytosol/ml; 1 mM 
ATP; 40 mM creatine phosphate; 10 U creatine kinase/ml) for 5 min at 26°C with or 
without 300 u.g nystatin/ml, 300 u.g filipin Ill/ml, 300 u.g amphotericin B/ml, 80 uM 
phosphoinositide-specific monoclonal antibodies, 1 mM ATP7S, 2 mM GTP7S or 3 mM 
GppNHp, in presence or absence of 1 mg/ml cytosol, which was prepared in ice-cold PF 
buffer [119]. Pretreated, unlabeled PI peroxisomes were mixed with pretreated, labeled 
P2 peroxisomes and incubated for 90 min at 26°C [118]. Fusion reactions were stopped 
by incubation on ice for 3 min and then diluted 10-fold in ice-cold buffer D (15 mM 
MES, pH 6.0, 250 mM sorbitol, protease inhibitors). Peroxisomes PI and P2 were re-
isolated by centrifugation at 100,000 x g for 8 min at 4°C using a Beckman TLA 120.2 
rotor, resuspended in 400 p.1 of buffer D and re-pelleted. The precursor (pTHI) and 
mature (mTHI) forms of thiolase were immunoprecipitated under denaturing conditions 
using anti-THI antibodies covalently coupled to protein A-Sepharose [41, 63]. 
Immunoprecipitates were resolved by SDS-PAGE, visualized by fluorography using 
Amersham Biosciences ECL Western Blotting Detection Reagents and quantitated by 
densitometry. Digital images were acquired using the Bio-Rad VersaDoc Imaging 
System. Peroxisomal fusion efficiency was calculated based on percent conversion of 
pTHI to mTHI [118]. LiposoFast Liposome "Factory" (Avestin) system was used to 
construct uniformly-sized, unilamellar liposomes from PC with or without ergosterol (3:1 
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weight ratio), as described previously [122]. The liposomes were assembled according to 
manufacturer's instructions by extrusion through polycarbonate membranes with pore 
diameter of 100 nm. 
2.3 Results 
2.3.1 Presence of ergosterol in the membranes of both fusion partners is required 
for peroxisomal fusion in vitro 
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Figure 2.2. Peroxisome fusion can be reversibly inhibited by ergosterol ligands nystatin, 
fillipin III and amphotericin B. (A) PI and P2 were preincubated individually for 5 min at 
26°C without inhibitor or with the indicated amounts of ergosterol ligands. Pretreated PI 
and P2 were then mixed and supplemented with cytosol and ATP to yield standard fusion 
reactions. After a 90-min incubation at 26°C, the percent conversion of the precursor 
form of thiolase to its mature form as a measure of fusion was calculated. (B) PI and P2 
were preincubated individually for 5 min at 26°C with nystatin (200 ug/ml). Pretreated PI 
and P2 were then mixed. The samples were supplemented with cytosol and ATP to yield 
standard fusion reactions and incubated at 26°C in the presence or absence of liposomes 
without or with the indicated amounts of ergosterol. After a 90-min incubation, fusion 
efficiency was measured. 
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2.3.2 Peroxisomal fusion depends on phosphoinositides PI(4)P and PI(4,5)P2 
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Figure 2.3. Antibodies to PI(4)P (A) and PI(4,5)P2 (B) inhibit peroxisome fusion in a 
reversible manner (C). (A and B) P1 and P2 were preincubated individually for 5 min at 
26°C without inhibitor or with the indicated amounts of phosphoinositide-specific 
antibodies (a). Pretreated PI and P2 were then mixed and supplemented with cytosol and 
ATP to yield standard fusion reactions. After a 90-min incubation at 26°C, the percent 
conversion of the precursor form of thiolase to its mature form as a measure of fusion 
was calculated. (C) PI and P2 were preincubated individually for 5 min at 26°C 
antibodies to PI(4)P (60 uM) or to PI(4,5)P2 (60 uM). Pretreated PI and P2 were then 
mixed. The samples were supplemented with cytosol and ATP to yield standard fusion 
reactions and incubated at 26°C without or with the indicated amounts of PI(4)P or 
PI(4,5)P2. After a 90-min incubation, fusion efficiency was measured. 
2.3.3 Peroxisomal fusion requires the hydrolysis of GTP 
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Figure 2.4. Nonhydrolyzable GTP analogues GTPTS and GppNHp inhibit peroxisome 
fusion (A) in a reversible manner (B). (A) PI and P2 were preincubated individually for 5 
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min at 26°C without inhibitor or with the indicated amounts of nonhydrolyzable GTP 
analogs. Pretreated PI and P2 were then mixed and supplemented with cytosol and ATP 
to yield standard fusion reactions. After a 90-min incubation at 26°C, the percent 
conversion of the precursor form of thiolase to its mature form as a measure of fusion 
was calculated. (B) PI and P2 were preincubated individually for 5 min at 26°C with 
GTPyS (2 mM) or GppNHp (2 mM). Pretreated PI and P2 were then mixed. The samples 
were supplemented with cytosol and ATP to yield standard fusion reactions and 
incubated at 26°C without or with the indicated amounts of GTP. After a 90-min 
incubation, fusion efficiency was measured. 
2.4 Discussion 
I found that peroxisomal fusion was inhibited by nystatin, filipin III, and amphotericin B 
(Figure 2.2A), each known for its propensity to sequester sterol lipids but not fully 
remove them from the membrane [123, 124]. The inhibitory effect of these ergosterol 
ligands on peroxisome fusion was specific as it could be reversed by phosphatidylcholine 
(PC)-based liposomes with ergosterol, but not by PC-based liposomes without it (Figure 
2.2B). Moreover, neither of these drugs caused the dissipation of the existing Ca 
gradient across the peroxisomal membrane, suggesting that the inhibitory effect of these 
compounds on peroxisomal fusion was not due to the impairment of overall peroxisome 
integrity (unpublished data from Dr. Titorenko's laboratory). Based on these findings, I 
concluded that ergosterol plays a specific role in the fusion of PI and P2 peroxisomes. On 
note, cholesterol has been previously implicated in modulating membrane fusion during 
viral entry into the host organism [128]. Furthermore, studies in yeast revealed that all of 
the ergosterol biosynthesis enzymes are required for the proper maintenance of 
mitochondrial morphology, suggesting that ergosterol may also be involved in regulation 
of mitochondrial fusion [129, 130]. 
The fusion of PI and P2 was also inhibited by monoclonal antibodies to the 
membrane phosphoinositides phosphatidylinositol (PI)-4-phosphate (P1(4)P) and PI-4,5-
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bisphosphate (PI(4,5)P2) (Figures 2.3A and 2.3B). I found that the negative effect of 
these antibodies on peroxisome fusion could be reversed by externally added PI(4)P and 
PI(4,5)P2, respectively (Figure 2.3C). In contrast, monoclonal antibodies to any other 
phosphoinositide tested did not affect peroxisome fusion (Figures 2.3A and 2.3B), 
showing the specificity of its inhibition by ligands of PI(4)P and PI(4,5)P2. Therefore, 
only these two phosphoinositides are needed for the fusion of PI and P2. Noteworthy, a 
recent study of proteins interacting with PI(4,5)P2 revealed 44 proteins that regulate ion 
transport and trafficking events, some of which also play an important role in membrane 
fusion and exocytosis [131]. Phosphoinositides also regulate a spatiotemporal 
organization of signal transduction pathways, either through direct interaction with 
proteins or as precursors of secondary messengers [133-136]. Furthermore, signal 
transduction pathways mediated by phosphoinositides are involved in key cellular 
processes such as vesicle and membrane trafficking, exocytosis and secretion, cell 
adhesion and migration, reorganization of actin skeleton, cellular proliferation, 
metabolism and apoptosis [138-142]. 
I also found that two nonhydrolyzable GTP analogs, GTPyS and GppNHp, are 
reversible inhibitors of peroxisome fusion. Importantly, their negative effect on the fusion 
can be overturned by reisolating pretreated PI and P2 and resuspending them in the 
standard fusion reaction mixture supplemented with GTP (Figures 2.4A and 2.4B). These 
data suggest that GTP hydrolysis by GTPase(s) is required for peroxisome fusion. Of 
note, recent studies in Xenopus laevis demonstrated that GTP hydrolysis is also required 
for vesicle fusion during nuclear envelope assembly [132]. Moreover, GTP hydrolysis is 
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also essential for successful docking and fusion events during homotypic vacuole fusion 
in yeast [143]. 
2.5 Conclusions 
My pharmacological analysis of peroxisome fusion in vitro provided the first evidence 
that, in addition to ATP hydrolysis and cytosolic proteins, the fusion of PI and P2 
peroxisomes requires ergosterol, the membrane phosphoinositides PI(4)P and PI(4,5)P2 
and GTP hydrolysis. In order to establish the roles of these compounds in peroxisome 
fusion, I next examined their contribution to the individual stages of the fusion process. 
The results of these studies are discussed below. 
3 Dynamics of peroxisome priming 
3.1 Introduction 
Fusion of PI and P2 is a multistep process that includes priming, docking and fusion 
events [62, 63]. Priming (activation) of PI and P2 prior to their physical contact commits 
both fusion partners to subsequent docking. Priming requires two AAA ATPases, Pexlp 
and Pex6p [62, 63]. Before priming, Pexlp is associated with the cytosolic surface of PI, 
while Pexlp and Pex6p are bound to the outer face of P2 [63]. During priming, ATP 
hydrolysis triggers cytosol-dependent release of Pexlp from PI and of Pex6p from P2, 
whereas P2-associated Pexlp remains bound to the organelle [63]. Using an in vitro 
peroxisome fusion assay, I evaluated the requirements for the release of AAA ATPases 
during peroxisome priming. The extent of release of Pexlp from PI and of Pex6p from 
P2 is known to be a measure of priming efficiency [62]. 
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3.2 Materials and methods 
In vitro assay for the release of Pexlp and Pex6p from PI and P2 
L-[ S] methionine-labeled PI and P2 were individually incubated for 5 min at 26°C in 
PF buffer with or without 300 pg nystatin/ml, 300 ug filipin Ill/ml, 300 u.g amphotericin 
B/ml, 80 uM phosphoinositide-specific monoclonal antibodies, 1 mM ATP1S, 2 mM 
GTP7S or 3 mM GppNHp, in presence or absence of 1 mg/ml cytosol. Pretreated 
peroxisomes PI and P2 were supplemented with 1 mM ATP, 40 mM creatine phosphate 
and 10 U creatine kinase/ml, and incubated individually for 10 min at 26°C with or 
without 1 pg unlabeled cytosol/ml. PI and P2 were re-isolated by centrifugation at 
100,000 x g for 5 min at 4°C using a Beckman TLA120.2 rotor. Proteins from pellet and 
supernatant fractions were immunoprecipitated under denaturing conditions with protein 
A-Sepharose-linked anti-Pexlp and/or anti-Pex6p antibodies, resuspended in 400 pi of 
buffer D and re-pelleted. 
Immunoaffinity chromatography 
Peroxisomal proteins recovered from pellet and supernatant fractions in the in vitro assay 
for the release of Pexlp and Pex6p from PI and P2 were subjected to immunoaffinity 
chromatography under denaturing conditions. Anti-Pexlp and anti-Pex6p antibodies were 
covalently linked to protein A-Sepharose [121]. Protein samples in PF buffer were 
diluted in equal volumes of 4% SDS, heated for 10 min at 65°C, cooled to room 
temperature and treated with four volumes of 62.5 mM Tris-HCl (pH 7.5) buffer 
containing 190 mM NaCl, 1.25% (vol/vol) Triton X-100 and 6 mM EDTA. Non-specific 
binding of proteins was eliminated by incubating samples for 20 min at 4°C with protein 
A-Sepharose that was washed five times with 10 mM Tris-HCl (pH 7.5) buffer. Proteins 
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specifically bound by protein A-Sepharose were washed five times with 50 mM Tris-HCl 
(pH 7.5) buffer containing 150 mM NaCl and 1% (vol/vol) Triton X-100. Washed 
proteins were eluted with 2% SDS solution for 5 min at 95°C, resolved by SDS-PAGE 
and visualized by fluorography [118]. 
Protein-lipid overlay assay 
PI and P2 were purified from L-[35S] methionine-labeled cells and osmotically lysed. 
Peroxisomal membranes were pelleted by centrifugation and subjected to a protein-lipid 
overlay assay to estimate the phospholipids-binding specificity of peroxisomal membrane 
proteins. Peroxisomal membrane pellets were resuspended in TBSO buffer (10 mM Tris-
HCl (pH 8.0), 150 mM NaCl and 0.5% n-OG), incubated on ice for 30 min and 
centrifuged at 100,000 x g for 30 min at 4°C. Supernatants of n-OG-solubilized 
membrane proteins were incubated at 5 u.g/ml with the PIP-Strip (Echelon Biosciences) 
at 4°C overnight. The PIP-Strips were then washed five times with TBSO buffer, and 
binding of phospholipids to peroxisomal membrane proteins was visualized by 
autoradiography. 
Detergent solubility of PI(4)P- and PI(4,5)P2-binding proteins was evaluated by 
spotting 100 pmol of PI(4)P- and PI(4,5)P2 on nitrocellulose membrane arrays and using 
the cut-out spots containing single phosphoinositides in the protein-lipid overlay assay. 
Membrane pellets recovered after centrifugation of osmotically lysed P1 and P2 were 
resuspended in ice-cold MBS buffer with or without the detergent of interest. Samples 
were incubated on ice for 30 min and centrifuged at 100,000 x g for 30 min at 4°C. 
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Supernatants of n-OG-solubilized membrane proteins were then used to perform the 
protein-lipid overlay assay as described previously. 
The levels of PI(4)P- and PI(4,5)P2-binding proteins in fractions of flotation 
gradients used for the fractionation of Brij 35-treated membranes of PI and P2 were 
evaluated by spotting 100 pmol of PI(4)P- and PI(4,5)P2 on nitrocellulose membrane 
arrays and using the cut-out spots containing single phosphoinositides in the protein-lipid 
overlay assay. Equal volumes of flotation gradient fractions were diluted with nine 
volumes of TBSO buffer and then processed for the protein-lipid overlay assay as 
described previously. 
3.3 Results 
3.3.1 The release of Pexlp from PI and Pex6p from P2 requires ergosterol, PI(4)P, 
















































Figure 3.1. Effect of various inhibitors of peroxisome fusion on the release of Pexlp 
from PI and Pex6p from P2 during priming of both fusion partners. L-[35S]methionine-
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labeled PI and L-[ S]methionine-labeled P2 were preincubated individually for 5 min at 
26°C with or without nystatin (an ergosterol ligand), phosphoinositide-specific 
antibodies, ATPyS, or nonhydrolyzable GTP analogs. Pretreated PI and P2 were then 
supplemented with ATP and incubated individually in the presence or absence of 
unlabeled cytosol, as indicated. After a 10-min incubation at 26°C, peroxisomal vesicles 
were pelleted. Pexlp and Pex6p were immunoprecipitated under denaturing conditions 
from the pellet (P) and supernatant (S) fractions. Immunoprecipitates were resolved by 
SDS-PAGE and visualized by fluorography. 
3.3.2 During peroxisome priming, membrane proteins of PI and P2 bind 
specifically to PI(4)P and PI(4,5)P2 and remain attached to the cytosolic 






























































Figure 3.2. Testing the ability of PI- and P2-associated proteins to bind to various 
phosphoinositides and phospholipids and assessing the topology of the association of 
PI(4)P- and PI(4,5)P2 -binding proteins with both fusion partners during their priming. 
Intact PI and P2 labeled with L-[35S]methionine were primed individually by incubation 
with unlabeled cytosol and ATP or remained unprimed. Equal aliquots of primed and 
unprimed peroxisomes (30 ug of protein per aliquot) were treated with 30 p.g of trypsin 
or 1 M NaCl for 30 min on ice. Peroxisomes were then osmotically lysed and subjected 
to centrifugation. The pellet of membranes recovered after such centrifugation was 
solubilized with a detergent, n-octyl-|3-D-glucopyranoside. Detergent-soluble membrane 
proteins were analyzed by protein-lipid overlay assay using commercial PIP-Strips. 
Lipid-binding proteins were visualized by autoradiography. 
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3.3.3 During peroxisome priming, GTP-binding proteins are permanently 
attached, through non-electrostatic interactions, only to the cytosolic surface 







































Figure 3.3. Testing the ability of PI- and P2-associated proteins to bind to GTP and 
assessing the topology of the association of GTP-binding proteins (GTP-bp) with PI 
during its priming. Unlabeled intact PI and P2 were primed individually by incubation 
with unlabeled cytosol and ATP or remained unprimed. Equal aliquots of primed and 
unprimed peroxisomes (30 \ig of protein per aliquot) were treated with 30 ug of trypsin 
or 1 M NaCl for 30 min on ice. Peroxisomes were then osmotically lysed and subjected 
to centrifugation. The pellet of membranes recovered after such centrifugation was 
solubilized with a detergent, n-octyl-P-D-glucopyranoside. Detergent-soluble membrane 
proteins were analyzed by GTP slot-blot with guanosine 5'-[a-32P]triphosphate. GTP-bp 
were visualized by autoradiography. 
3.4 Discussion 
My data provide evidence that priming of both fusion partners requires 1) cytosolic 
proteins; 2) ATP hydrolysis; 3) a particular type of AAA ATPase (Pexlp for PI and 
Pex6p for P2); 4) ergosterol; and 5) PI(4)P and PI(4,5)P2 (Figure 3.1). However, priming 
of PI and P2 does not depend on GTP hydrolysis (Figure 3.1). 
The observed susceptibility of peroxisome fusion to anti-PI(4)P and anti-PI(4,5)P2 
antibodies suggests that PI(4)P- and PI(4,5)P2-binding proteins (bp) associate with PI 
and/or P2. Using PIP-Strips spotted with various phosphoinositides and phospholipids, 1 
demonstrated that membrane proteins of PI and P2 solubilized with a detergent, n-octyl-
P-D-glucopyranoside (n-OG), bind only to PI(4)P and PI(4,5)P2 but not to any other 
phosphoinositide or phospholipid tested (Figure 3.2). PI(4)P- and PI(4,5)P2-bp of intact 
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peroxisomes were sensitive to digestion by external protease and were completely 
solubilized by 1 M NaCl (Figure 3.2). Thus, these proteins are attached to the cytosolic 
surfaces of PI and P2 through electrostatic interactions. Importantly, I found that neither 
PI(4)P- nor PI(4,5)P2-bp release from the outer faces of PI and P2 during their priming 
(Figure 3.2). 
Peroxisome fusion was sensitive to nonhydrolyzable GTP analogs, suggesting the 
involvement of PI- and/or P2-attached GTP-binding and hydrolyzing proteins in this 
process. The association of GTP-bp with PI was confirmed by GTP slot-blot (Figure 
3.3). The observed susceptibility of the PI-attached GTP-bp to digestion by trypsin added 
to intact PI and the inability of 1 M NaCl to solubilize the GTP-bp (Figure 3.3) imply 
that the association of GTP-bp with the outer face of PI is not due to electrostatic 
interactions. Importantly, I found that GTP-bp does not release from the outer face of P1 
vesicles during its priming (Figure 3.3). 
3.5 Conclusions 
Altogether, my findings provide evidence that the release of AAA ATPases Pexlp and 
Pex6p from the cytosolic surfaces of PI and P2 peroxisomes, a hallmark event of 
peroxisome priming for docking, requires ergosterol, PI(4)P, PI(4,5)P2, cytosolic proteins 
and ATP hydrolysis but does not depend on GTP hydrolysis. Furthermore, both fusion 
partners have PI(4)P and PI(4,5)P2-bp attached to their outer faces. Moreover, the 
cytosolic surface of PI (but not of P2) carries GTP-bp. It should be stressed that neither 
PI(4)P-, PI(4,5)P2- nor GTP-bp dissociate from the cytosolic surfaces of PI and P2 
during their priming for docking, suggesting that they might be required on the 
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subsequent membrane docking and/or merging steps of the peroxisome fusion process. 
The importance of PI(4)P-, PI(4,5)P2- nor GTP-bp in membrane docking and merging is 
addressed in the following chapters of the thesis. 
4 Dynamics of peroxisome docking 
4.1 Introduction 
Following their priming, peroxisomes PI and P2 form a stable docking complex, called 
P1/P2, in the presence of ATP and cytosolic proteins [62, 63]. The docking of PI and P2 
is characterized by the release of Pexlp from the surface of P2, which is driven by ATP 
hydrolysis and requires cytosolic proteins [62]. The formation of the docking complex 
P1/P2 can be reconstituted in vitro by first individually priming PI and P2 with ATP and 
cytosol and then incubating the pre-primed fusion partners together in the presence of 
ATP and cytosol [62, 63]. The P1/P2 docking complex can then be separated from 
undocked PI and P2 peroxisomes, as well as from the fusion product P3, by flotation on a 
multistep sucrose gradient [62, 63]. The requirements for docking of PI and P2 can 
therefore be evaluated using a previously described in vitro assay, in which the efficiency 
of peroxisome docking for fusion is assessed by monitoring the extent of the recovery of 
P1/P2 in the flotation gradient [62, 63]. In addition, by evaluating the effect of various 
compounds on the release of Pexlp from individually pre-primed P2 following their 
addition to separately pre-primed PI, the requirements for this hallmark event of 
peroxisome docking for fusion can be established. 
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4.2 Materials and methods 
In vitro assay for peroxisome docking 
PI and P2 vesicles were individually preprimed by incubation in PF buffer (15 mM MES, 
pH 6.0, 100 mM KC1, 50 mM KOAc, 3 mM MgCl2, 2 mM MgOAc) containing 250 mM 
sorbitol, 1 mg cytosol/ml, 1 mM ATP, 40 mM creatine phosphate, and 10 U creatine 
kinase/ml. After incubation for 10 min at 26°C, peroxisomal vesicles were pelleted by 
centrifugation at 100,000 x g for 5 min at 4°C in a TLA 120.2 rotor, resuspended in ice-
cold PF buffer containing 250 mM sorbitol, and repelleted. Peroxisomal vesicles were 
then resuspended in PF buffer supplemented with 250 mM sorbitol and incubated 
individually with or without 300 pg nystatin/ml, 80 uM phosphoinositide-specific 
monoclonal antibodies, 2 mM GTPyS or 1 mM ATPyS, in the presence or absence of 1 
mg cytosol/ml, as indicated. After incubation for 5 min at 26°C, PI and P2 were mixed 
and supplemented with 1 mM ATP, 40 mM creatine phosphate and 10 U creatine 
kinase/ml. After a 10-min incubation at 26°C, a 80-pl sample of peroxisomal vesicles was 
transferred to the bottom of a 5-ml ultraclear centrifuge tube (Beckman) and 
supplemented with 4 volumes of 62.5% (w/w) sucrose in ice-cold PF buffer in order to 
adjust the sucrose concentration of the sample to 50% (w/w). The sample was then 
overlaid with 500 pi of 30% sucrose, 600 pi of 28% sucrose, 1 ml of 26% sucrose, 1 ml 
of 24% sucrose, 1 ml of 22% sucrose, and 500 pi of 10% sucrose (all w/w in PF buffer). 
After centrifugation at 200,000 x g for 18 h at 4°C in a SW50.1 rotor (Beckman), 9 
fractions of 555 pi each were collected. Proteins recovered in equal volumes of gradient 
fractions were precipitated by adding 6 volumes of acetone, resolved by SDS-PAGE, and 
then visualized by immunoblotting with anti-Pexlp, anti-Pexl6p and anti-thiolase 
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antibodies. Equal volumes of gradient fractions were also subjected to the protein-lipid 
overlay assay, GTP slot-blot, lipid extraction, and thin-layer chromatography. 
In vitro assay of association of Pexlp with P2 during peroxisome docking 
PI and P2 were individually preprimed by incubation with cytosol and ATP for 10 min at 
26°C. Peroxisomal vesicles were then reisolated by centrifugation, washed, and 
resuspended in buffer. Reisolated PI and P2 were incubated individually for 5 min at 
26°C with or without ergosterol ligands, phosphoinositide-specific antibodies, ATPyS, or 
nonhydrolyzable GTP analogs in the presence or absence of cytosol, as indicated. P1 and 
P2 were then mixed and supplemented with ATP. Following a 10-min incubation at 
26°C, peroxisomal vesicles were subjected to centrifugation to yield supernatant and 
pellet fractions. Recovered proteins were resolved by SDS-PAGE and immunoblotted 
with antibodies to Pexlp. 
In vitro assay of association of lipid- and GTP-bp with PI and P2 during 
peroxisome docking 
Intact PI and P2, either labeled with Z-[35S]methionine or unlabeled, were primed 
individually by incubation with cytosol and ATP for 10 min at 26°C. Peroxisomal 
vesicles were then reisolated by centrifugation, washed, and resuspended in buffer. 
Preprimed PI and P2 were mixed and supplemented with ATP. After a 10-min incubation 
at 26°C, peroxisomal vesicles were osmotically lysed and subjected to centrifugation to 
yield supernatant (matrix proteins) and pellet (membrane proteins) fractions. Pelleted 
membrane proteins were solubilized with a detergent, n-OG. Detergent-soluble 
membrane proteins were analyzed by protein-lipid overlay assay using commercial PIP-
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Strips or by GTP slot-blot with guanosine 5'-[a- Pjtriphosphate. Lipid- and GTP-binding 
proteins were visualized by autoradiography. 
To evaluate the requirements for the release of PI(4,5)P2-bp from PI and P2 during 
peroxisome priming, I-[35S]methionine-labeled PI and P2 were individually preprinted 
by incubation with cytosol and ATP for 10 min at 26°C. Peroxisomal vesicles were then 
reisolated by centrifugation, washed, and resuspended in buffer. Reisolated PI and P2 
were incubated individually for 5 min at 26°C with or without nystatin, GTPyS, ATPyS, 
or anti-Pexlp antibodies in the presence or absence of cytosol, as indicated. PI and P2 
were then mixed and supplemented with ATP. Following a 10-min incubation at 26°C, 
peroxisomal vesicles were osmotically lysed and subjected to centrifugation to yield 
supernatant (matrix proteins) and pellet (membrane proteins) fractions. Pelleted 
membrane proteins were solubilized with n-OG. Detergent-soluble membrane proteins 
were analyzed by protein-lipid overlay assay using commercial PIP-Strips. Lipid-binding 
proteins were visualized by autoradiography. 
41 
4.3 Results 
4.3.1 Peroxisome docking requires ergosterol, PI(4,5)P2, cytosolic proteins and the 
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Figure 4.1. Peroxisome docking is inhibited by the ergosterol ligand nystatin, antibodies 
specific to PI(4,5)P2, absence of cytosol, nonhydrolyzable GTP analogue GTP'/S and 
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nonhydrolyzable ATP analogue ATP'/S. PI and P2 were individually preprimed by 
incubation with cytosol and ATP for 10 min at 26°C. Peroxisomal vesicles were then 
reisolated by centrifugation, washed, and resuspended in buffer. Reisolated PI and P2 
were incubated individually for 5 min at 26°C with or without nystatin, phosphoinositide-
specific monoclonal antibodies, GTPyS, or ATPyS in the presence or absence of cytosol, 
as indicated. PI and P2 were then mixed and supplemented with ATP. After a 10-min 
incubation at 26°C, peroxisomal vesicles were subjected to fractionation by flotation on a 
multistep sucrose gradient. The percent recovery of loaded protein is presented. Equal 
volumes of gradient fractions were analyzed by immunoblotting with anti-Pexl6p and 
anti-THI antibodies. The peak fractions for PI and P2, their docking complex (P1/P2) 
and the product of their fusion (P3) are indicated. The positions of pTHI, which was 
found in P2 and P1/P2, and of mTHI, which was associated with P3, are shown. 
4.3.2 The docking-specific release of P2-associated Pexlp from the membrane to 
the cytosol depends on ergosterol, cytosolic proteins, and the hydrolysis of 
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Figure 4.2. The docking-specific release of Pexlp from P2 to the cytosol is inhibited by 
several ergosterol ligands, the absence of cytosol, nonhydrolyzable analogues of ATP and 
GTP, but not by antibodies specific to PI(4)P or PI(4,5)P2. PI and P2 were individually 
preprimed by incubation with cytosol and ATP for 10 min at 26°C. Peroxisomal vesicles 
were then reisolated by centrifugation, washed, and resuspended in buffer. Reisolated PI 
and P2 were incubated individually for 5 min at 26°C with or without ergosterol ligands, 
phosphoinositide-specific antibodies, ATPyS, or nonhydrolyzable GTP analogs in the 
presence or absence of cytosol, as indicated. PI and P2 were then mixed and 
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supplemented with ATP. Following a 10-min incubation at 26°C, peroxisomal vesicles 
were subjected to centrifugation to yield supernatant (S) and pellet (P) fractions. 
Recovered proteins were resolved by SDS-PAGE and immunoblotted with antibodies to 
Pexlp. 
4.3.3 Docking-specific dissociation of PI(4,5)P2-bp from the membranes of both 
fusion partners depends on ergosterol, GTP hydrolysis, cytosolic proteins, 
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Figure 4.3. Docking-specific dissociation of PI(4,5)P2-bp from the membranes of both 
fusion partners (A) is inhibited by the ergosterol ligand nystatin, the absence of cytosol, 
nonhydrolyzable analogues of ATP and GTP, and antibodies specific to Pexlp (B). (A) 
Intact PI and P2 labeled with I-[35S]methionine were primed individually by incubation 
with cytosol and ATP for 10 min at 26°C. Peroxisomal vesicles were then reisolated by 
centrifugation, washed, and resuspended in buffer. Preprimed PI and P2 were mixed and 
supplemented with ATP. After a 10-min incubation at 26°C, peroxisomal vesicles were 
osmotically lysed and subjected to centrifugation to yield supernatant (matrix proteins) 
and pellet (membrane proteins) fractions. Pelleted membrane proteins were solubilized 
with a detergent, n-OG. Detergent-soluble membrane proteins were analyzed by protein-
lipid overlay assay using commercial PIP-Strips. Lipid-binding proteins were visualized 
by autoradiography. (B) Z,-[35S]methionine-labeled PI and P2 were individually 
preprimed by incubation with cytosol and ATP for 10 min at 26°C. Peroxisomal vesicles 
were then reisolated by centrifugation, washed, and resuspended in buffer. Reisolated P1 
and P2 were incubated individually for 5 min at 26°C with or without nystatin, GTPyS, 
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ATPyS, or anti-Pexlp antibodies in the presence or absence of cytosol, as indicated. PI 
and P2 were then mixed and supplemented with ATP. Following a 10-min incubation at 
26°C, peroxisomal vesicles were osmotically lysed and subjected to centrifugation to 
yield supernatant (matrix proteins) and pellet (membrane proteins) fractions. Pelleted 
membrane proteins were solubilized with n-OG. Detergent-soluble membrane proteins 
were analyzed by protein-lipid overlay assay using commercial PIP-Strips. Lipid-binding 
proteins were visualized by autoradiography. 
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Figure 4.4. During docking of primed PI and P2, GTP-bp do not dissociate from the 
surface of PI. Unlabeled intact PI and P2 were primed individually by incubation with 
cytosol and ATP for 10 min at 26°C. Peroxisomal vesicles were then reisolated by 
centrifugation, washed, and resuspended in buffer. Preprimed PI and P2 were mixed and 
supplemented with ATP. After a 10-min incubation at 26°C, peroxisomal vesicles were 
osmotically lysed and subjected to centrifugation to yield supernatant (matrix proteins) 
and pellet (membrane proteins) fractions. Pelleted membrane proteins were solubilized 
with a detergent, n-OG. Detergent-soluble membrane proteins were analyzed by GTP 
slot-blot with guanosine 5'-[ot-32P]triphosphate. GTP-binding proteins were visualized by 
autoradiography. 
4.4 Discussion 
I found that the formation of the P1/P2 docking complex between primed PI and P2 was 
compromised when primed peroxisomes PI and P2 were individually treated with the 
ergosterol ligand nystatin, monoclonal antibodies to PI(4,5)P2, GTP1S, ATP7S, or in the 
absence of cytosol, prior to being mixed to initiate their docking (Figure 4.1). These 
findings suggest that the peroxisome docking process cannot proceed without ergosterol, 
PI(4,5)P2, GTP hydrolysis, ATP hydrolysis and cytosolic proteins. Furthermore, I 
demonstrated that the release of Pexlp from P2 to the cytosol, a hallmark event of 
peroxisome docking, requires ergosterol, cytosolic proteins, ATP and GTP hydrolysis, 
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but does not depend on PI(4)P- or PI(4,5)P2-bp (Figure 4.2). In addition, I found that 
PI(4,5)P2-bp, but not PI(4)P-bp, dissociated from the outer faces of both fusion partners 
during the docking process (Figure 4.3A), and that this release depends on ergosterol, 
hydrolysis of ATP and GTP, cytosolic proteins, as well as Pexlp (Figure 4.3B). In 
contrast, GTP-bp remained associated to the outer face of PI peroxisomes during and 
after the docking process (Figure 4.4), suggesting that GTP hydrolysis might be required 
for the fusion of docked PI and P2. Of note, studies of vacuole fusion in yeast provided 
evidence that the docking step of vacuole fusion may trigger a GTPase-regulated Ca2+ 
release from the vacuole. This, in turn, promotes the recruitment of calmodulin, a calcium 
sensor protein, to the vacuole and its complex formation with phosphatase 1, thereby 
activating a downstream signaling cascade that leads to membrane fusion [144, 145]. 
4.5 Conclusions 
Using the in vitro docking assay for evaluating the recovery of the P1/P2 docking 
complex following the treatment of primed P1 and P2 with various inhibitors of the 
overall process of peroxisome fusion, I provided evidence that peroxisome docking 
depends on 1) ATP hydrolysis; 2) cytosolic proteins; 3) P2-bound Pexlp; 4) ergosterol; 
5) PI(4,5)P2; and 5) GTP hydrolysis by GTPase(s). In contrast, the docking of primed PI 
and P2 does not require PI(4)P. My data also demonstrated that only PI(4,5)P2-bp 
dissociate from the outer faces of both fusion partners during the docking process, and 
that such dissociation depends on ergosterol, ATP and GTP hydrolysis, cytosolic 
proteins, as well as Pexlp. On the contrary, GTP-bp remain associated with the cytosolic 
face of PI peroxisomes during and after their docking with primed P2, suggesting a 
possible involvement of these proteins in the subsequent fusion of docked PI and P2. 
46 
5 Ergosterol- and ceramide-rich domains in the peroxisomal membrane 
5.1 Introduction 
Cholesterol in mammals and ergosterol in yeasts are the major constituents of lipid rafts, 
dynamic domains of the plasma membrane that have been implicated in membrane 
protein trafficking, signal transduction, organization of the cytoskeleton, and pathogen 
internalization [123, 147, 149, 150]. My observation that ergosterol ligands prevent the 
release of Pexlp and Pex6p from PI and P2 vesicles, thereby inhibiting their priming and 
docking for fusion, suggests that ergosterol-rich domains, perhaps lipid raft(s), in the 
membranes of PI and P2 carry both these AAA ATPases and somehow activate the 
peroxisome fusion machinery. Lipid rafts are defined operationally as membrane 
domains that are insoluble in cold nonionic detergents and are enriched in sterols, 
sphingolipids and glycolipids [147]. To verify the existence of such domains in the 
membranes of PI and P2 and to purify them for further characterization, I solubilized the 
membranes of unprimed PI and P2 with Brij35, a nonionic detergent with the highest 
hydrophilic-lipophilic (HLB) ratio, and then isolated the detergent-resistant membrane 
domains by centrifugation on a discontinuous sucrose density gradient. These purified 
membrane domains of PI and P2 were rich in ergosterol and ceramide. I therefore call 
them the ergosterol- and ceramide-rich (ECR) membrane domains. Following their 
purification, ECR domains were visualized by electron microscopy and subjected to a 
detailed analysis of their protein and lipid composition. My mass spectrometric analysis 
identified Pexlp and Pex6p as abundant constituents of ECR domains in the peroxisomal 
membrane. 
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5.2 Materials and methods 
Osmotic lysis of peroxisomes 
PI and P2 peroxisomes were lysed by incubation on ice for 20 min in LC buffer (20 mM 
HEPES-KOH (pH 8.0) and 50 mM NaCl). 
Detergent treatment of peroxisomal membranes 
The pellet of membranes recovered after centrifugation of osmotically lysed PI or P2 was 
resuspended in ice-cold MBS buffer (25 mM MES-KOH, pH 6.5, 150 mM NaCl) to a 
final concentration of 2 mg/ml. Equal aliquots of the suspension of membranes were then 
supplemented with one of the following detergents: Brij 30, Brij 35, Brij 72, Brij 96V, 
CHAPS, cholic acid (sodium salt), n-octyl-B-D-glucopyranoside (n-OG), Triton X-100, 
and Tween 20. 5 mg of detergent was used for the treatment of 1 mg of peroxisomal 
membrane protein. After incubation on ice for 30 min, samples were subjected to 
centrifugation at 100,000 x g for 30 min at 4°C. Equal portions of the pellet and 
supernatant fractions were analyzed by SDS-PAGE, followed by immunoblotting or 
silver staining. Equal portions of both fractions were also subjected to protein-lipid 
overlay assays, GTP slot-blot, lipid extraction, and thin-layer chromatography (TLC). 
Isolation of ECR membrane domains 
Peroxisomes PI and P2 were osmotically lysed and centrifuged. The membrane pellets 
were then resuspended in ice-cold MBS buffer (25 mMMES/KOH, pH 6.5, and 150 mM 
NaCl) to a final concentration of 2 mg/ml, supplemented with Brij 35 detergent (5mg of 
detergent/mg of peroxisomal membrane protein), and incubated on ice for 30 min. A 300 
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jj,l-aliquot of Brij 35-treated membranes was transferred to the bottom of a 5 ml Ultraclear 
centrifuge tube (Beckman Coulter) and supplemented with four volumes of 65% (wt/wt) 
sucrose in ice-cold MBS buffer in order to adjust the sucrose concentration of the sample 
to 52% (wt/wt). The sample was overlaid with 600 ul of 30% sucrose, 600 ul of 25% 
sucrose, 600 ul of 20% sucrose, 600 ul of 15% sucrose, 600 ul of 10% sucrose, and 500 
ul of 5% sucrose (all wt/wt in MBS buffer). The sample was then centrifuged for 18 h at 
200,000 g at 4°C using a SW50.1 rotor (Beckman Coulter). Nine fractions of 555 ul each 
were collected. Peroxisomal proteins recovered in equal volumes of gradient fractions 
were precipitated by adding six volumes of acetone, resolved by SDS-PAGE, and 
visualized by immunoblotting or silver staining. Equal volumes of gradient fractions were 
also used for the protein-lipid overlay assay, GTP slot-blot, lipid extraction, and TLC. 
Electron microscopy 
Detergent-resistant ECR domains floated to low density during centrifugation in a 
sucrose density gradient and peaked in fraction 7 of the gradient. A 200-ul aliquot of 
purified ECR domains in MBS buffer (25 mM MES/KOH, pH 6.5, and 150 mM NaCl) 
was mixed with 400 ul of ice-cold 150 mM sodium cacodylate buffer, pH 7.2, containing 
3% glutaraldehyde. Immediately after mixing the sample and glutaraldehyde solution, 
600 ul of 2% Os04 in ice-cold CD buffer (100 mM sodium cacodylate, pH 7.2) was 
added. After a 2-h incubation on ice, fixed ECR domains were sedimented at 100,000 x g 
for 20 min at 4°C in a Beckman TLS55 rotor onto a bed (25-50 ul) of hardened, low-
melting 2.5% NuSieve GTG agarose (FMC). The pellet was postfixed in a solution of 1 % 
OsQ4 plus 2.5% K2Cr207 in ice-cold CD buffer for 2 h on ice. The pellet was then rinsed 
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twice with ice-cold CD buffer and exposed to 0.05% tannic acid in the same buffer. After 
a 30-min incubation on ice, the pellet was washed once with ice-cold CD buffer and three 
times with water. The pellet was incubated overnight with 2% uranyl acetate in water at 
4°C and then washed three times with water. After dehydration in a graded ethanol series, 
the fixed and stained sample was embedded in Poly/Bed 812 epoxy resin (Polysciences). 
Silver/gold thin sections from the embedded blocks were examined in a JEOL JEM-
2000FX transmission electron microscope. 
Lipid analyses 
For extraction of lipids, 1.2 ml of chloroform/methanol (1:1, v/v) were added to each of 
the 555-ul fractions recovered in the sucrose density gradient for isolation of ergosterol-
and ceramide-rich membrane domains. After incubation on ice for 15 min, samples were 
subjected to centrifugation at 20,000 x g for 15 min at 4°C. The chloroform phase was 
separated and dried under nitrogen. The lipid film was dissolved in 60 p.1 of chloroform 
(for the analysis of ergosterol and ceramide) or 60 \i\ of chloroform/methanol (1:1, v/v) 
(for the analysis of glycerophospholipids). 20 u.1 of each sample were spotted on 60A 
silica gel plates for TLC (Whatman). The lipids were developed in the following solvent 
systems: chloroform/acetone (4:1, v/v) (for the analysis of ergosterol and ceramide) and 
chloroform/methanol/water (65:25:4, v/v) (for the analysis of glycerophospholipids). All 
lipids were detected using 5% phosphomolybdic acid in ethanol and visualized by heating 
for 30 min at 110°C. Lipids were quantitated by densitometric analysis of TLC plates as 
described previously [151], using lipid standards in the 0.1-0.5 jig range for calibration. 
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To evaluate the distribution of ceramide and PS between the two leaflets of the 
membrane bilayers of PI and P2 vesicles, the suspension of purified PI or P2 in ice-cold 
buffer H (10 mM MES-KOH, pH 5.5, 250 raM sorbitol, 1 mM KC1, 0.5 mM EDTA, 1 x 
protease inhibitor cocktail [PIC] [84]) at 1 mg protein/ml was divided into two equal 
aliquots. One aliquot remained untreated, whereas peroxisomal vesicles in the other 
aliquot were lysed by incubation on ice for 20 min in 20 mM HEPES-KOH buffer, pH 
8.0, containing 50 mM NaCl and 1 x PIC. The pellet of membranes recovered after 
centrifugation of osmotically lysed PI or P2 was resuspended in ice-cold buffer H at 1 
mg protein/ml. Two-fold serial dilutions of intact PI or P2 vesicles (from the first 
aliquot) and of the membranes recovered after osmotic lysis of these vesicles (from the 
second aliquot) in the range of 10-160 ug protein/ml were made in ice-cold buffer H. 
Anti-ceramide mouse IgG or anti-PS mouse IgM were added to concentrations 0.5 and 1 
ug/ml, respectively. After incubation for 30 min on ice, samples were subjected to 
centrifugation at 100,000 x g for 8 min at 4°C. The pellets were resuspended in 200 ul of 
ice-cold buffer H and supplemented with fluorescein-conjugated goat anti-mouse IgG or 
fiuorescein-conjugated goat anti-mouse IgM antibodies at 2.5 and 5 ug/ml, respectively. 
After incubation for 30 min on ice, samples were subjected to centrifugation at 100,000 x 
g for 8 min at 4°C. The pellets were resuspended in 200 ul of ice-cold buffer H and 
supplemented with Alexa Fluor 488 rabbit anti-fluorescein/Oregon Green IgG at 15 
ug/ml. Following incubation for 30 min on ice, samples were subjected to centrifugation 
at 100,000 x g for 8 min at 4°C. The pellets were resuspended in 200 ul of ice-cold buffer 
H and supplemented with Alexa Fluor 488 goat anti-rabbit IgG at 20 ug/ml. After 
incubation for 30 min on ice, samples were subjected to centrifugation at 100,000 x g for 
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8 min at 4°C. The pellets were resuspended in 200 JJ.1 of ice-cold buffer H and placed into 
the wells of a 96-well microplate. The fluorescence of samples was measured using the 
Wallac Victor 2 Multi-label microplate fluorescence reader with filters set at 485 (+/- 7.5) 
nm (excitation) and 510 (+/- 5) nm (emission). Controls were made for each dilution of 
intact PI and P2 and of peroxisomal membranes recovered after osmotic lysis of these 
peroxisomal vesicles. The controls included normal mouse IgG or IgM at 0.5 and 1 
ug/ml, respectively, added instead of anti-ceramide mouse IgG or anti-PS mouse IgM. 
Background fluorescence, which was due to the nonspecific binding of mouse IgG, 
mouse IgM, and/or fluorescein- or Alexa Fluor 488-labeled antibodies to the peroxisomal 
membrane, was subtracted. 
Protein identification by mass spectrometry 
Proteins were precipitated by adding trichloroacetic acid to the final concentration of 
10%, incubated on ice for 30 min, pelleted by centrifugation, and then washed with ice-
cold 80% acetone. Dried protein pellets were then resuspended in the SDS-PAGE sample 
buffer and the pH was adjusted to neutral using 2 M Tris/HCl (pH 8.8). The samples were 
boiled for 5 min at 63°C, centrifuged for 30 sec at 16,000 x g, loaded onto a 7.5%, 10%, 
12.5% or 16% gel and resolved by SDS-PAGE. Following an overnight incubation of the 
gels in 50% methanol, proteins were visualized by silver staining using the mass 
spectrometry-compatible silver staining kit (Bio-Rad Silver Staining Plus) according to 
the manufacturer's instructions. To optimize subsequent mass spectrometry analysis, two 
modifications were made to the original procedure: the fixing step was reduced to 10 min 
and the staining step was terminated no later then 10 min following its beginning. The 
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protein bands of interest were excised from the silver-stained gel using razor blades along 
with a piece of a gel lacking proteins to be used as a control sample. The excised bands 
were cut into pieces (1mm3) and then placed into siliconized 0.5 ml Eppendorf tubes. The 
gel pieces were then washed with distilled water and destained for 30 min at room 
temperature. The destaining solution was then removed and the gel pieces were washed 
twice with distilled water. The gel pieces were subsequently dehydrated by incubation in 
acetonitrile for 5 min at 37°C and dried at 37°C for 10 min to remove any residual 
acetonitrile. The proteins were then reduced by incubation in 10 mM DTT for 30 min at 
37°C and alkylated by incubation in 55 mM IAA in the dark for 20 min at 37°C. Reduced 
and alkylated proteins were then dehydrated twice by 5-min incubation in acetonitrile at 
37°C and dried for 10 min at 37°C to remove any residual acetonitrile. The proteins were 
then subjected to trypsin digestion. Following a 6-hr incubation at 37°C, the supernatants 
containing the majority of the peptides were placed in a new set of siliconized 0.5 ml 
Eppendorf tubes and the remaining peptides were extracted from the gel pieces first by 
incubation in 50% acetonitrile and then by incubation in 5% formic acid pre-mixed with 
an equal volume of acetonitrile. The pooled peptide extracts for each sample were 
supplemented with a 10 mM DTT solution to a final concentration of 1 mM in order to 
reduce oxidation during the subsequent drying and storage steps. The peptide extracts 
were dried overnight in the SpeedVac centrifuge at room temperature ('Low' temperature 
setting). The peptide extracts were then resuspended in 10 ul of the 5% methanol, 0.1% 
TFA solution and desalted using a CI8 ZipTip (Millipore), according to the 
manufacture's instructions. Desalted peptides were then mixed in 1:1 ratio with the 
matrix solution, spotted on the MALDI plate, dried and subjected to mass spectrometric 
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analysis of peptide masses by MALDI [154, 155]. Three standard peptides (i.e., 
angiotensin I, glufibrinopeptide and ACTH, all from Sigma) premixed with the matrix 
solution in 1:1 ratio were used to calibrate the Micromass M@LDI Mass Spectrometer 
(Micromass) prior to sample analysis. The mass spectrometer operated in the positive ion 
mode with an added reflection feature. The following instrumental settings were used to 
optimize the reflection/positive mode operation: 1) the pulse voltage, which has been 
optimized for the highest resolution of peptides, was 2375 V; 2) the source voltage used 
for the ion acceleration was set at 15000 V; 3) the reflection voltage used to refract ions 
was set at 2000 V; 4) the detector voltage was set at 1900 V; and 5) the TLF Delay was 
750ms. The laser energy settings were manually adjusted prior to data acquisition in 
order to obtain a good signal to noise ratio for analyte ions and on-scale peaks with 
sustained signal after multiple laser shots. The instrument calibration using the three 
peptide standards mentioned above provided the most accurate mass measurements in the 
range of 1200-2500 m/z. Once calibrated, the mass spectrometer was used to acquire 10-
15 individual mass spectra for each sample spot, which were then combined into one and 
manually analyzed to make a list of sample-specific monoisotopic peptide masses and 
their respective intensities for each recovered peptide. Protein identity was established 
using Mascot Peptide Mass Fingerprinting method (Matrix Science). Sample-specific 
peptide masses were used to search an NCBI database, a non-redundant protein database 
maintained by the National Center for Biotechnology Information (NCBI) that feature 
additional search tools like BLAST (The Basic Local Alignment Search Tool) and Entrez 
(The Life Sciences Search Engine). The search criteria were set as follows: 1) NCBInr as 
the protein sequence database; 2) Saccharomyces cerevisiae as the search-limiting 
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taxonomy group; 3) trypsin as the enzyme used for protein digestion; with up to one 
allowed missed cleavage site; 4) monoisotopic as the peptide mass value used; 5) 
carbamidomethyl (cysteine as S-carbamidomethyl derivate) as a fixed type of the protein 
modification; 6) oxidation (M) (oxidized forms of methionine) as a variable type of the 
protein modification that may have occurred during the sample preparation/handling; 7) 
unrestricted protein mass; 8) peptide mass tolerance of 100 ppm or lower; 9) MH+ as the 
precursor peptide charge state being expected as "1+"; and 10) the experimentally 
generated list of peptide masses as the query, with maximum number of hits set at 50. 
The experimental mass spectrometry data is then compared to the calculated peptide 
masses for each database sequence entry by the Mascot engine using the Mowse scoring 
algorithm, which assigns a probability-based Mowse score for each individual set of 
experimental mass spectrometry data. Based on this probability score, Mascot can then 
provide an objective measure of the significance of a protein hit by defining the cut-off 
score for the calculated protein hit to be significant (i.e. p < 0.05). Only significant 
protein hits with p < 0.05 and sequence coverage > 10% were considered and selected 
based on their molecular weight and the probability-based Mowse score. Pexlp, a 100 
kDa protein, was identified by 12 specific peptide matches (m/z ratio of 700 to 2400) 
covering 15.4% of its sequence with mass accuracy better then 100 ppm. Pex6p, a 116 
kDa protein, was identified by 10 specific peptide matches (m/z ratio of 1000 to 2400) 
covering 14.1% of its sequence with mass accuracy better then 100 ppm. 
5.3 Results 
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5.3.1 Different protein and lipid constituents of the membranes of unprimed PI 
and P2 differ in their solubility in detergents with various HLB values 
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Figure 5.1. Effect of various detergents on the solubility of proteins and lipids associated 
with the membranes of unprimed PI and P2. (A and B) The pellet of membranes 
recovered after centrifugation of osmotically lysed unprimed PI (A) or P2 (B) was 
resuspended in ice-cold MBS buffer. Equal aliquots of the suspension of membranes 
were then exposed to various detergents as described in "Materials and methods". After a 
30-min incubation on ice, samples were subjected to centrifugation at 100,000 x g for 30 
min at 4°C to yield pellet (P, detergent-insoluble) and supernatant (S, detergent-soluble) 
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fractions. Proteins from equal portions of the pellet and supernatant fractions were 
immunoblotted with the indicated antibodies. Equal portions of the pellet and supernatant 
fractions were also subjected to protein-lipid overlay assays using nitrocellulose 
membrane arrays spotted with PI(4)P or PI(4,5)P2, GTP slot-blot, and lipid extraction, 
which was followed by thin-layer chromatography (TLC) and visualization of lipids. (C) 
The extent of insolubility of PI- and P2-bound Pexlp and Pex6p in various nonionic 
detergents of the polyoxyethylene group was quantitated by densitometric analysis of 
immunoblots presented in (A) and (B). The values of hydrophilic-lipophilic balance 
(HLB) for the indicated detergents are from [154]. 
5.3.2 Many membrane proteins of peroxisomes PI and P2 resist solubilization by 
various detergents 
J* # <& 
Figure 5.2. Spectra of detergent-soluble and detergent-insoluble membrane proteins of 
the immature peroxisomal vesicles PI and P2. Unprimed PI (A) or P2 (B) vesicles were 
osmotically lysed and subjected to centrifugation at 4°C to yield supernatant (matrix 
proteins) and pellet (peroxisomal membranes) fractions. Pelleted membranes were 
resuspended in ice-cold MBS buffer. Equal aliquots of the suspension of membranes 
were then exposed to various detergents as described in Supplemental Materials and 
Methods. The samples were subjected to centrifugation at 100,000 x g for 30 min at 4°C 
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to yield pellet (P, detergent-insoluble) and supernatant (S, detergent-soluble) fractions. 
Proteins from equal portions of the pellet and supernatant fractions were analyzed by 
SDS-PAGE and silver staining. 
5.3.3 Membranes of unprimed PI and P2 peroxisomes contain detergent-resistant 
domains that are highly enriched in ergosterol and ceramide and carry key 
components of the peroxisome fusogenic machinery including Pexlp, Pex6p, 
GTP-bp, PI(4)P-bp and PI(4,5)P2-bp 
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Figure 5.3. Pexlp, Pex6p, phosphoinositide- and GTP-binding proteins associate with 
ECR membrane domains that can float to low density during centrifugation in a sucrose 
density gradient. (A and B) The pellet of membranes recovered after centrifugation of 
osmotically lysed unprimed PI (A) or P2 (B) was resuspended in ice-cold MBS buffer 
and supplemented with a nonionic detergent, Brij 35. After incubation on ice for 30 min, 
the Brij 35-treated membranes were subjected to centrifugation by flotation in a 
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discontinuous sucrose density gradient. Proteins from equal volumes of gradient fractions 
were immunoblotted with the indicated antibodies. Equal volumes of gradient fractions 
were also subjected to protein-lipid overlay assays using nitrocellulose membrane arrays 
spotted with PI(4)P or PI(4,5)P2, GTP slot-blot, and lipid extraction, which was followed 
by thin-layer chromatography and visualization of lipids. The positions of Pexlp (arrow) 
and Pex6p (arrowhead), which were identified by mass spectrometric peptide mapping, 
are indicated. (C and D) Electron micrographs of ECR domains recovered in the low-
density fraction 7 of the flotation sucrose density gradients presented in (A) and (B), 
respectively. Bar, 100 nm. 
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Figure 5.4. Lipid concentrations in the total membranes of PI and P2 vesicles. Lipids 
extracted from membranes of unprimed PI and P2 were analyzed by TLC and quantitated 
as described in "Materials and methods". Concentrations of individual lipid species are 
presented in mole percent (mol %). 
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5.3.5 ECR domains in the membranes of unprimed PI and P2 are enriched in 
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Figure 5.5. Lipid concentrations in ECR domains of membranes of PI and P2 vesicles. 
ECR domains were purified as described in "Materials and methods". The mol % 
concentrations of individual lipid species recovered in the low-density fractions 5 to 9 of 
the flotation gradients are shown. Ergosterol/total glycerophospholipids and 
ceramide/total glycerophospholipids ratios for ECR domains were calculated. 
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5.3.6 ECR domains represent a substantial fraction of the membranes of 
unprimed PI and P2 
Unprimed PI Unprimed P2 
] ECR membrane domains IHH Detergent-soluble membrane domains 
Figure 5.6. Lipids and proteins in fractions of the flotation gradients shown in Figure 5.3 
were quantitated. Percent recoveries of lipids and proteins in ECR domains and in 
detergent-soluble portions of the membranes of PI and P2 are presented. 
61 
5.3.7 Ceramide, a sphingolipid component of ECR domains, is distributed 
symmetrically between the two leaflets of the membrane in unprimed PI and 
P2 
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Figure 5.7. Ceramide is distributed symmetrically between the two leaflets of the 
peroxisomal membrane, while phosphatidylserine (PS) associates mostly with the 
cytosolic leaflet. (A-D) A suspension of purified PI or P2 was divided into two equal 
aliquots. One aliquot remained untreated, while peroxisomal vesicles in the other aliquot 
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were osmotically lysed. Two-fold serial dilutions of intact PI or P2 (from the first 
aliquot) and of the membranes recovered after centrifugation of osmotically lysed PI or 
P2 (from the second aliquot) in the range of 10-160 ji.g protein/ml were exposed to anti-
ceramide mouse IgG or anti-PS mouse IgM. All samples were then treated with 
fluorescein-conjugated goat anti-mouse IgG or fluorescein-conjugated goat anti-mouse 
IgM antibodies. To amplify the signals from fluorescein-labeled secondary antibodies, 
the samples were first labeled with Alexa Fluor 488 rabbit anti-fluorescein/Oregon Green 
IgG and then treated with Alexa Fluor 488 goat anti-rabbit IgG. The Alexa Fluor 488 
fluorescence at 510 nm was monitored in individual samples. Controls were made for the 
nonspecific binding of mouse IgG, mouse IgM, and/or fluorescein- or Alexa Fluor 488-
labeled antibodies to the membrane, and background fluorescence was subtracted. (E and 
F) The ratio "fluorescence for intact vesicles (Fi)/fluorescence for osmotically lysed 
vesicles (F0i)" was calculated for each dilution of intact PI and P2 and of the membranes 
recovered after osmotic lysis of these peroxisomal vesicles. This ratio is equal to the 
fraction of the total pool of a monitored lipid that is located in the outer (cytosolic) leaflet 
of the membrane. 
5.4 Discussion 
Treatment with the cold nonionic detergent Brij 35 followed by sucrose density gradient 
centrifugation by flotation allowed me to separate the detergent-insoluble protein and 
lipid constituents of the membranes of unprimed PI and P2 from their detergent-soluble 
counterparts. My analysis of the protein compositions of gradient fractions revealed that 
the PI-bound membrane proteins Pexlp, PI(4)P-bp, PI(4,5)P2-bp and GTP-bp (Figure 
5.3A) as well as the P2-bound membrane proteins Pexlp, Pex6p, PI(4)P-bp and 
PI(4,5)P2-bp (Figure 5.3B) were recovered in the low density fractions (fractions 5-9), 
demonstrating that they resist solubilization by Brij 35 and, thus, reside in distinct 
detergent-resistant membrane domains. In contrast, the peroxisomal membrane proteins 
Pex2p and Pexl6p were recovered in the high density fractions of the gradient (fractions 
1-3), indicating that they were completely solubilized by Brij35 (Figures 5.3A and 5.3B). 
Moreover, I found that the ability of various nonionic detergents of the polyoxyethylene 
group to solubilize Pexlp and Pex6p is inversely proportional to their HLB values 
(Figure 5.1C). Taken together, these findings suggest that the observed propensity of 
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Pexlp, Pex6p, phosphoinositide- and GTP-bp to resist solubilization by Brij 35 was not 
due to an overall lower efficiency of Brij 35 as a detergent, but reflected a specific 
phenomenon. Of note, a nonionic detergent of the nonpolyoxyethylene group, n-octyl-13-
D-glucopyranoside (n-OG), solubilized most of the membrane proteins, including Pexlp 
and Pex6p, that resisted solubilization by Brij 35 and other detergents (Figures 5.1 A, 
5. IB and 5.2). Considering the demonstrated ability of n-OG to preserve the membrane-
bound complexes of cytoskeletal proteins and their interacting protein partners [150], it is 
unlikely that the PI- and P2-bound membrane proteins associate with the cytoskeleton. 
Thus, it seems that the observed insolubility of a distinct set of membrane proteins in Brij 
35 was not due to their interactions with components of the cytoskeleton. 
My TLC analysis of the lipid composition of the Brij 35-treated membranes of PI 
and P2 revealed that the fractions of the flotation gradient that contained detergent-
insoluble proteins were significantly enriched in ergosterol and ceramide but contained 
only minor amounts of glycerophospholipids (Figure 5.3). In contrast, the major portion 
of each of the five glycerophospholipids associated with the membranes of PI and P2 
was soluble in the detergent and was found in the high-density bottom fractions 1 to 3 
(Figure 5.3). Only minor amounts of the glycerophospholipids phosphatidylcholine (PC) 
and phosphatidylserine (PS) and traces of phosphatidylinositol (PI) were seen in the low-
density fractions 6 to 8 enriched in the components of ECR domains, whereas 
phosphatidylethanolamine (PE) and lysophosphatidic acid (LPA) were not found in these 
fractions (Figure 5.3). The Brij 35-insoluble structures purified from the membranes of 
PI and P2 and recovered in the low-density fractions of the gradient appeared as 25- to 
80-nm unilamellar vesicles of varied shape (Figure 5.3C). 
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My detailed analysis of the lipid makeup of the membranes of both fusion partners 
revealed that both ergosterol and ceramide were at high levels in the membranes of 
unprimed PI and P2 (Figure 5.4). Ergosterol constituted 28-32 mol % of lipids in these 
membranes, whereas ceramide was present at 15-17 mol % (Figure 5.4). ECR domains 
were substantially enriched in both these lipids as compared to the total membranes of PI 
and P2 (Figure 5.5). These detergent-resistant membrane domains contained 58-60 mol 
% of ergosterol and 29-31 mol % of ceramide (Figure 5.5). In contrast, ECR domains 
were highly depleted in all five glycerophospholipids (Figure 5.5). Accordingly, 
ergosterol/total glycerophospholipids and ceramide/total glycerophospholipids ratios for 
ECR domains greatly exceeded the ratios for the total membranes of P1 and P2 (Figure 
5.5). My data also imply that ECR domains represent a substantial fraction of the 
membranes of unprimed PI and P2 vesicles, as 47-54 mol % of membrane lipids and 40-
46 % of membrane proteins were recovered in these domains (Figure 5.6). 
In eukaryotic cells, lipids are asymmetrically arranged between the two leaflets of 
the plasma membrane bilayer [123]. Glycolipids and sphingomyelin, the two major 
sphingolipid components of lipid rafts in mammals, and the glycerophospholipid PC 
reside predominantly in the outer (exoplasmic) leaflet of the plasma membrane [123]. In 
contrast, the glycerophospholipids PE, PI and PS are restricted to the inner (cytosolic) 
leaflet of the plasma membrane [123]. Cholesterol, a major sterol constituent of lipid rafts 
in mammals, is equally distributed across the bilayer [142]. Using monoclonal antibodies 
to ceramide and PS, I evaluated the transbilayer distribution of these two lipids in the 
membranes of unprimed PI and P2. In the membranes of osmotically lysed PI and P2, 
both leaflets of the bilayer were accessible to anti-ceramide and anti-PS antibodies 
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(Figure 5.7). In contract, in the membranes of intact PI and P2, these monoclonal 
antibodies could detect only ceramide and PS that resided in the cytosolic leaflet (Figure 
5.7). The levels of ceramide recovered in the membranes of osmotically lysed PI and P2 
exceeded the levels of this sphingolipid detected in intact membranes of both vesicles 
(Figures 5.7A and 5.7C), with about half of the ceramide located in the outer (cytosolic) 
leaflet of the bilayer (Figure 5.7E). I therefore concluded that the sphingolipid component 
of ECR domains is distributed symmetrically between the two leaflets of the membrane 
bilayers in PI and P2. In contrast, the glycerophospholipid PS resides predominantly in 
the outer (cytosolic) leaflets of the membranes of PI and P2. In fact, the vast majority of 
this lipid in intact PI and P2 was accessible to anti-PS antibodies (Figures 5.7B, 5.7D and 
5.7F). 
Taken together, my findings provide evidence for the existence of detergent-
resistant ECR domains in the membranes of unprimed PI and P2 vesicles. These 
domains: 1) contain a distinct set of membrane proteins, including Pexlp, Pex6p and 
several other essential components of the peroxisome fusion machinery; 2) are highly 
enriched, as compared to a detergent-soluble portion of the peroxisomal membrane, in 
ergosterol and ceramide; and 3) differ from well characterized detergent-insoluble lipid 
rafts in the plasma membrane with respect to the nature of their sphingolipid constituent 
and its unusual distribution across the membrane bilayer. Of note, studies in plants 
Arabidopsis thaliana and Allium porrum demonstrated the existence of distinct detergent-
resistant domains in the plasma membrane and Golgi apparatus that, akin to ECR 
domains in the membranes of PI and P2 peroxisomes, are also enriched in sterols, 
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sterylglucosides, and glucosylceramides (GluCer) and contain only minute amounts of 
glycerophospholipids [153]. 
5.5 Conclusion 
In sum, my findings provide the comprehensive evidence for the existence of detergent-
resistant ECR domains in the membranes of unprimedPl and P2 peroxisomes. In contrast 
to a detergent-soluble portion of the peroxisomal membrane, these unique membrane 
domains are highly enriched in ergosterol and ceramide. ECR domains house a distinct 
set of peroxisomal membrane proteins, such as Pexlp and Pex6p, along with several other 
key components of the peroxisome fusogenic machinery, including proteins that bind to 
GTP, PI(4)P and PI(4,5)P2. Furthermore, my data on a symmetrical distribution of the 
ceramide component of ECR domains between the two leaflets of the peroxisomal 
membrane imply that these detergent-resistant domains in the peroxisomal membrane 
differ from the lipid raft domains in the plasma membrane. 
6 Remodeling of ECR domains during peroxisome priming and docking 
6.1 Introduction 
My findings described in chapter 5 of this thesis imply that many essential protein 
components of the peroxisome fusion machinery, including the AAA ATPases Pexlp and 
Pex6p, PI(4)P-bp, PI(4,5)P2-bp and GTP-bp, reside in ECR domains in the membranes of 
unprimed PI and P2 peroxisomes. The release of Pl-bound Pexlp and of P2-associated 
Pex6p from the organelle surface to the cytosol is a hallmark event of the priming of PI 
and P2 [64]. It was unclear if during priming these AAA ATPases are released to the 
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cytosol directly from ECR domains or, alternatively, if they first relocate from ECR 
domains to an ergosterol- and ceramide-poor portion of the membrane and only then 
dissociate from the peroxisome surface. I therefore sought to define the dynamics of 
changes (if any) in the association of Pexlp, Pex6p and other components of the 
peroxisome fusion machinery with ECR domains during peroxisome priming and 
docking. 
6.2 Materials and methods 
Analysis of the remodeling of protein and lipid constituents of ECR domains during 
peroxisome priming 
PI or P2 vesicles were incubated individually with cytosol and ATP at 26°C. Equal 
aliquots of peroxisomal vesicles were taken at different time points. PI and P2 were 
subjected to osmotic lysis, followed by centrifugation. The pellets of membranes 
recovered after such centrifugation were resuspended in ice-cold MBS buffer and 
supplemented with a detergent, Brij 35. After incubation on ice for 30 min, the Brij 35-
treated membranes were subjected to centrifugation by flotation in a discontinuous 
sucrose density gradient. Equal volumes of gradient fractions were subjected to 
immunoblotting with antibodies to peroxisomal membrane proteins, protein-lipid overlay 
assay using nitrocellulose membrane arrays spotted with PI(4)P or P1(4,5)P2, GTP slot-
blot, and lipid extraction, which was followed by TLC and visualization of lipids. 
Analysis of the remodeling of protein and lipid constituents of ECR domains during 
peroxisome docking 
PI and P2 were incubated individually with cytosol and ATP at 26°C. After a 10-min 
incubation, PI and P2 were pelleted, resuspended in a buffer, and mixed. Samples were 
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incubated at 26°C with or without cytosol, ATP, nystatin, GTPyS, ATPyS, antibodies to 
Pexlp or antibodies to PI(4)P. Equal aliquots of peroxisomal vesicles were taken at the 
times indicated. Samples were subjected to osmotic lysis, followed by centrifugation. The 
pellets of membranes recovered after such centrifugation were resuspended in ice-cold 
MBS buffer and supplemented with a detergent, Brij 35. After incubation on ice for 30 
min, the Brij 35-treated membranes were subjected to centrifugation by flotation in a 
discontinuous sucrose density gradient. Equal volumes of gradient fractions were 
subjected to immunoblotting with antibodies to peroxisomal membrane proteins, protein-
lipid overlay assay using nitrocellulose membrane arrays spotted with PI(4)P or 
PI(4,5)P2, GTP slot-blot, and lipid extraction, which was followed by TLC and 
visualization of lipids. 
6.3 Results 
6.3.1 Priming-specific relocation of Pexlp in PI and of Pex6p in P2 from ECR 
domains to a detergent-soluble portion of the membrane requires ergosterol, 
PI(4)P and PI(4,5)P2, whereas the subsequent release of both these AAA 
ATPases into the cytosol depends on ATP hydrolysis and cytosolic proteins 
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Figure 6.1. Pexlp and Pex6p move from detergent-resistant ECR domains to a detergent-
soluble portion of the membrane during peroxisome priming. PI (A) or P2 (B) vesicles 
were incubated individually with cytosol and ATP at 26°C. Equal aliquots of peroxisomal 
vesicles were taken at the times indicated. PI and P2 were subjected to osmotic lysis, 
followed by centrifugation. The pellets of membranes recovered after such centrifugation 
were resuspended in ice-cold MBS buffer and supplemented with a detergent, Brij 35. 
After incubation on ice for 30 min, the Brij 35-treated membranes were subjected to 
centrifugation by flotation in a discontinuous sucrose density gradient. Equal volumes of 
gradient fractions were subjected to immunoblotting with antibodies to peroxisomal 
membrane proteins, protein-lipid overlay assay using nitrocellulose membrane arrays 
spotted with PI(4)P or PI(4,5)P2, GTP slot-blot, and lipid extraction, which was followed 
by TLC and visualization of lipids. The positions of Pexlp (arrow) and Pex6p 
(arrowhead), which were identified by mass spectrometric peptide mapping, are 
indicated. 
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6.3.2 Docking-specific relocation of PI(4,5)P2-bp from ECR domains to an 
ergosterol- and ceramide-poor portion of the membrane requires ergosterol, 
GTP hydrolysis and Pexlp, whereas similar lateral movement of Pexlp along 
the membrane depends on ergosterol only; the subsequent release of Pexlp 
and PI(4,5)P2-bp from ergosterol- and ceramide-poor membrane domains to 
the cytosol requires cytosolic proteins and ATP hydrolysis 
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Figure 6.2. PI(4,5)P2-binding proteins and P2-bound Pexlp segregate from ECR 
domains during peroxisome docking. PI and P2 were incubated individually with cytosol 
and ATP at 26°C. After a 10-min incubation, PI and P2 were pelleted, resuspended in a 
buffer, and mixed. Samples were incubated at 26°C with or without cytosol, ATP, 
nystatin, GTPyS, ATPyS, antibodies to Pexlp or antibodies to PI(4)P. Equal aliquots of 
peroxisomal vesicles were taken at the times indicated. Samples were subjected to 
osmotic lysis, followed by centrifugation. The pellets of membranes recovered after such 
centrifugation were resuspended in ice-cold MBS buffer and supplemented with a 
detergent, Brij 35. After incubation on ice for 30 min, the Brij 35-treated membranes 
were subjected to centrifugation by flotation in a discontinuous sucrose density gradient. 
Equal volumes of gradient fractions were subjected to immunoblotting with antibodies to 
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peroxisomal membrane proteins, protein-lipid overlay assay using nitrocellulose 
membrane arrays spotted with PI(4)P or PI(4,5)P2, GTP slot-blot, and lipid extraction, 
which was followed by TLC and visualization of lipids. 
6.4 Discussion 
The release of PI-bound Pexlp and of P2-associated Pex6p from the organelle surface to 
the cytosol is a hallmark event of the priming of PI and P2 [64]. My findings provide 
evidence that this event includes two consecutive steps. Specifically, both AAA ATPases 
initially relocate from ECR domains to an ergosterol- and ceramide-poor portion of the 
membrane, from which they are then released to the cytosol. In fact, when Brij 35 
extracts of the membranes of unprimed PI and P2 were subjected to centrifugation by 
flotation in a sucrose density gradient, the majority of PI-bound Pexlp and of P2-
associated Pex6p was recovered in detergent-resistant ECR domains (Figures 6.1 A and 
6. IB). However, already by 3 min of priming, both proteins were seen only in detergent-
soluble, ergosterol- and ceramide-poor membrane domains that were recovered in the 
high-density bottom fractions 1 to 3 of the gradient (Figures 6.1 A and 6. IB). By 6 min of 
priming, both AAA ATPases were released from these detergent-soluble domains to the 
cytosol (Figures 6.1 A and 6.IB). The two consecutive steps in the priming-specific 
release of Pexlp and Pex6p from the organelle surface to the cytosol have different 
requirements. Whereas the relocation of both proteins from ECR domains to an 
ergosterol- and ceramide-poor portion of the membrane depends on ergosterol, PI(4)P, 
and PI(4,5)P2, their subsequent release to the cytosol requires cytosolic proteins and ATP 
hydrolysis (Figures 6.1 A and 6.IB). 
I also found that priming of PI and P2 led to dramatic changes in protein 
composition of ECR domains, with the majority of proteins being relocated from these 
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domains to ergosterol- and ceramide-poor domains already by 3 min of priming (Figures 
6.1A and 6.1B). Only a few proteins, including Pl-bound GTP-bp, P2-associated Pexlp 
and proteins that bind PI(4)P or PI(4,5)P2 on the cytosolic faces of both fusion partners, 
remained associated with ECR domains (Figures 6.1 A and 6.IB). On the other hand, the 
lipid repertoire of ECR domains did not undergo any noticeable remodeling during 
priming of PI and P2 (compare Figures 5.3 and 6.1). 
My findings also imply that the docking of preprimed P1 and P2 results in further 
remodeling of the protein repertoire of their ECR domains (Figure 6.2). As I found, by 5 
min of docking, P2-associated Pexlp and proteins that bind PI(4,5)P2 on the cytosolic 
faces of both fusion partners moved from these floating membrane domains to detergent-
soluble, ergosterol- and ceramide-poor domains recovered in the high-density bottom 
fractions of the flotation gradient (Figure 6.2). The movement of Pexlp and PI(4,5)P2-bp 
to a detergent-soluble portion of the membranes was followed by the release of these 
proteins to the cytosol, which was evident after 10 min of docking (Figure 6.2). Not all 
proteins moved away from ECR domains during peroxisome docking. The group of ECR 
resident proteins included PI-associated GTP-bp and proteins that bind PI(4)P on the 
cytosolic faces of both fusion partners (Figure 6.2). Furthermore, no dramatic changes in 
lipid composition of ECR domains were observed during docking of separately primed 
PI and P2 (compare Figs. 6.1 and 6.2). 
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6.5 Conclusions 
My analysis of the dynamics of changes in the association of several essential 
components of the peroxisome fusion machinery with ECR domains and an ergosterol-
and ceramide-poor portion of the membrane during peroxisome priming and docking for 
fusion suggest the following order of events. The priming-specific release of Pexlp from 
PI and of Pex6p from P2 to the cytosol occurs in two consecutive steps. The priming of 
PI is initiated by the relocation of Pexlp from its ECR domains to its ergosterol- and 
ceramide-poor membrane domains, which depends on ergosterol, PI(4)P and PI(4,5)P2-
The subsequent release of Pexlp from the ergosterol- and ceramide-poor membrane 
domains of PI to the cytosol requires cytosolic proteins and ATP hydrolysis. Similarly, 
the priming of P2 commences with the relocation of Pex6p from its ECR domains to its 
ergosterol- and ceramide-poor membrane domains and depends on ergosterol, PI(4)P and 
PI(4,5)P2. The subsequent release of Pex6p from P2 to the cytosol requires cytosolic 
proteins and ATP hydrolysis. Furthermore, peroxisome docking is initiated by the 
relocation of PI(4,5)P2-binding proteins from ECR domains to ergosterol- and ceramide-
poor membrane domains of both fusion partners, and needs ergosterol, GTP hydrolysis 
and Pexlp. The next step of peroxisome docking is characterized by the relocation of 
Pexlp from ECR domains to ergosterol- and ceramide-poor membrane domains of P2, 
which depends on ergosterol. The formation of the P1/P2 docking complex is completed 
by the release of Pexlp and PI(4,5)P2-bp into the cytosol from an ergosterol- and 
ceramide-poor portion of the peroxisomal membrane, which takes place in an ATP 
hydrolysis- and cytosol-dependent fashion. 
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7 Hierarchy of the multi-step remodeling of ECR domains during 
peroxisome priming and docking 
7.1 Introduction 
In order to explore the hierarchy of ergosterol-, PI(4)P-, PI(4,5)P2-, GTP hydrolysis-, 
cytosol-, and ATP hydrolysis-dependent steps during the priming- and docking-specific 
remodeling of the membrane-associated peroxisome fusion machinery, I developed and 
then used a two-stage inhibition assay. This assay examines whether the step affected by 
one inhibitor precedes, occurs in parallel, or follows the step sensitive to another 
inhibitor. For example, in the two-stage assay for the priming-specific movement of Pl-
bound Pexlp and of P2-associated Pex6p from detergent-resistant ECR domains to 
detergent-soluble, ergosterol- and ceramide-poor membrane domains, the fusion partners 
PI and P2 are initially (the first stage) incubated individually with inhibitor 1. Separately 
pretreated PI and P2 vesicles are then reisolated by centrifugation and washed in buffer. 
During the second stage, pretreated and washed peroxisomal vesicles are supplemented 
with inhibitor 2 and the compound that overcomes the block imposed by inhibitor 1. 
After incubation, the effect of the sequential treatment with inhibitors on the monitored 
event, i.e. the relocation of PI-bound Pexlp and of P2-associated Pex6p from ECR 
domains to an ergosterol- and ceramide-poor portion of the peroxisomal membrane, is 
assessed. To evaluate the efficiency of the monitored event, Brij 35-treated membranes of 
PI and P2 are subjected to centrifugation by flotation in a discontinuous sucrose density 
gradient as described in "Materials and methods" in chapter 5 of this thesis, and the 
recovery of Pexlp or Pex6p in gradient fractions is examined by immunoblotting. If the 
step affected by inhibitor 2 precedes the step sensitive to inhibitor 1, or if these steps 
occur in parallel to each other, the requirement for the inhibitor 2-sensitive step must be 
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fulfilled while the inhibitor 1-susceptible step is affected. In this case, the monitored 
event will proceed during the second stage. In contrast, if the step affected by inhibitor 2 
occurs after the step sensitive to inhibitor 1, the monitored event will not proceed during 
the second stage, even in the presence of the compound that overcomes the block 
imposed by inhibitor 1. The same logic can be applied when the two inhibitors are added 
in the reverse order, namely when the exposure to inhibitor 2 precedes the treatment with 
inhibitor 1, which is supplemented together with the compound that overcomes the block 
imposed by inhibitor 2. Based on the results of the sequential treatment with two 
inhibitors added in two different orders, the decisive conclusion about the order of any 
pair of steps, which are sensitive to these inhibitors, can be made. In fact, if step 1 
precedes step 2, the monitored event will be affected only when the exposure to inhibitor 
1 precedes the treatment with inhibitor 2. In contrast, if step 1 follows step 2, the 
monitored hallmark event will be affected only when the exposure to inhibitor 1 follows 
the treatment with inhibitor 2. 
7.2 Materials and methods 
Two-stage assay for establishing the order of individual steps during peroxisome 
priming 
PI or P2 were preincubated individually for 5 min at 26°C with or without nystatin (an 
ergosterol ligand), phosphoinositide-specific monoclonal antibodies, or ATPyS in the 
presence or absence of cytosol. Pretreated peroxisomal vesicles were then reisolated by 
centrifugation, washed, and resuspended in buffer containing liposomes with ergosterol, 
nystatin, phosphoinositides, phosphoinositide-specific antibodies, cytosol, ATPyS, or 
ATP. After a 5-min incubation at 26°C, samples were supplemented with cytosol and 
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ATP to yield standard fusion reactions and incubated at 26°C. Equal aliquots of 
peroxisomal vesicles were taken at different time points. PI and P2 were then pelleted by 
centrifugation. Samples were subjected to osmotic lysis, followed by centrifugation. The 
pellets of membranes recovered after such centrifugation were resuspended in ice-cold 
MBS buffer and supplemented with a detergent, Brij 35. After incubation on ice for 30 
min, the Brij 35-treated membranes were subjected to centrifugation by flotation in a 
discontinuous sucrose density gradient. Proteins recovered in equal volumes of gradient 
fractions were resolved by SDS-PAGE and immunoblotted with antibodies to Pexlp or 
Pex6p. 
Two-stage assay for defining the hierarchy of individual steps during peroxisome 
docking 
PI and P2 were individually preprimed by incubation with cytosol and ATP for 10 min at 
26°C. Peroxisomal vesicles were then reisolated by centrifugation, washed, and 
resuspended in a buffer. Reisolated PI and P2 were incubated individually for 5 min at 
26°C with or without GTPyS, ATPyS or nystatin in the presence or absence of cytosol. PI 
and P2 were then reisolated by centrifugation, washed, and resuspended in buffer 
containing GTP, GTPyS, ATPyS, ATP, liposomes with ergosterol, antibodies to Pexlp, 
or nystatin in the presence or absence of cytosol. After a 5-min incubation at 26°C, PI 
and P2 were mixed and supplemented with cytosol and ATP to yield standard fusion 
reactions. Samples were incubated at 26°C. Equal aliquots of peroxisomal vesicles were 
taken at different time points. PI and P2 were then pelleted by centrifugation. Samples 
were subjected to osmotic lysis, followed by centrifugation. The pellets of membranes 
recovered after such centrifugation were resuspended in ice-cold MBS buffer and 
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supplemented with a detergent, Brij 35. After incubation on ice for 30 min, the Brij 35-
treated membranes were subjected to centrifugation by flotation in a discontinuous 
sucrose density gradient. Proteins recovered in equal volumes of gradient fractions were 
resolved by SDS-PAGE and immunoblotted with antibodies to Pexlp. Equal volumes of 
gradient fractions were also subjected to protein-lipid overlay assays using nitrocellulose 
membrane arrays spotted with PI(4,5)P2. 
7.3 Results 
7.3.1 Priming-specific relocation of Pexlp and Pex6p from ECR domains to 
ergosterol- and ceramide-poor membrane domains of PI and P2 is a multi-
step process in which the ergosterol-dependent step occurs first and is 
followed by the steps requiring PI(4)P and PI(4,5)P2, respectively; the 
subsequent dissociation of both AAA ATPases is initiated by a cytosol-
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Figure 7.1. The hierarchy of peroxisome priming-specific events that result in the 
relocation of Pexlp, Pex6p and PI(4,5)P2-binding proteins from ECR domains to a 
detergent-soluble portion of the membrane, followed by their release to the cytosol. PI 
(A) or P2 (B) vesicles were preincubated individually for 5 min at 26°C with or without 
nystatin (an ergosterol ligand), phosphoinositide-specific monoclonal antibodies, or 
ATPyS in the presence or absence of cytosol, as indicated. Pretreated peroxisomal 
vesicles were then reisolated by centrifugation, washed, and resuspended in buffer 
containing liposomes with ergosterol, nystatin, phosphoinositides, phosphoinositide-
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specific antibodies, cytosol, ATPyS, or ATP, as indicated. After a 5-min incubation at 
26°C, samples were supplemented with cytosol and ATP to yield standard fusion 
reactions and incubated at 26°C. Equal aliquots of peroxisomal vesicles were taken at the 
times indicated. PI and P2 were then pelleted by centrifugation. Samples were subjected 
to osmotic lysis, followed by centrifugation. The pellets of membranes recovered after 
such centrifugation were resuspended in ice-cold MBS buffer and supplemented with a 
detergent, Brij 35. After incubation on ice for 30 min, the Brij 35-treated membranes 
were subjected to centrifugation by flotation in a discontinuous sucrose density gradient. 
Proteins recovered in equal volumes of gradient fractions were resolved by SDS-PAGE 
and immunoblotted with antibodies to Pexlp (A) or Pex6p (B). 
7.3.2 Docking-specific relocation of PI(4,5)P2-bp from ECR domains to ergosterol-
and ceramide-poor membrane domains is a multi-step process in which the 
ergosterol-dependent step occurs first and is followed by the step requiring 
both GTP hydrolysis and Pexlp; the subsequent relocation of Pexlp from 
ECR domains to ergosterol- and ceramide-poor membrane domains of P2 
progresses in an ergosterol-dependent fashion; the following dissociation of 
Pexlp and PI(4,5)P2-bp from the membrane is initiated by a cytosol-
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Figure 7.2. The hierarchy of peroxisome docking-specific events that result in the 
relocation of Pexlp and PI(4,5)P2-binding proteins from ECR domains to a detergent-
soluble portion of the membrane, followed by their release to the cytosol. PI and P2 were 
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individually preprimed by incubation with cytosol and ATP for 10 min at 26°C. 
Peroxisomal vesicles were then reisolated by centrifugation, washed, and resuspended in 
a buffer. Reisolated PI and P2 were incubated individually for 5 min at 26°C with or 
without GTPyS, ATPyS or nystatin in the presence or absence of cytosol, as indicated. PI 
and P2 were then reisolated by centrifugation, washed, and resuspended in buffer 
containing GTP, GTPyS, ATPyS, ATP, liposomes with ergosterol, antibodies to Pexlp, 
or nystatin in the presence or absence of cytosol, as indicated. After a 5-min incubation at 
26°C, PI and P2 were mixed and supplemented with cytosol and ATP to yield standard 
fusion reactions. Samples were incubated at 26°C. Equal aliquots of peroxisomal vesicles 
were taken at the times indicated. PI and P2 were then pelleted by centrifugation. 
Samples were subjected to osmotic lysis, followed by centrifugation. The pellets of 
membranes recovered after such centrifugation were resuspended in ice-cold MBS buffer 
and supplemented with a detergent, Brij 35. After incubation on ice for 30 min, the Brij 
35-treated membranes were subjected to centrifugation by flotation in a discontinuous 
sucrose density gradient. Proteins recovered in equal volumes of gradient fractions were 
resolved by SDS-PAGE and immunoblotted with antibodies to Pexlp. Equal volumes of 
gradient fractions were also subjected to protein-lipid overlay assays using nitrocellulose 
membrane arrays spotted with PI(4,5)P2. 
7.4 Discussion 
Using the two-stage assay for the priming-specific lateral movement of Pexlp and Pex6p 
in the membrane, I found that the ergosterol-dependent step precedes the PI(4)P-requiring 
step. In fact, no such movement was seen when unprimed peroxisomes were initially 
exposed to nystatin, then reisolated, washed and exposed to anti-PI(4)P antibody in the 
presence of ergosterol-containing liposomes that overcome the block imposed by nystatin 
treatment (Figure 7.1). In contrast, when nystatin and anti-PI(4)P antibody were added in 
the reverse order and PI(4)P was used during the second stage to overcome the block 
imposed by anti-PI(4)P antibody, the priming-specific lateral movement of Pexlp and 
Pex6p was not impaired, and both AAA ATPases were successfully released to the 
cytosol (Figure 7.1). Using the two-stage assay, I also established that the PI(4)P-
dependent step during the priming-specific relocation of Pexlp and Pex6p to ergosterol-
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and ceramide-poor domains is followed by the PI(4,5)P2-requiring step (Figure 7.1). 
Moreover, my findings imply that the lateral movement of Pexlp and Pex6p to 
ergosterol- and ceramide-poor membrane domains during peroxisome priming is 
followed by their cytosol- and ATP hydrolysis-dependent release from these domains to 
the cytosol (Figure 7.1). In the two-stage assay, such release of both AAA ATPases was 
impaired when unprimed peroxisomes were initially incubated in the presence of ATP, 
but in the absence of cytosol, then reisolated and exposed to cytosol and the 
nonhydrolyzable analogue ATPyS (Figure 7.1). In contrast, both AAA ATPases were 
successfully released to the cytosol when cytosolic proteins and ATPyS were added in the 
reverse order (Figure 7.1). Thus, the cytosol-dependent step during this priming-specific 
event is a prerequisite for a step that needs ATP hydrolysis. 
Using the two-stage assay for the docking-specific release of Pexlp to the cytosol, 
I also established that the GTP hydrolysis-dependent step precedes a step that requires 
cytosolic proteins. In fact, Pexlp was not released to the cytosol when separately primed 
P1 and P2 were mixed, treated with the nonhydrolyzable analogue GTPyS in the presence 
of cytosol, then reisolated and exposed to GTP, which overcomes the block imposed by 
GTPyS treatment (Figure 7.2). In contrast, the release of Pexlp to the cytosol was not 
compromised when separately primed PI and P2 were mixed, incubated in the absence of 
cytosol, then reisolated and exposed to cytosol and GTPyS (Figure 7.2). Using the two-
stage assay, I also showed that the cytosol-dependent step during the docking-specific 
release of Pexlp to the cytosol is followed by a step that requires ATP hydrolysis (Figure 
7.2). 
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Moreover, I found that, another docking-specific event, the lateral segregation of 
PI(4,5)P2-bp from ECR domains, requires ergosterol, Pexlp and GTP hydrolysis (Figure 
7.2). In the two-stage assay, both the Pexlp- and the GTP hydrolysis-dependent steps 
follow a step that requires ergosterol. Indeed, the PI(4,5)P2-bp did not move to a 
detergent-soluble portion of the membrane when the exposure of separately primed and 
mixed PI and P2 to nystatin preceded the treatment with monospecific antibodies to 
Pexlp or with GTPyS, added together with ergosterol-containing liposomes to overcome 
the block imposed by nystatin exposure (Figure 7.2). Noteworthy, in the beginning of 
peroxisome docking, PI(4,5)P2-bp are attached to both fusion partners, Pexlp can only be 
found on the cytosolic face of P2, and the only GTP-bp that can be detected is the one(s) 
that reside(s) on the outer surface of PI. Together, these findings suggest that the 
docking-specific segregation of PI-bound PI(4,5)P2-bp from ECR domains requires GTP-
bp, whereas such segregation of P2-associated PI(4,5)P2-bp depends on Pexlp. 
The last stage in the process of spatial rearrangement of PI(4,5)P2-bp on the 
cytosolic surfaces of both fusion partners involves their cytosol- and ATP hydrolysis-
dependent release from a detergent-soluble portion of the membrane to the cytosol. Using 
the two-stage assay, I found that the cytosol-dependent step during such release of 
PI(4,5)P2-bp is followed by a step that requires ATP hydrolysis (Figure 7.2). 
7.5 Conclusions 
Altogether, my findings suggest the following model for the multistep remodeling of the 
peroxisome fusion machinery in the membranes of PI and P2 (Figure 7.3). In unprimed 
PI and P2, all identified essential components of this machinery, including Pexlp, Pex6p, 
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PI(4)P-bp, PI(4,5)P2-bp and GTP-bp, are attached to the cytosolic surface of ECR 
domains. Priming of fusion partners is initiated by the lateral movement of PI-associated 
Pexlp and P2-bound Pex6p from ECR domains to an ergosterol- and ceramide-poor 
portion of the membrane. This essential event in the process of activating fusion partners 
for subsequent docking includes at least three consecutive steps. The initial ergosterol-
dependent step is followed by a PI(4)P-dependent step, which precedes a step that 
requires PI(4,5)P2. After their segregation from ECR domains, both PI-associated Pexlp 
and P2-bound Pex6p are released to the cytosol. Such release of both AAA ATPases 
from an ergosterol- and ceramide-poor portion of the membrane is mandatory for the 
priming of both fusion partners and includes two steps. The first step requires cytosolic 
proteins, whereas the next step is driven by ATP hydrolysis. Priming of PI and P2 is 
followed by their docking. 
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outer (cyiosolic) face 
Detergent-resistant ECR domains Detergent-soluble portion of the membrane 
inner (matrix) face 
Figure 7.3. A model for the multistep remodeling of the peroxisome fusion machinery. 
The multicomponent peroxisome fusion machinery, which only transiently resides in 
ECR membrane domains of PI and P2 vesicles, undergoes multiple rounds of temporal 
and spatial reorganization during priming and docking of both fusion partners. 
Docking of primed peroxisomal vesicles is a multistep process, which begins with the 
lateral movement of PI(4,5)P2-bp in the membranes of PI and P2 from ECR domains to 
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ergosterol- and ceramide-poor domains. This lateral movement of PI(4,5)P2-bp occurs in 
three consecutive steps. The first step needs ergosterol in the membranes of both fusion 
partners. The second step depends on Pexlp that resides in ECR domains of P2 vesicles. 
The third step requires GTP hydrolysis by GTPase(s), perhaps by GTP-bp in ECR 
domains of P1 vesicles. The docking-specific lateral movement of PI(4,5)P2-bp in the 
membranes of PI and P2 is followed by the ergosterol-dependent relocation of P2-bound 
Pexlp from ECR domains to ergosterol- and ceramide-poor domains. After their lateral 
movement to ergosterol- and ceramide-poor portions of the membranes of both fusion 
partners, PI-associated PI(4,5)P2-bp and P2-bound PI(4,5)P2-bp and Pexlp are released 
to the cytosol. Such release of PI(4,5)P2-bp and Pexlp begins with a cytosol-dependent 
step, which is followed by a step that requires ATP hydrolysis. By the end of the docking 
process, PI(4)P-bp and GTP-bp remain in ECR domains of PI and P2. 
8 Dynamics of peroxisomal fusion 
8.1 Introduction 
In order to establish the requirements for the fusion of docked PI and P2, I isolated the 
P1/P2 peroxisome docking complex by flotation on a multistep sucrose gradient and used 
the in vitro fusion assay to assess how various compounds known to inhibit fusion of 
other organellar membranes influence the merge of lipid bilayers of docked PI and P2 
peroxisomes. For instance, 1 used the proton ionophore carbonyl cyanide m-
chlorophenylhydrazone (CCCP), which is known to impair vacuole fusion and the fusion 
of the mitochondrial inner membranes, to define the role of proton gradient across the 
peroxisomal membrane in the fusion between docked PI and P2 [156-159]. Furthermore, 
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to test if the fusion of docked PI and P2 requires Ca gradient across the peroxisomal 
membrane along with Ca2+-ATPases, I used the Ca2+-sequestering compounds 
ionomycin, thapsigargin and cyclopiazonic acid, all of which have been shown to prevent 
the homotypic fusion of vacuoles [159, 160]. Moreover, to evaluate if peroxisome fusion 
depends on extracellular Ca2+ and its intracellular sensor protein calmodulin (CaM), I 
used the membrane non-permeable Ca2+ chelator 1,2-bis(o-aminophenoxy)ethane 
N,N,N',N'-tetraacetic acid (BAPTA) and the CaM antagonist W7, which have been 
shown to inhibit endosome and homotypic vacuole fusion [144, 159, 161-163]. 
Noteworthy, calmodulin is a highly conserved intracellular Ca2+~binding protein, which is 
expressed in all cell types [164, 165]. The binding of CaM to Ca2+ leads to the 
conformational change in its structure by exposing the two hydrophobic domains of 
CaM, which in turn activate the receptor proteins that it targets [165]. W7 is a CaM 
antagonist that binds to CaM in a Ca2+-dependent manner through hydrophobic and 
electrostatic interactions, thereby preventing other proteins from interacting with CaM 
[161]. Therefore, in order to test if the peroxisome fusion process also requires 
Ca /CaM-activated proteins, I used anti-CaM antibodies, calmodulin binding domain 
(CBD) and calmodulin inhibitory peptide (CIP) in order to impair the CaM-dependent 
activation of these proteins. 
Following the identification of a set of components inhibiting the peroxisome fusion 
process, I used the two-stage assay described in chapter 7 of this thesis in order to 
establish the hierarchy of fusion-specific steps that involve these components and to 
define a mechanism by which each of these components drives the merge of lipid bilayers 
surrounding docked PI and P2 peroxisomes. 
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8.2 Materials and methods 
In vitro assay for evaluating the importance of the proton and calcium gradients for 
peroxisome fusion 
Unprimed peroxisomes PI and P2 were resuspended in a buffer containing cytosol, ATP 
and ATP regenerative system, mixed, and incubated on ice for 15 min in the presence or 
absence of CCCP, ionomycin, cyclopiazonic acid or thapsigargin at various 
concentrations. The samples were then transferred to 26°C. After a 90-min incubation of 
the standard fusion reactions at 26°C, the fusion efficiency was evaluated as described 
previously in the section "Materials and methods' of chapter 2. 
In vitro assay for assessing the role of peroxisomal Ca2+ in the peroxisome fusion 
process 
Unprimed peroxisomes PI and P2 were resuspended in a buffer containing cytosol, 
mixed, and incubated on ice for 15 min in the presence or absence of BAPTA at various 
concentrations. The standard fusion reactions were then set up by adding ATP and ATP 
regenerative system. The samples were then transferred to 26°C. After incubation for 90 
min at 26°C, the efficiency of peroxisome fusion was evaluated as described in the 
section "Materials and methods' of chapter 2. 
In vitro assay for evaluating the role of CaM in peroxisome fusion 
Unprimed peroxisomes PI and P2 were resuspended in a buffer, mixed, and incubated on 
ice for 15 min in the presence of either intact or heat-inactivated anti-CaM antibodies at 
various concentrations. The peroxisomes were then reisolated by centrifugation at 4°C 
and supplemented with cytosol, ATP and ATP regenerative system. The samples were 
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then transferred to 26°C. The standard fusion reactions were incubated for 90 min at 
26°C. The efficiency of peroxisome fusion was then evaluated as described in the section 
"Materials and methods' of chapter 2. 
In vitro assay for evaluating the importance of CaM-activated proteins for 
peroxisome fusion 
Unprimed peroxisomes PI and P2 were resuspended in a buffer, mixed, and incubated on 
ice for 15 min in the presence or absence of CaM antagonists W7, CaM Binding Domain 
(CBD), or CaM Inhibitory Peptide (CIP) at various concentrations. The peroxisomes 
were then reisolated by centrifugation at 4°C and supplemented with cytosol, ATP and 
ATP regenerative system. The samples were then transferred to 26°C. The standard 
fusion reactions were allowed to proceed for 90 min at 26°C. The efficiency of 
peroxisome fusion was then evaluated as described in the section "Materials and 
methods' of chapter 2. To determine if the effects of various CaM-binding compounds 
and CaM antagonists on peroxisome fusion were reversible (and, therefore, specific), 
unprimed peroxisomes PI and P2 were resuspended in a buffer, mixed, and incubated on 
ice for 15 min in the presence or absence of anti-CaM antibodies, W7, CBD or CIP at 
various concentrations. The peroxisomes were then reisolated by centrifugation at 4°C 
and resuspended in a buffer with or without purified CaM added to a final concentration 
of 10 uM or 50 uM. The standard fusion reactions were then set up by adding cytosol, 
ATP and ATP regenerative system. After a 90-min incubation at 26°C, the efficiency of 
peroxisome fusion was evaluated as described in the section "Materials and methods' of 
chapter 2. 
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In vitro assay for evaluating the requirements for the fusion of docked PI and P2 
PI and P2 were primed individually with cytosol and ATP at 26°C, mixed, and incubated 
with cytosol and ATP at 26°C. The resulting P1/P2 docking complex was purified by 
flotation centrifugation on a multi-step sucrose gradient and resuspended in a buffer 
containing cytosol. This complex was incubated for 15 min on ice with or without 
nystatin, fillipin III, amphotericin B, anti-PI(4)P, anti-PI(4,5)P2, ATPKS, anti-Pexlp, anti-
Pex6p, GTP7S, GppNHp, CCCP, ionomycin, cyclopiazonic acid, thapsigargin, BAPTA, 
anti-CaM antibodies, W7, CBD or CIP in the presence or absence of cytosol. The 
peroxisomes were then reisolated by centrifugation at 4°C and resuspended in a buffer 
containing cytosol, ATP and ATP regenerative system. The samples were then 
transferred to 26°C. After a 90-min incubation at 26°C, the efficiency of peroxisome 
fusion was evaluated as described in the section "Materials and methods" of chapter 2. 
Two-stage assay for defining the order of individual steps during peroxisome fusion 
PI and P2 were primed individually with cytosol and ATP at 26°C, mixed, and incubated 
with cytosol and ATP at 26°C. The resulting P1/P2 docking complex was purified by 
flotation centrifugation on a multi-step sucrose gradient and then incubated on ice for 15 
min in presence of CCCP. The peroxisomes were then reisolated by centrifugation at 4°C, 
washed, and resuspended in a buffer containing ionomycin. The samples were then 
transferred to 26°C. After a 90-min incubation at 26°C, the efficiency of peroxisome 
fusion was evaluated as described in the section "Materials and methods" of chapter 2. 
The order of inhibitor addition was then reversed and the docking complex was first 
incubated on ice for 15 min in the presence of ionomycin, reisolated by centrifugation, 
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washed and incubated in the presence of CCCP on ice for 15 min. The samples were then 
transferred to 26°C. After a 90-min incubation at 26°C, the efficiency of peroxisome 
fusion was evaluated as described in the section "Materials and methods" of chapter 2. 
The two-stage inhibition assay was also performed using the following inhibitors tested 
in a pair-wise manner: nystatin, anti-PI(4)P, anti-PI(4,5)P2, cytosol, ATP1S, anti-Pexlp, 
anti-Pex6p, GTP7S, GppNHp, CCCP, ionomycin, cyclopiazonic acid, thapsigargin, 
BAPTA, anti-CaM, W7, CBD, or CIP. 
In vitro assay for evaluating the dynamics of CaM association with the peroxisomal 
membrane and of changes in Ca2+ concentration during peroxisome fusion 
PI and P2 were primed individually with cytosol and ATP at 26°C, mixed, and incubated 
with cytosol and ATP at 26°C. The resulting P1/P2 docking complex was purified by 
flotation centrifugation on a multi-step sucrose gradient and then incubated for 90 min at 
26°C in the presence or absence of CCCP or nonhydrolyzable GTP analogues, with 
aliquots taken at different time points. The samples were then centrifuged to obtain the 
peroxisomal (pellet) and extraperoxisomal (supernatant) fractions. The level of 
peroxisome-bound CaM was assessed by immunoblotting with anti-CaM antibodies. The 
concentration of extracellular Ca2+ was monitored by spectrophotometry. 
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8.3 Results 
8.3.1 Proton gradient across the peroxisomal membrane is essential for 
peroxisome fusion 
0 1* 20 30 40 
CCCP OiM) 
Figure 8.1. Peroxisome fusion is inhibited by the H+ ionophore CCCP. Unprimed 
peroxisomes PI and P2 were resuspended in a buffer containing cytosol, ATP and ATP 
regenerative system, mixed, and incubated on ice for 15 min in the presence or absence 
of CCCP at various concentrations. The samples were then transferred to 26°C. After a 
90-min incubation of the standard fusion reactions at 26°C, the fusion efficiency was 
evaluated as described previously in the section "Materials and methods' of chapter 2. 
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8.3.2 Peroxisome fusion requires active maintenance of the Ca 
the peroxisomal membrane 
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Figure 8.2. Peroxisome fusion is inhibited by the Ca2+ ionophore ionomycin and two 
inhibitors of Ca2+-dependent ATPases, cyclopiazonic acid and thapsigargin. Unprimed 
peroxisomes PI and P2 were resuspended in a buffer containing cytosol, ATP and ATP 
regenerative system, mixed, and incubated on ice for 15 min in the presence or absence 
of ionomycin, cyclopiazonic acid or thapsigargin at various concentrations. The samples 
were then transferred to 26°C. After a 90-min incubation of the standard fusion reactions 
at 26°C, the fusion efficiency was evaluated as described previously in the section 
"Materials and methods' of chapter 2. 
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8.3.3 Peroxisome fusion depends on the presence of Ca + on the peroxisome 
surface 
o mem brane -non - perinea b le 
Caz+ chelator 
BAPTA (fflM) 
Figure 8.3. Peroxisome fusion is inhibited by the membrane-non-permeable Ca + 
chelator BAPTA (l,2-Bjs(2-aminophenoxy)ethane-Af,Af,Ar,A^-tetraacetic acid). Unprimed 
peroxisomes PI and P2 were resuspended in a buffer containing cytosol, mixed, and 
incubated on ice for 15 min in the presence or absence of BAPTA at various 
concentrations. The standard fusion reactions were then set up by adding ATP and ATP 
regenerative system. The samples were then transferred to 26°C. After incubation for 90 
min at 26°C, the efficiency of peroxisome fusion was evaluated as described in the 
section "Materials and methods' of chapter 2. 
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8.3.4 Peroxisome fusion requires CaM, a cytosolic Ca +-binding protein 
o 2 4 i 3 10 
anti-CaM (uM) 
Figure 8.4. Peroxisome fusion is inhibited by monoclonal antibodies to CaM. Unprimed 
peroxisomes PI and P2 were resuspended in a buffer, mixed, and incubated on ice for 15 
min in the presence of either intact or heat-inactivated anti-CaM antibodies at various 
concentrations. The peroxisomes were then reisolated by centrifugation at 4°C and 
supplemented with cytosol, ATP and ATP regenerative system. The samples were then 
transferred to 26°C. The standard fusion reactions were incubated for 90 min at 26°C. The 
efficiency of peroxisome fusion was then evaluated as described in the section "Materials 
and methods' of chapter 2. 
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8.3.5 Peroxisome fusion depends on Ca /CaM-dependent protein kinases and 
phosphodiesterases 
Control Cg, 117-aa ccatidc: Ae-An-
Arj-Lys-Gb-Sbi-lys-Tlir-Cly-HB-Alo. 
0 100 200 0 50 100 150 0 10 20 30 40 
W7 (MM) CBD ("M) CIP OP Control CIP (nM) 
Figure 8.5. Peroxisome fusion is inhibited by the CaM antagonists W7, Calmodulin 
Binding Domain (CBD) and Calmodulin Inhibitory Peptide (CIP), all of which impair the 
activation of Ca2+/CaM-dependent protein kinases and phosphodiesterases. Unprimed 
peroxisomes PI and P2 were resuspended in a buffer, mixed, and incubated on ice for 15 
min in the presence or absence of W7, CBD or CIP at various concentrations. The 
peroxisomes were then reisolated by centrifugation at 4°C and supplemented with 
cytosol, ATP and ATP regenerative system. The samples were then transferred to 26°C. 
The standard fusion reactions were allowed to proceed for 90 min at 26°C. The efficiency 
of peroxisome fusion was then evaluated as described in the section "Materials and 
methods' of chapter 2. 
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8.3.6 Inhibitory effects of anti-CaM antibodies and CaM antagonists on 
peroxisome fusion can be reversed by CaM in a concentration-dependent 
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Figure 8.6. The negative effect of anti-CaM antibodies and CaM antagonists is specific 
because it can be reversed by CaM in a concentration-dependent manner. Unprimed 
peroxisomes P1 and P2 were resuspended in a buffer, mixed, and incubated on ice for 15 
min in the presence or absence of anti-CaM antibodies, W7, CBD or CIP at various 
concentrations. The peroxisomes were then reisolated by centrifugation at 4°C and 
resuspended in a buffer with or without purified CaM added to a final concentration of 10 
u.M or 50 uM. The standard fusion reactions were then set up by adding cytosol, ATP 
and ATP regenerative system. After a 90-min incubation at 26°C, the efficiency of 
peroxisome fusion was evaluated as described in the section "Materials and methods' of 
chapter 2. 
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8.3.7 Fusion of the docked peroxisomes requires GTP hydrolysis, the gradients of 
H+ and Ca2+ across the peroxisomal membrane, presence of Ca2+ on the 
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Figure 8.7. The requirements for the fusion of docked peroxisomes PI and P2. PI and P2 
were primed individually with cytosol and ATP at 26°C, mixed, and incubated with 
cytosol and ATP at 26°C. The resulting P1/P2 docking complex was purified by flotation 
centrifugation on a multi-step sucrose gradient and resuspended in a buffer containing 
cytosol. This complex was incubated for 15 min on ice with or without nystatin, fillipin 
III, amphotericin B, anti-PI(4)P, anti-PI(4,5)P2, ATP7S, anti-Pexlp, anti-Pex6p, GTP*?S, 
GppNHp, CCCP, ionomycin, cyclopiazonic acid, thapsigargin, BAPTA, anti-CaM 
antibodies, W7, CBD or CIP in the presence or absence of cytosol. The peroxisomes 
were then reisolated by centrifugation at 4°C and resuspended in a buffer containing 
cytosol, ATP and ATP regenerative system. The samples were then transferred to 26°C. 
After a 90-min incubation at 26°C, the efficiency of peroxisome fusion was evaluated as 
described in the section "Materials and methods" of chapter 2. 
97 
8.3.8 The H+ gradient-dependent step during fusion of docked PI and P2 precedes 
the steps that require the Ca2+ gradient across the peroxisomal membrane 
and Ca2+ on the outer peroxisome surface 
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Figure 8.8. The fusion of docked PI and P2 is initiated by the H+ gradient-dependent 
step that precedes the steps requiring the Ca2+ gradient across the peroxisomal membrane 
and presence of Ca2+ on the outer face of the peroxisome. PI and P2 were primed 
individually with cytosol and ATP at 26°C, mixed, and incubated with cytosol and ATP 
at 26°C. The resulting P1/P2 docking complex was purified by flotation centrifugation on 
a multi-step sucrose gradient and then incubated on ice for 15 min in presence of CCCP. 
The peroxisomes were then reisolated by centrifugation at 4°C, washed, and resuspended 
in a buffer containing ionomycin. The samples were then transferred to 26°C. After a 90-
min incubation at 26°C, the efficiency of peroxisome fusion was evaluated as described 
in the section "Materials and methods" of chapter 2. The order of inhibitor addition was 
then reversed and the docking complex was first incubated on ice for 15 min in the 
presence of ionomycin, reisolated by centrifugation, washed and incubated in the 
presence of CCCP on ice for 15 min. The samples were then transferred to 26°C. After a 
90-min incubation at 26°C, the efficiency of peroxisome fusion was evaluated as 
described in the section "Materials and methods" of chapter 2. This two-stage inhibition 
assay was also performed using other inhibitors of peroxisome fusion that were tested in 
a pair-wise manner as indicated. 
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8.3.8 The H+ gradient-dependent step during fusion of docked PI and P2 precedes 
the step that requires CaM 
CCCP—• S-CaM 




CCCP — * W7 
— CaM + CCCP 
CCCP — CBP 
— CaM + CCCP 
CCCP — * CIP 









20 40 60 
Fusion (%) 
80 
Figure 8.9. The H+ gradient-dependent step of the peroxisome fusion process precedes 
the step that requires CaM. P1 and P2 were primed individually with cytosol and ATP at 
26°C, mixed, and incubated with cytosol and ATP at 26°C. The resulting P1/P2 docking 
complex was purified by flotation centrifugation on a multi-step sucrose gradient and 
then incubated on ice for 15 min in presence of CCCP. The peroxisomes were then 
reisolated by centrifugation at 4°C, washed, and resuspended in a buffer containing anti-
CaM antibodies. Following a 15-min incubation on ice, the samples were transferred to 
26°C. After a 90-min incubation at 26°C, the efficiency of peroxisome fusion was 
evaluated as described in the section "Materials and methods" of chapter 2. The order of 
inhibitor addition was then reversed and the docking complex was first incubated on ice 
for 15 min in the presence of anti-CaM antibodies, reisolated by centrifugation, washed 
and incubated in the presence of CCCP on ice for 15 min. The samples were then 
transferred to 26°C. After a 90-min incubation at 26°C, the efficiency of peroxisome 
fusion was evaluated as described in the section "Materials and methods" of chapter 2. 
This two-stage inhibition assay was also performed using other inhibitors of peroxisome 
fusion that were tested in a pair-wise manner as indicated. 
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-2+ 8.3.10 The Ca gradient-dependent step during fusion of docked PI and P2 occurs 
before CaM-dependent step 
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Figure 8.10. During fusion of docked PI and P2, the Ca gradient-dependent step 
precedes the step requiring CaM. PI and P2 were primed individually with cytosol and 
ATP at 26°C, mixed, and incubated with cytosol and ATP at 26°C. The resulting P1/P2 
docking complex was purified by flotation centrifugation on a multi-step sucrose gradient 
and then incubated on ice for 15 min in presence of ionomycin. The peroxisomes were 
then reisolated by centrifugation at 4°C, washed, and resuspended in a buffer containing 
Ca2+ and anti-CaM antibodies. Following a 15-min incubation on ice, the samples were 
transferred to 26°C. After a 90-min incubation at 26°C, the efficiency of peroxisome 
fusion was evaluated as described in the section "Materials and methods" of chapter 2. 
The order of inhibitor addition was then reversed and the docking complex was first 
incubated on ice for 15 min in the presence of anti-CaM antibodies, reisolated by 
centrifugation, washed and incubated in the presence of CaM and ionomycin on ice for 
15 min. The samples were then transferred to 26°C. After a 90-min incubation at 26°C, 
the efficiency of peroxisome fusion was evaluated as described in the section "Materials 
and methods" of chapter 2. This two-stage inhibition assay was also performed using 
other inhibitors of peroxisome fusion that were tested in a pair-wise manner as indicated. 
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8.3.11 The CaM-dependent step during fusion of docked PI and P2 precedes the 
step that requires GTP hydrolysis by GTPase(s) 
a-CaM 
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Figure 8.11. During fusion of docked PI and P2, the CaM-dependent step occurs before 
the step that requires GTP hydrolysis. PI and P2 were primed individually with cytosol 
and ATP at 26°C, mixed, and incubated with cytosol and ATP at 26°C. The resulting 
P1/P2 docking complex was purified by flotation centrifugation on a multi-step sucrose 
gradient and then incubated on ice for 15 min in presence of anti-CaM antibodies. The 
peroxisomes were then reisolated by centrifugation at 4°C, washed, and resuspended in a 
buffer containing CaM and the nonhydrolyzable GTP analogue GTPyS. Following a 15-
min incubation on ice, the samples were transferred to 26°C. After a 90-min incubation at 
26°C, the efficiency of peroxisome fusion was evaluated as described in the section 
"Materials and methods" of chapter 2. The order of inhibitor addition was then reversed 
and the docking complex was first incubated on ice for 15 min in the presence of GTP-yS, 
reisolated by centrifugation, washed and incubated in the presence of GTP and GTPyS on 
ice for 15 min. The samples were then transferred to 26°C. After a 90-min incubation at 
26°C, the efficiency of peroxisome fusion was evaluated as described in the section 
"Materials and methods" of chapter 2. This two-stage inhibition assay was also 
performed using other inhibitors of peroxisome fusion that were tested in a pair-wise 
manner as indicated. 
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.2+ 8.3.12 During fusion of PI and P2, the CCCP-sensitive release of Ca^  from the 
organelle lumen and subsequent recruitment of cytosolic CaM to the 
organelle surface are followed by the uptake of Ca2+ into the lumen and 
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Figure 8.12. Fusion of docked PI and P2 is initiated by the release of Ca2+ from the 
organelle lumen, which is followed by the recruitment of cytosolic CaM to the organelle 
surface, influx of Ca2+ into the peroxisomal lumen and release of CaM from the 
peroxisomal surface back to the cytosol. PI and P2 were primed individually with cytosol 
and ATP at 26°C, mixed, and incubated with cytosol and ATP at 26°C. The resulting 
P1/P2 docking complex was purified by flotation centrifugation on a multi-step sucrose 
gradient and then incubated for 90 min at 26°C in the presence or absence of CCCP, with 
aliquots taken at different time points. The samples were then centrifuged to obtain the 
peroxisomal (pellet) and extraperoxisomal (supernatant) fractions. The level of 
peroxisome-bound CaM was assessed by immunoblotting with anti-CaM antibodies. The 
concentration of extracellular Ca2+ was monitored by spectrophotometry. 
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8.3.13 During fusion of PI and P2, both the uptake of Ca2+ into the lumen and 
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2+ Figure 8.13. Inhibition of GTP hydrolysis prevents the influx of Ca back into the 
peroxisomal lumen and impairs the release of CaM from the peroxisomal surface back to 
the cytosol. PI and P2 were primed individually with cytosol and ATP at 26°C, mixed, 
and incubated with cytosol and ATP at 26°C. The resulting P1/P2 docking complex was 
purified by flotation centrifugation on a multi-step sucrose gradient and then incubated 
for 90 min at 26°C in the presence or absence of the nonhydrolyzable GTP analogues 
GTPyS or GppNHp, with aliquots taken at different time points. The samples were then 
centrifuged to obtain the peroxisomal (pellet) and extraperoxisomal (supernatant) 
fractions. The level of peroxisome-bound CaM was assessed by immunoblotting with 
anti-CaM antibodies. The concentration of extracellular Ca + was monitored by 
spectrophotometry. 
8.4 Discussion 
I found that fusion of docked PI and P2 is inhibited by CCCP, an H+ ionophore that 
disrupts the proton gradient across the peroxisomal membrane, thus demonstrating the 
importance of establishing such gradient for the fusion process (Figure 8.1). Peroxisome 
fusion was also inhibited by the Ca2+ ionophore ionomycin and by two inhibitors of Ca~+-
dependent ATPases, namely cyclopiazonic acid and thapsigargin, suggesting that the 
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maintenance of Ca gradient across the peroxisomal membrane is also essential for the 
fusion process (Figure 8.2). Furthermore, fusion of docked PI and P2 depends on the 
presence of Ca2+ and CaM on the outer peroxisomal face, as can be concluded from the 
inhibitory effect of both the membrane non-permeable Ca2+ chelator BAPTA and anti-
CaM monoclonal antibodies on the fusion process (Figures 8.3 and 8.4). Moreover, 
certain CaM- and Ca2+-activated proteins are also required for peroxisome fusion since 
the fusion of docked PI and P2 was impaired in the presence of compounds that inhibit 
Ca +/CaM-dependent protein kinases and phosphodiesterases (Figure 8.5). Importantly, 
the negative effect of anti-CaM antibodies and CaM antagonists (W7, CBD or CIP) on 
the fusion of docked PI and P2 is specific because it can be reversed by CaM in a 
concentration-dependent manner (Figure 8.6). 
Of note, my findings imply that, in contrast to peroxisome priming and docking for 
fusion, the fusion of docked peroxisomes does not depend on ergosterol, PI(4)P, 
PI(4,5)P2, cytosolic proteins, ATP hydrolysis, Pexlp or Pex6p (Figure 8.7). However, 
akin to the docking of primed PI and P2, their subsequent fusion requires GTP hydrolysis 
since the nonhydrolyzable GTP analogues GTP1S and GppNHp inhibit peroxisome 
fusion in vitro (Figure 8.7). Interestingly, the PI-associated GTP-bp remains bound to 
the organelle surface throughout the entire fusion process, suggesting that these 
membrane-attached GTP-binding and hydrolyzing proteins may constitute an important 
part of the machinery driving the fusion of docked peroxisomes. 
My data on the two-stage inhibition assay enabled to establish the hierarchy of 
individual steps taking place during fusion of docked PI and P2. Specifically, using this 
assay I revealed that fusion of docked P1 and P2 is initiated by the H+ gradient-dependent 
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step, which precedes the steps that require the Ca gradient across the peroxisomal 
membrane, Ca2+ on the outer peroxisome surface, and CaM (Figures 8.8 and 8.9). 
Importantly, the Ca2+ gradient-dependent step during fusion of docked PI and P2 occurs 
before CaM-dependent step (Figure 8.10). Moreover, my data imply that the CaM-
dependent step during fusion of docked PI and P2 precedes the step that requires GTP 
hydrolysis by GTPase(s) (Figure 8.11). 
By monitoring the dynamics of changes in the association of CaM with the outer 
peroxisome face and in the concentration of Ca2+ in the extra-peroxisomal medium, I 
provided evidence that, during fusion of PI and P2, the CCCP-sensitive (i.e., the H+ 
membrane gradient-dependent) release of Ca2+ from the organelle lumen and subsequent 
recruitment of cytosolic CaM to the organelle surface are followed by the uptake of Ca 
into the lumen and release of CaM from the surface to the cytosol (Figure 8.12). 
Moreover, my data imply that, during fusion of PI and P2, both the uptake of Ca into 
the lumen and release of CaM from the surface to the cytosol require GTP hydrolysis 
(Figure 8.13). 
Taken together, my findings suggest the following model for fusion of docked P1 and P2 
peroxisomes (Figure 8.14). The fusion of PI and P2 is amultistep process that is initiated 
by the proton gradient-dependent release of the Ca2+ ions from the peroxisomal lumen to 
the cytosol and their tight association with the peroxisomal surface (Figure 8.14). 
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Figure 8.14. My model for fusion of docked peroxisomes PI and P2. See text for details. 
The Ca2+ ions that tightly associate with the peroxisome surface then recruit cytosolic 
CaM, which in turn activates the Ca2+/CaM-dependent protein kinases and/or 
phosphodiesterases. The signal transduction pathways initiated by these Ca~+/CaM-
dependent protein kinases and/or phosphodiesterases promote the hydrolysis of GTP by 
the peroxisome-bound GTPase(s), which drive the fusion of docked PI and P2 
peroxisomes. During the resulting merge of lipid bilayers surrounding PI and P2, CaM is 
released from the peroxisomal surface to the cytosol, perhaps due to the influx of the Ca 2+ 
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ions into the peroxisomal lumen (Figure 8.14). Importantly, all the merge of lipid 
bilayers, release of CaM and influx of Ca2+ are driven by the hydrolysis of GTP by the 
peroxisome-bound GTPase(s). 
8.5 Conclusions 
My molecular analysis of a multi-step process of the fusion of docked PI and P2 
peroxisomes revealed the fusion process is initiated by the H+-gradient driven efflux of 
Ca + from the peroxisome lumen and is followed by the recruitment of CaM from the 
cytosol to the peroxisomal surface. CaM on the outer face of the docking complex 
activates the Ca2+/CaM-dependent protein kinases and/or phosphodiesterases, which in 
turn activate the hydrolysis of GTP by the peroxisome-bound GTPase(s). GTP hydrolysis 
drives the merge of lipid bilayers surrounding PI and P2, release of CaM from the 
peroxisomal surface to the cytosol, and influx of the Ca2+ ions into the peroxisomal 
lumen. 
9 The mechanism of peroxisome fusion: Summary and suggestions for future 
work 
9.1 Do ECR domains exist in the peroxisomal membrane or are they an artifact 
of the detergent insolubility assay? 
The assay for insolubility of protein and lipid constituents of cellular membranes in cold 
detergents has been widely used for the identification of lipid rafts [124, 146]. The 
validity of this assay has been demonstrated by the identification of numerous detergent-
resistant membrane assemblies of proteins and lipids that have been implicated in a 
variety of essential cellular processes [87, 149]. However, recent findings suggested 
potential caveats associated with the interpretation of results of the detergent insolubility 
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assay [149]. It was concluded that only a decrease or an increase in the detergent 
insolubility of a membrane protein at different consecutive steps of a cellular process 
could provide proof for the lateral movement of the protein of interest from one 
membrane domain to another [87, 149]. 
I used the detergent solubilization approach to study the dynamics of temporal and 
spatial reorganization of the multicomponent peroxisome fusion machinery in the 
membranes of PI and P2. I found that a distinct set of protein components of this 
machinery in unprimed PI and P2 resisted solubilization by the detergent Brij 35. 
Individual components of the fusion machinery became detergent-soluble, and were 
eventually released to the cytosol, at different steps of the peroxisome fusion process. 
Moreover, I defined a hierarchy in which various inhibitors of peroxisome fusion 
selectively affected the lateral movement of their protein targets in the peroxisomal 
membrane. Taken together, my findings provide evidence that detergent-resistant ECR 
domains in the membranes of P1 and P2 do not represent an artifact of the detergent 
insolubility assay. On the contrary, these membrane domains exist as dynamic assemblies 
of a distinct set of proteins and lipids whose remodeling during peroxisome priming and 
docking is mandatory for the fusion of peroxisomal membranes. 
9.2 Unique properties of ECR domains in the peroxisomal membrane 
My analysis of ECR domains in the peroxisomal membrane revealed that they have two 
important features in common with the well characterized lipid raft domains in the 
plasma membrane. First, ECR domains constitute a significant portion of the membranes 
of unprimed PI and P2, with about half of membrane lipids and proteins being recovered 
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in these membrane domains. Lipid rafts in the plasma membrane also represent a 
substantial fraction of the membrane [116, 167]. In certain cells, the plasma membrane 
resembles a dense assembly of numerous types of small lipid rafts that, once cells are 
stimulated, form larger assemblies (or flotillas) [167]. It remains to be established if ECR 
domains in the peroxisomal membrane represent several distinct types of ergosterol- and 
ceramide-rich microdomains, which differ in their protein composition and collide in 
response to certain stimuli. Second, both ECR domains in the peroxisomal membrane and 
lipid rafts in the plasma membrane are dynamic. As I found, when PI and P2 vesicles are 
stimulated for priming and docking, numerous protein constituents of ECR domains 
rapidly move from these domains to an ergosterol- and ceramide-poor portion of the 
membrane. Likewise, lipid raft proteins in the plasma membrane are extremely mobile 
and undergo rapid lateral diffusion even in unstimulated cell membranes [168]. 
My findings also imply that some properties of ECR domains in the membranes of 
PI and P2 vesicles distinguish them from well characterized lipid raft domains in the 
plasma membrane. Sphingolipids of lipid rafts in the plasma membrane have large polar 
head groups that are attached to their sphingosine base [90]. In contrast, no polar head 
group is attached to the sphingosine base of ceramide [90], an abundant sphingolipid 
component of ECR domains. It should be noted that ceramide in model membranes forms 
detergent-insoluble lipid domains that are significantly more stable than those formed in 
the presence of plasma membrane sphingolipids [120]. Moreover, by stabilizing lipid raft 
domains in endoplasmic reticulum (ER) membranes, ceramide could enhance the 
association of glycosylphosphatidylinositol (GPI)-anchored proteins with lipid rafts, 
thereby promoting selective sorting of these proteins into vesicles distinct from those 
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carrying many other secretory and plasma membrane proteins [73]. It remains to be 
elucidated if ceramide could promote the assembly of the ECR domain-based peroxisome 
fusion machinery in unprimed P1 and P2. 
Another distinct feature of ECR domains is the unusual distribution of their 
sphingolipid component, ceramide, across the membrane bilayers in PI and P2. In the 
plasma membrane, sphingolipids are restricted to the outer leaflet, as they are unable to 
move across the bilayer [116, 149, 166]. These lipids cluster with cholesterol, which 
preferentially interacts with sphingolipids rather than glycerophospholipids, thereby 
forming distinct lipid raft domains in the outer leaflet of the plasma membrane [149]. In 
contrast, in the membranes of PI and P2, the sphingolipid ceramide is distributed 
symmetrically between the two leaflets of the bilayers. The bulk of ceramide, which 
spontaneously flips across the membrane bilayer with a half-time of ~ 10 min [90, 166], 
is in ECR domains of the membranes of PI and P2. It remains to be seen whether the 
symmetric distribution of ceramide across the peroxisomal membrane and its ability to 
flip between the two leaflets of the bilayer promote the coordination of events that occur 
in the cytosolic and lumenal leaflets of ECR domains. 
9.3 ECR domains undergo remodeling during peroxisomal fusion 
My findings provided evidence that that ECR domains in the membranes of PI and P2 
are dynamic assemblies of a distinct set of lipids and proteins, including Pexlp, Pex6p, 
GTP-binding and hydrolyzing proteins, and proteins that specifically bind to two 
membrane phosphoinositides, PI(4)P and PI(4,5)P2 [116]. Moreover, I demonstrated that 
ECR domains act as organizing platforms during peroxisomal fusion by orchestrating the 
110 
spatiotemporal reorganization of protein teams that transiently reside in ECR domains 
and control peroxisome fusion [116]. Based on my findings, I proposed a model for the 
multistep remodeling of the peroxisomal fusion machinery in the membrane bilayers of 
PI and P2 [116]. According to this model, all identified essential components of the 
peroxisomal fusogenic machinery, including Pexlp, Pex6p, GTP-bp, PI(4)P-bp and 
PI(4,5)P2-bp, are associated with the cytosolic face of ECR domains in membranes of 
unprimed PI and P2. Priming of both peroxisomal fusion partners is initiated by the 
lateral movement of PI-bound Pexlp and P2-associated Pex6p from ECR domains to an 
ergosterol- and ceramide-poor portion of peroxisomal membranes. The priming event 
consists of three consecutive steps, with the first step requiring ergosterol in the 
peroxisomal membrane, the second step depending on PI(4)P, and the third step relying 
on PI(4,5)P2. The priming step is completed after both AAA ATPases, Pexlp and Pex6p, 
get released from the peroxisome surface to the cytosol, which occurs in two consecutive 
steps that require cytosolic proteins and ATP hydrolysis, respectively. The priming of PI 
and P2 activates them for subsequent docking, which also proceeds through multiple 
steps. Peroxisome docking begins with the relocation of PI(4,5)P2-bp from ECR domains 
to ergosterol- and ceramide-poor portions in the their membranes of both fusion partners. 
This lateral movement progresses through three consecutive steps, with the first step 
requiring ergosterol in the membrane bilayers of both fusion partners, second depending 
on Pexlp on the cytosolic face of ECR domains in P2, and the third step requiring GTP 
hydrolysis by GTPase(s), perhaps by GTP-bp in ECR domains of PI. Following the 
lateral movement of PI(4,5)P2-bp in the membranes of PI and P2, Pexlp also relocates 
from ECR domains of P2 to its ergosterol- and ceramide-poor domains in an ergosterol-
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dependent fashion. The formation of a stable docking complex is completed by the 
release of PI-associated PI(4,5)P2-bp as well as of P2-bound PI(4,5)P2-bp and Pexlp into 
the cytosol, which occurs in two consecutive steps that depend on cytosolic proteins and 
ATP hydrolysis, respectively. Of note, PI(4)P-bp and GTP-bp remain associated with 
ECR domains of the membrane bilayers of PI and P2 after the P1/P2 docking complex 
has been formed, suggesting that these proteins are required for the subsequent fusion 
process. The fusion of docked peroxisomes begins with the H+-gradient-driven efflux of 
Ca2+ from the peroxisomal lumen, which recruits CaM from the cytosol to the 
peroxisomal surface where CaM activates Ca2+/CaM-dependent protein kinases and/or 
phosphodiesterases. The signal transduction pathway(s) activated by these proteins, 
including the hydrolysis of GTP, drives the fusion reaction leading to the formation of 
larger peroxisome P3. The fusion of docked PI and P2 is culminated by the influx of 
Ca2+ back into the peroxisomal lumen and by the concomitant release of CaM from the 
peroxisomal surface back to the cytosol. It would be interesting to see how this 
established remodeling of the peroxisome fusogenic machinery residing in the 
membranes of both fusion partners changes the physical properties and topology of lipid 
bilayers in which this machinery operates, thereby triggering peroxisome docking and 
subsequent fusion of the peroxisomal membranes. Future studies could also focus on 
identifying the interacting partners of the currently known protein components of the 
peroxisome fusion machinery, such as Pexlp, Pex6p and CaM. Furthermore, it would be 
interesting to see if these interacting protein partners dissociate from Pexlp, Pex6p and 
CaM following their lateral relocation from ECR domains to an ergosterol- and ceramide-
poor portion of the membrane or their release to the cytosol. Immunoaffinity 
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chromatography using anti-Pexlp, anti-Pex6p and anti-CaM antibodies covalently linked 
to Protein A Sepharose can be used to purify the corresponding bait proteins along with 
their interacting protein partners from the structurally and functionally distinct membrane 
domains isolated from both PI and P2 peroxisomes in their unprimed, individually pre-
primed, docked or fused states and at the different consecutive steps of the peroxisome 
fusion process. Moreover, these experiments could be carried out not only with 
peroxisomes purified from wild-type strain, but also with peroxisomes isolated from 
mutant strains that lack individual components of the peroxisome fusogenic protein 
machinery identified that I identified. These future studies would provide new insight 
into the molecular dynamics of the complex machinery governing peroxisome fusion 
though coordination of numerous protein and lipid constituents of the peroxisomal 
membrane. 
113 
10 Comparative analyses of cellular and mitochondrial proteomes of wild-type 
strain of the yeast S. cerevisiae that aged chronologically under CR or non-
CR conditions 
10.1 Introduction 
The identification and characterization of numerous long-lived mutants resulted in the 
establishment of a distinct set of proteins that regulate longevity in yeast, worms, flies 
and mice. These regulatory proteins function in a wide range of cellular processes such as 
stress response and protein folding, programmed cell death (apoptosis), cell cycle and 
growth, autophagy and proteasomal protein degradation, actin organization, signal 
transduction, nuclear DNA replication, chromatin assembly and maintenance, ribosome 
translation and biogenesis, carbohydrate and lipid metabolism, oxidative metabolism in 
mitochondria, NAD+ homeostasis, amino acid biosynthesis and degradation, and 
ammonium and amino acid uptake [210, 217, 218, 238, 239]. It should be stressed that 
the spatiotemporal organization and function of these numerous cellular processes is 
controlled by a limited set of evolutionarily conserved proteins referred to as the "master 
regulators". They include 1) the sirtuins family of NAD+-dependent protein deacetylases 
and ADP ribosylases in yeast, worms, flies and mammals [211, 217, 239, 240]; 2) the 
proteins involved in nutrient- or insulin/IGF-1-like signaling pathways in evolutionarily 
distant organisms [210, 242, 243]; 3) the nutrient-responsive protein kinases TORC1, 
Sch9p and PKA in yeast [217]; 4) the stress-response activating transcriptional factors 
Msn2p, Msn4p and Rim 15, which are modulated in yeast by TORC1, Sch9p and PKA 
[217, 217, 241]; 5) the transcriptional factors Rtglp and Rtg3p that are required for the 
maintenance of glutamate homeostasis and are modulated in yeast by a mitochondrion-to-
nucleus signal transduction pathway [244]; 6) the transcription factor DAF-16 in worms 
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regulated by the insulin/IGF-1 signaling (IIS) pathway as well as other US-independent 
mechanisms [242, 243]; 7) the transcription factor PHA-4 specific for the diet restriction 
in worms [245]; and 8) some transcription factors of the FOXO forkhead family in flies 
and mammals [246]. 
To identify the cellular processes that might play a critical role in longevity 
regulation and, perhaps, to rank their relative contributions to aging, I used mass 
spectrometry to compare cellular and mitochondrial proteomes of wild-type strain of the 
yeast S. cerevisiae that aged chronologically under CR or non-CR conditions. I have 
identified numerous proteins that are enriched or depleted in total cell lysates and pure 
mitochondria of long-lived yeast grown under CR conditions on 0.2% or 0.5% glucose, 
as compared to those of short-lived yeast grown under non-CR conditions on 1 % or 2% 
glucose. 
10.2 Materials and methods 
Strains and media 
The wild-type strain BY4742 (MATa his3Al leu2A0 fys2A0 ura3A0) was grown in YP 
medium (1% yeast extract, 2% peptone) containing 0.2%, 0.5%, 1% or 2% glucose as 
carbon source. Cells were cultured at 30°C with rotational shaking at 200 rpm in 
Erlenmeyer flasks at a "flask volume/medium volume" ratio of 5:1. 
Preparation of total cell lysates 
An aliquot containing 1 x 109 cells was centrifuged for 7 min at 3,000 rpm at room 
temperature. Pelleted cells were washed twice with distilled water and further centrifuged 
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for 3 min at 16,000 x g at room temperature. The recovered cell pellet was then 
resuspended in 500 ul of 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5) and centrifuged 
for 15 sec at 16,000 x g at room temperature. The cells were then washed again, first by 
resuspending them in 500 ul of 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5) and then 
by centrifuging for 15 sec at 16,000 x g at room temperature. The pellet of washed cells 
was then resuspended in 1 ml of ice-cold 4% CHAPS in 25 mM Tris/HCl buffer (pH 8.5), 
divided into 5 equal aliquots of 200 ul each and placed in Eppendorf tubes kept on ice. 
Each 200 ul aliquot was supplemented with ~100 ul of glass beads and vortexed three 
times for 1 minute. Apart from the vortexing steps, the samples were kept on ice at all 
times. Glass beads and cell debris were then pelleted by 5 min centrifugation at 16,000 x 
g at 4°C. The resulting supernatant of the glass bead lysate was immediately transferred 
into a pre-chilled Eppendorf tube and stored at -20°C for further analysis. 
Isolation of the crude mitochondrial fraction 
Yeast cells were pelleted at 3,000 x g for 5 min at room temperature, washed twice with 
distilled water, resuspended in DTT buffer (100 mM Tris-H2S04; pH 9.4, 10 mM 
dithiothreitol [DTT]), and incubated for 20 min at 30°C to weaken the cell wall. The cells 
were then washed with Zymolyase buffer (1.2 M sorbitol, 20 mM potassium phosphate, 
pH 7.4), centrifuged at 3,000 x g for 5 min at room temperature, and incubated with 3 
mg/g (wet wt) of Zymolyase-100T in 7 ml/g (wet wt) Zymolyase buffer for 45 min at 
30°C. Following an 8-min centrifugation at 2,200 x g at 4°C, the isolated spheroplasts 
were washed in ice-cold homogenization buffer (5 ml/g) (0.6 M sorbitol, 10 mM Tris-
HC1, pH7.4, 1 mM EDTA, 0.2% (w/v) BSA) and then centrifuged at 2,200 x g for 8 min 
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at 4°C. Washed spheroplasts were homogenized in ice-cold homogenization buffer using 
15 strokes. The cell debris was removed by centrifuging the resulting homogenates at 
1,500 x g for 5 min at 4°C. The supernatant was further centrifuged at 3,000 x g for 5 min 
at 4°C to remove residual cell debris. The resulting supernatant was then centrifuged at 
12,000 x g for 15 min at 4°C to pellet mitochondria. The remnant cell debris was 
removed by centrifuging the mitochondrial fraction at 3,000 x g for 5 min at 4°C. The 
resulting supernatant was then centrifuged at 12,000 x g for 15 min at 4°C to obtain the 
crude mitochondrial pellet, which was then resuspended in 3 ml of SEM Buffer (250 mM 
sucrose, 1 mM EDTA, 10 mM MOPS, pH 7.2) and used for the purification of 
mitochondria as described below. 
Purification of mitochondria devoid of microsomal and cytosolic contaminations 
A sucrose gradient was made by carefully overlaying 1.5 ml of 60% sucrose with 4 ml of 
32% sucrose, 1.5 ml of 23% sucrose, and then 1.5 ml of 15% sucrose (all in EM buffer; 1 
mM EDTA, 10 mM MOPS, pH 7.2). Finally, a 3-ml aliquot of the crude mitochondrial 
fraction in SEM buffer was applied to the gradient and centrifuged at 134,000 x g (33,000 
rpm) overnight at 2°C in vacuum (Rotor SW50Ti, Beckman). The purified mitochondria 
found at the 60%/32% sucrose interface were carefully removed and stored at - 80°C. 
Protein precipitation, SDS-PAGE and silver staining of gels 
Protein concentration was determined using the RC DC protein assay kit (Bio-Rad) 
according to the manufacturer's instructions. Proteins were then precipitated using TCA 
as described previously (section "Materials and methods" in chapter 5.2) and resuspended 
117 
in the SDS-PAGE sample buffer to a final concentration of 1 mg/ml. Proteins were then 
resolved on 7.5%, 10%, 12.5% or 16% SDS-PAGE gels as described previously (section 
"Materials and methods" in chapter 5.2). The Bio-Rad unstained molecular marker and a 
0.1 mg/ml solution of BSA in the SDS-PAGE sample buffer were also subjected to SDS-
PAGE. The proteins were then visualized by silver staining as described previously 
(section "Materials and methods" in chapter 5.2). 
Protein identification by mass spectrometry 
Selected protein bands were excised from a silver-stained gel and prepared for the mass-
spectrometric peptide mapping as described previously (section "Materials and methods" 
in chapter 5.2). My modifications to the standard procedure included supplementing the 
excised protein bands with a band containing 2 |ig of bovine serum albumin (BSA) 
protein, which was resolved in a different well of the same SDS-PAGE gel. Therefore, 
the samples were supplemented with double volumes (as compared to the standard 
volumes) of all reagents, including the trypsin buffer (100 ul/tube). Mass accuracy was 
further improved by performing the internal calibration of peptide mass spectra for each 
sample using two intense peptide masses from BSA (1479.8 and 1639.9) and one intense 
peptide mass from trypsin (1045.5). The proteins were identified by the Mascot peptide 
mass fingerprinting method as described previously (see section "Materials and methods" 
in chapter 5.2). 
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Calculating the relative level of a protein of interest using BSA 
For calculating the relative level of a protein of interest, the intensity of the monoisotopic 
peak of each peptide recovered from the band containing this protein was divided by the 
intensity of the monoisotopic peak of a BSA peptide with the monoisotopic mass closest 
to the mass of the peptide of interest. For evaluating relative levels of the protein of 
interest found in the samples to be compared, a ratio "the intensity of the monoisotopic 
peak of a peptide originated from the protein of interest/the intensity of the monoisotopic 
peak of a BSA peptide with the monoisotopic mass closest to the mass of the peptide of 
interest" was calculated for each peptide originated from the protein of interest. Based on 
these data, the average value for relative levels of the protein of interest found in the two 
compared samples was calculated. The method for evaluating relative levels of the 
protein of interest recovered in different samples was validated by calculating relative 
levels of several standard proteins in the samples supplemented with different quantities 
of each of these proteins. 
Validation of the BSA-based relative quantitation method 
Several control experiments have been performed in order to validate the mass 
spectrometric approach for protein identification and quantitation described above. The 
amount of BSA required for the simultaneous trypsin digestion along with the protein 
band of interest has been optimized as outlined below. Four protein bands stained with 
silver and containing different amounts of BSA (i.e., 2 ug, 5 ug, 10 ug or 20 ug) were 
excised from the SDS-PAGE gel, cut into 1 -mm3 pieces and combined in an Eppendorf 
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Figure 10.1. Different quantities of BSA were subjected to SDS-PAGE in a 12.5%-gel 
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Figure 10.2. The protein bands of interest (labeled 1 and 2) were randomly selected 
among the proteins that were recovered in total cell lysates of S. cerevisiae following 
SDS-PAGE in a 12.5%-gel and silver staining. 10 pg of protein were loaded per a well. 
Two unknown proteins with different abundance observed on the silver-stained gel were 
used in the experiment. Both proteins were recovered from the total cell lysate of S. 
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cerevisiae that has been subjected to SDS-PAGE followed by silver staining (Figure 
10.2). The same amount of each protein was added as a protein band excised from the gel 
to each of the tubes containing 2 ug, 5 ug, 10 ug or 20 ug of BSA. The resulting 
unknown protein/BSA mixtures were then subjected to the mass spectrometric analysis as 
described previously. The monoisotopic peptide masses of BSA and unknown protein, 
along with their respective intensities, were grouped separately for each sample. The 
identities of unknown proteins were established (using the Mascot Peptide Mass 
Fingerprinting engine) as Actlp for the major component of the protein band 1 and 
Adhlp for the major component of the protein band 2 (Figure 10.2). The identification of 
Actlp, a 42 kD yeast actin protein, was based on the mass spectrometric peptide mapping 
analysis of 7 peptides that covered 24% of the Actlp sequence with mass accuracy 50 
ppm over the mass to charge (m/z) ratio range of 763 to 2705. The identification of 
Adhlp, a 37 kD yeast alcohol dehydrogenase I protein, was based on the mass 
spectrometric peptide mapping analysis of 8 peptides that covered 28% of the Adhlp 
sequence with mass accuracy 50 ppm over the range of 709 to 2312 m/z. The intensity of 
the monoisotopic peak for each of the recovered BSA, Actlp and Adhlp peptides was 
then used to calculate: 1) the relative to each other levels of Actlp and Adhlp, with each 
of these two proteins being initially added in the same amount to each of the four samples 
that were supplemented with different amounts of BSA; and 2) the relative to Actlp and 
Adhlp levels of BSA in each of the four samples initially supplemented with different 
amounts of BSA. To calculate the relative to each other levels of Actlp and Adhlp, the 
intensity of the monoisotopic peak of each peptide originated from Actlp or Adhlp was 
divided by the intensity of the monoisotopic peak of a BSA peptide with the 
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monoisotopic mass closest to the mass of the analyzed peptide. Based on this ratio, the 
average value for the levels of Actlp and Adhlp relative to BSA was calculated in each 
of the four samples supplemented with different amounts of BSA (Figure 10.3 A). 
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Figure 10.3. (A) The average value for the levels of Actlp and Adhlp relative to BSA in 
each of the four samples containing 2 ug, 5 ug, 10 ug and 20 ug of BSA. (B) The relative 
to each other levels of Actlp and Adhlp in each of the four samples supplemented with 2 
ug, 5 ug, 10 ug and 20 jag of BSA. (C) The average value for the levels of BSA relative 
to Actlp or Adhlp in each of the four samples supplemented with 2 ug, 5 jag, 10 ug and 
20 ug of BSA. 
The ratio of the Actlp and Adhlp levels to each other was then calculated in each of the 
four samples supplemented with different amounts of BSA. Of note, the calculated ratio 
of the Actlp levels relative to the Adhlp levels did not show significant deviation for 
each of the four samples, regardless of the amount of BSA added to them (Figure 10.3B). 
The relative levels of BSA to the levels of Actlp and Adhlp were then calculated 
in each of the four samples initially supplemented with different amounts of BSA. The 
intensity of the monoisotopic peak of each BSA peptide was then divided by the intensity 
of the monoisotopic peak of an Actlp or Adhlp peptide, with the monoisotopic mass of 
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the average value for the levels of BSA relative to Actlp or Adhlp was calculated in each 
of the four samples initially supplemented with different amounts of BSA (Figure 10.3C). 
Importantly, the calculated ratio of the BSA levels versus the levels of either Actlp or 
Adhlp in the four samples containing different amounts of BSA correlated with the 
amount of BSA added to each of them (Figure 10.3C). Taken together, the results of the 
control experiments have validated the developed mass spectrometric approach for 
relative quantitation of the proteins of interest. 
10.3 Results 
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Figure 10.4. Silver-stained 12.5% SDS-PAGE gels of proteins recovered from total 
lysates of wild-type S. cerevisiae cells grown under CR (0.2% or 0.5% glucose) or non-
CR (1% or 2% glucose) conditions. 
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10.3.2 CR alter the age-dependent dynamics of changes in the levels of numerous 
proteins that function in carbohydrate and lipid metabolism 
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Figure 10.5. Relative levels of proteins recovered in total lysates of wild-type S. 
cerevisiae cells grown under CR conditions, as compared to those under non-CR 
conditions. 
124 
10.3.3 CR increases the levels of components of the pyruvate dehydrogenase (PDH) 
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Figure 10.6. Relative levels of protein components of the mitochondrial PDH complex 
and TCA cycle recovered in purified mitochondria of wild-type S. cerevisiae cells grown 
under CR conditions, as compared to those under non-CR conditions. 
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10.3.4 CR remodels the mitochondrial electron transfer chain (ETC), heme 
synthesis and attachment, ATP synthesis, and carriers for ATP/ADP and Pi 
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Figure 10.7. Relative levels of proteins involved in the mitochondrial ETC, heme 
synthesis and attachment, ATP synthesis, and ATP/ADP and Pj carriers recovered in 
purified mitochondria of wild-type S. cerevisiae cells grown under CR conditions, as 
compared to those under non-CR conditions. 
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10.3.5 CR alters the levels of proteins that bind to mitochondrial DNA (mtDNA) 
and modulates the age-dependent dynamics of such binding for 
mitochondrial aconitase 
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Figure 10.8. Relative levels of proteins that bind to mtDNA and the age-dependent 
dynamics of such binding for one of them (i.e., aconitase Acolp) in mitochondria of 
wild-type yeast cells grown under CR conditions, as compared to those under non-CR 
conditions. 
10.4 Discussion 
My mass spectrometric analysis of the age-dependent dynamics of changes in proteomes 
of chronologically aging yeast revealed that the CR diet remodels several key cellular 
processes, including carbohydrate and lipid metabolism, ethanol biosynthesis and 
degradation, the synthesis and transport of ATP, the production of ROS and stress 
response. Importantly, my conclusion that chronologically aging yeast placed on the CR 
diet undergo specific remodeling of a distinct set of metabolic processes are in agreement 
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with the results of metabolomic and lipidomic analyses carried out in Dr. Titorenko's 
laboratory. 
10.4.1 During chronological aging of yeast, CR specifically remodels carbohydrate 
and lipid metabolism 
Data from Dr. Titorenko's laboratory imply that CR promotes the age-dependent 
accumulation of glycogen and trehalose, the two major glucose storage compounds in 
yeast [247]. 
The intracellular levels of glycogen increased sharply in logarithmic (L) phase, 
regardless of initial glucose concentration in the medium (Figure 10.9A). During the 
subsequent diauxic (D) and post-diauxic (PD) phases, CR yeast continued to accumulate 
glycogen, whereas non-CR yeast rapidly consumed it (Figure 10.9A). In contrast to non-
CR yeast, yeast under CR began to degrade their reserved glycogen only when they 
entered stationary (ST) phase (Figure 10.9A). Of note, the degree of CR influenced both 
glycogen storage and its consumption. In fact, CR yeast grown on 0.5% glucose reserved 
more glycogen by the end of PD phase and then consumed it in ST phase somewhat 
faster, as compared to CR yeast grown on 0.2% glucose (Figure 10.9A). 
The non-reducing disaccharide trehalose accumulates in yeast undergoing nutrient 
starvation or entering ST growth phase [247-250]. Therefore, it has been considered as a 
reserve carbohydrate [247-250]. Recent studies, however, revealed that the major 
function of trehalose in yeast consists in enabling the survival of cells exposed to elevated 
temperature or ROS [250, 251]. By maintaining the optimal steady-state level of 
trehalose, yeast preserve native conformation of their proteins during and immediately 
after being exposed to these stresses [250, 251]. As recent findings from Dr. Titorenko's 
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laboratory revealed, yeast began to accumulate trehalose when they entered PD phase 
(Figure 10.9B). Trehalose levels increased during PD and ST phases. The rise of 
trehalose was considerably greater in slowly aging CR yeast than in rapidly aging non-
CR yeast (Figure 10.9B). Thus, CR promotes the age-dependent accumulation of this 
non-reducing disaccharide. Noteworthy, trehalose in CR yeast grown on 0.5% glucose, a 
diet that provides the maximal benefit of CR for longevity, increased mainly in PD phase 
and reached a plateau soon after cells have entered ST phase (Figure 10.9B). Conversely, 
trehalose in CR yeast grown on 0.2% glucose, a diet providing only a modest CR-
dependent life-span extension, increased predominantly throughout ST phase and 
eventually reached the steady-state level exceeding that in CR yeast grown on 0.5% 
glucose (Figure 10.9B). 
Days in culture Days in culture 
Figure 10.9. The dynamics of age-dependent changes in the intracellular levels of 
glycogen (A) and trehalose (B) during chronological aging of wild-type of the yeast S. 
cerevisiae (data from Dr. Titorenko's laboratory). 
These findings from Dr. Titorenko's laboratory on the effect of CR on the age-
dependent accumulation of glycogen and trehalose are in agreement with the data of my 
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proteomic analysis. In fact, I found that CR not only elevates the levels of proteins 
involved in glycogen biosynthesis, such as Glg2p, Glc3p and Gsy2p, but also decreases 
the level of Gphlp, which function in glycogen degradation (Figure 10.5). Furthermore, 
my proteomic analysis revealed that the levels of proteins involved in trehalose 
biosynthesis, such as Tpslp and Tps2p, are increased in CR yeast, as compared to those 
observed in non-CR yeast, with the most significant increase in the protein levels seen 
during ST phase (Figure 10.5). In addition, Athlp, Nthlp and Nth2p, all of which are 
involved in trehalose degradation, are present at lower levels in CR yeast as compared to 
non-CR yeast (Figure 10.5). 
My conclusion that CR causes a specific remodeling of lipid metabolism by 
altering the age-related dynamics of changes in the levels of proteins that function in lipid 
biosynthesis and degradation is supported by recent findings from Dr. Titorenko's 
laboratory. Proper control of fat deposition and mobilization is essential for maintaining 
energy homeostasis, thereby playing a role in longevity regulation [252-255]. In yeast, 
triacylglycerols (TAG) and ergosteryl esters (EE) are two major species of neutral lipids 
that are deposited in so-called lipid bodies (LB; [256]). TAG and EE serve as the main 
storage molecules for free fatty acids (FFA), diacylglycerols (DAG) and ergosterol 
(ERG). Therefore, the ability of yeast to modulate the biosynthesis and degradation of 
neutral lipids is crucial for regulating 1) energy homeostasis; 2) phospholipid and 
cardiolipin biosynthesis; 3) neutralization of excessive amounts of membrane-perturbing 
species of FFA and ERG; 4) FFA- and DAG-induced lipoapoptosis; and 5) DAG-
dependent signal transduction networks [29, 30]. All these processes are currently viewed 
as vital for modulating the pace of aging [211, 239, 252-260]. Using thin-layer 
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chromatography (TLC) for measuring TAG and EE extracted from whole yeast cells, Dr. 
Titorenko's laboratory found that the concentrations of TAG and EE in wild-type cells 
increased gradually in L and D phases, reaching substantially higher levels in non-CR 
yeast than in CR yeast (Figures 10.10 and 10.12). During the subsequent PD phase, CR 
yeast rapidly consumed TAG and EE until their complete exhaustion in early ST phase, 
whereas non-CR yeast continued to accumulate both these lipids (Figures 10.10 and 
10.12). 
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Figure 10.10. CR promotes the consumption of neutral lipids deposited in lipid bodies. 
Spectra of lipids extracted from equal numbers of yeast cells and analyzed by TLC. Cells 
were cultured in YP medium containing 0.2%, 0.5%, 1% or 2% glucose. Abbreviations: 
DAG, diacylglycerols; EE, ergosteryl esters; ERG, ergosterol; ER, endoplasmic 
reticulum; FA-CoA, CoA esters of fatty acids; FFA, free fatty acids; TAG, 
triacylglycerols (data from Dr. Titorenko's laboratory). 
In contrast to yeast under CR, non-CR yeast began to degrade their deposited neutral 
lipids only after they have entered ST phase (Figures 10.10 and 10.12). The use of 
fluorescence microscopy for visualizing TAG and EE in living cells supported the notion 
that CR diet considerably accelerates the mobilization of LB-deposited neutral lipids 
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Figure 10.11. CR promotes the consumption of neutral lipids deposited in lipid bodies. 
Yeast cells were visualized using Calcofluor White M2R (CW; 25 uM) and stained with 
BODIPY 493/503 to detect neutral lipids of lipid bodies (LB). Cells were cultured in YP 
medium containing 0.2% or 2% glucose (data from Dr. Titorenko's laboratory). 
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Figure 10.12 CR promotes the consumption of neutral lipids deposited in lipid bodies. 
(C) Percent of cells that contain lipid bodies. Images similar to the representative images 
shown in Figure 10.11 were quantitated. (D-F) Lipid species shown in Figure 10.10 were 
quantitated by densitometric analysis of TLC plates. Cells were cultured in YP medium 
containing 0.2%, 0.5%, 1% or 2% glucose. Abbreviations: EE, ergosteryl esters; FFA, 
free fatty acids; TAG, triacylglycerols (data from Dr. Titorenko's laboratory). 
As Dr. Titorenko's laboratory found, consistent with the ER origin of LB, both 
TAG and EE were initially synthesized in the ER of CR and non-CR cells during L and D 
phases, prior to being relocated to LB (Figure 10.13). CR yeast rapidly consumed these 
LB-confined lipids during PD phase, completely exhausting their fat depot by the end of 
it (Figure 10.13). In contrast, non-CR yeast continued to accumulate both TAG and EE 
within their LB during PD phase. The age-dependent buildup of neutral lipids in LB of 
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non-CR yeast coincided with the deceleration of their exit from the ER en route to LB 
(Figure 10.13), perhaps due to a negative feedback loop regulating this process. 
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Figure 10.13. CR promotes the consumption of neutral lipids deposited in lipid bodies. 
Spectra of lipids that were extracted from purified endoplasmic reticulum (ER) and lipid 
bodies (LB) of yeast. The equivalent of 200 ug of ER proteins and 20 ug of lipid body 
proteins was used for lipid extraction at each time point. Lipids were analyzed by TLC 
and quantitated by densitometric analysis of TLC plates. Each plot shows a representative 
experiment repeated 3 times with similar results. Cells were cultured in YP medium 
containing 0.2% or 2% glucose. Abbreviations: DAG, diacylglycerols; EE, ergosteryl 
esters; ERG, ergosterol; ER, endoplasmic reticulum; FA-CoA, CoA esters of fatty acids; 
FFA, free fatty acids; TAG, triacylglycerols (data from Dr. Titorenko's laboratory). 
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As Dr. Titorenko's laboratory found, the biosynthesis of FFA and DAG during early D 
phase was followed by their ER-confmed incorporation into TAG during late D phase 
(Figure 10.13). Soon after their relocation from the ER to LB, TAG in CR yeast were 
subjected to lipolysis resulting in the formation of FFA and DAG, both of which were 
rapidly degraded by the end of PD phase (Figure 10.13). Alternatively, non-CR yeast 
accumulated significant quantities of both FFA and DAG within the ER during PD phase 
(Figure 10.13). 
All these data from Dr. Titorenko's laboratory on the age-dependent dynamics of 
lipidomes in chronologically aging CR and non-CR yeast are in agreement with the 
results of my quantitative proteomic analysis (Figure 10.5). As I found, during L phase, 
the levels of proteins involved in the biosynthesis of TAG and EE, such as Gpt2p, Ayrlp, 
Slclp, Pahlp, Lpplp, Dgalp, and Are2p, in CR yeast are lower than in non-CR yeast 
(Figure 10.5). During the subsequent D and PD phases, the levels of these proteins in Cr 
yeast decrease even further and become significantly lower than in non-CR yeast (Figure 
10.5). In contrast, as my proteomic analysis revealed, the CR diet has an opposite effect 
on the levels of proteins involved in the degradation of TAG and EE, such as Tgllp, 
Tgl3p, Tgl4, and Yehlp. Specifically, during L phase, the levels of these proteins in CR 
yeast are higher than in non-CR yeast (Figure 10.5). The stimulating effect of the CR diet 
on the levels of proteins that function in lipid degradation becomes even more 
pronounced in D and PD phases (Figure 10.5). Taken together, my findings support the 
notion that the CR diet increases the levels of the key enzymes involved in the lipolytic 
consumption of neutral lipids deposited in lipid bodies, concurrently decreasing the levels 
of enzymes catalyzing the biosynthesis of these storage lipids. 
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Furthermore, according to my proteomic analysis, CR also modulates the levels of 
proteins that function in the formation of CoA esters of fatty acids (FA-CoA) and in their 
subsequent uptake and oxidation by peroxisomes. In fact, the CR diet greatly elevates the 
levels of Fatlp, Faalp, Faa2p, Faa4p, Foxlp, Fox2p and Fox3p throughout yeast life span 
(Figure 10.5). My findings satisfactorily explain a stimulating effect of the CR diet on the 
consumption of fatty acids during an early stage of yeast chronological aging, which has 
recently bee reported by Dr. Titorenko's laboratory (Figures 10.10, 10.11 and 10.12). 
10.4.2 CR alters the age-related dynamics of ethanol biosynthesis and degradation 
Recent data from Dr. Titorenko's laboratory imply that CR greatly accelerates catabolism 
of ethanol, a product of glucose fermentation in yeast (Figure 10.14). Ethanol has been 
shown to modulate the rate of chronological aging in yeast by a yet-to-be characterized 
mechanism [261]. As Dr. Titorenko's laboratory recently found, CR greatly accelerated 
the catabolism of ethanol, a product of glucose fermentation (Figure 10.14). Importantly, 
it seems that such stimulatory effect of CR on ethanol catabolism is important for 
providing the benefit of CR for longevity. In fact, CR yeast completely consumed ethanol 
by day 2, at least 10 days before the beginning of their viability decline (Figure 10.14). 
Conversely, non-CR yeast were unable to consume substantial quantities of ethanol prior 
the age-dependent decline of their viability has begun (Figures 10.14 and 1C). Moreover, 
the level of ethanol accumulated in non-CR yeast correlated with the initial concentration 
of glucose in the medium, being inversely proportional to their chronological life span 
(Figure 10.14 and ID). Therefore, it is likely that the stimulatory effect of CR on ethanol 
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Figure 10.14. CR greatly accelerates ethanol catabolism. The dynamics of age-dependent 
changes in the extracellular concentrations of ethanol during chronological aging of wild-
type cells. Cells were continuously cultivated in rich YP medium initially containing 
0.2%, 0.5%, 1% or (data from Dr. Titorenko's laboratory). 
The results of my quantitative proteomic analysis provide an explanation for the 
observed by Dr. Titorenko's laboratory ability of the CR diet to accelerate ethanol 
consumption. As I found, CR substantially increases the level of Adhlp, an enzyme 
catalyzing ethanol biosynthesis, and greatly increases the level of Adh2p, an enzyme 
involved in ethanol degradation (Figure 10.5). Thus, it is conceivable that the CR diet 
increases ethanol consumption (Figure 10.14) by altering the levels of enzymes involved 
in its biosynthesis and degradation. 
10.4.3 CR remodels mitochondrial functions 
My quantitative proteomic analysis also revealed that the CR diet remodel several protein 
teams that function in essential processes confined to mitochondria (Figure 10.5). In fact, 
according to my data, CR increases the levels of such mitochondrial proteins as Pdalp, 
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Acolp, Ndilp, Sdhlp, Cytlp, Heml4p, Cyc3p, Ssqlp, Sod2p, Prxlp, Atplp, Atp2p, 
Pet9p and Mirlp (Figure 10.5). These proteins play the major roles in 1) the formation of 
acetyl-CoA and its subsequent oxidation via the tricarboxylic acid (TCA) cycle; 2) the 
mitochondrial electron transport chain (ETC) and oxidative phosphorylation coupled to 
ATP synthesis; and 3) the detoxification of mitochondrially formed ROS. Furthermore, 
my quantitative proteomic analysis of mitochondria purified from S. cerevisiae cells 
grown under CR and non-CR conditions (Figure 10.6) showed that the CR diet increases 
the levels of all five protein components of the mitochondrial PDH complex (Pdalp, 
Pdblp, Latlp, Pdxlp, and Lpdlp), along with all of the TCA cycle enzymes (Citlp, 
Cit2p, Cit3p, Acolp, Idhlp, Idh2p, Kgdlp, Kgd2p, Lsclp, Lsc2p, Sdhlp, Sdh2p, Sdh3p, 
Sdh4p, Fumlp and Mdhlp). In addition, my quantitative analysis of the mitochondrial 
proteomes revealed that the CR diet also increases the levels of proteins involved in the 
mitochondrial ETC (Ndilp, Sdh2p, Corlp and Qcrlp), ATP synthesis (Atplp, Atp2p, 
Atp4p and Atp5p), ATP/ADP and P; carriers (Pet9p and Mirlp), and heme biosynthesis 
(HemHp) and attachment (Cyc3p) (Figure 10.7). Moreover, I demonstrated that the CR 
diet also increases the levels of certain proteins that bind to mitochondrial DNA 
(mtDNA), such as Pdalp, Pdblp, Lpdlp, Acolp, Idhlp, Kgdlp, Kgd2p, Lsclp, Ald4p, 
Atplp, Sislp, Hsp60p and Ssclp (Figure 10.8). Of note, the levels of some other 
mtDNA-binding proteins, such as Abf2p and Ilv5p, were decreased under CR conditions 
(Figure 10.8). 
Altogether, the results of my quantitative proteomic analysis provide evidence that 
the CR diet greatly promotes the production of acetyl-CoA by the PDH complex and its 
subsequent oxidation in the TCA cycle. Furthermore, by specifically altering the levels of 
138 
components of the mitochondrial ETC and ROS detoxification, CR specifically 
modulates the age-dependent dynamics of changes in the concentration of ROS. 
10.4.4 Specific remodeling of metabolism in yeast placed on the CR diet 
Altogether, the results of my quantitative proteomic analysis and the data of metabolomic 
and functional analyses conducted in Dr. Titorenko's laboratory suggest the following 
model for the remodeling of carbohydrate and lipid metabolism in chronologically aging 
CR yeast (Figure 10.15). 
Figure 10.15. A model for the remodeling of carbohydrate and lipid metabolism in 
chronologically aging yeast 5. cerevisiae grown under CR conditions (The processes that 
are accelerated under CR conditions are shown in red, while those processes that are 
decelerated under CR conditions are shown in green). 
139 
In this model, chronologically aging non-CR yeast meet their metabolic requirements 
primarily by carrying out glycolysis and degrading the storage carbohydrates glycogen 
and trehalose. The resulting production of ethanol due to fermentation affects the 
peroxisomal function by inhibiting the synthesis of enzymes involved in the breakdown 
of free fatty acids through peroxisomal p-oxidation pathway. The resulting diminished 
peroxisomal production of acetyl-CoA leads to a decrease in the mitochondrial function 
and promotes mitochondrial fragmentation, thereby triggering cytochrome c release and 
the resulting activation of mitochondria-controlled apoptosis. In addition, the 
accumulation of free fatty acids and DAG in non-CR yeast promotes the necrotic cell 
death. The cumulative effect of these age-related changes in cellular processes shortens 
the chronological life span of non-CR yeast. In contrast to non-CR yeast, chronologically 
aging CR yeast fulfill their metabolic requirements by establishing a distinct pattern of 
carbohydrate and lipid metabolism, in which the bulk of ATP is produced through 
gluconeogenetic pathways and the increased consumption of neutral lipids. Under CR 
conditions, yeast accumulate glycogen and trehalose, the two major glucose storage 
compounds, by elevating the levels of enzymes catalyzing their biosynthesis and 
decreasing the levels of enzymes required for their degradation. At the same time, CR 
promotes the remodeling of lipid metabolism in chronologically aging yeast by 
accelerating the lipolytic consumption of the LB-deposited neutral lipids TAG and EE. 
The considerable amounts of FFAs generated due to such lipolysis are rapidly converted 
to FA-CoA, which is then metabolized into acetyl-CoA through the peroxisomal P-
oxidation pathway, whose function is greatly accelerated by the CR diet. The 
peroxisomally-produced acetyl-CoA is then used by mitochondria of CR yeast to 
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synthesize the bulk of ATP. As a result, increased peroxisomal activity leads to an 
increase in the mitochondrial function and promotes the maintenance of the 
mitochondrial network, thereby down-regulating the proapoptotic mitochondrial 
signaling. At the same time, the concentration of ROS generated in mitochondria of CR 
yeast during oxidative phosphorylation is maintained at a threshold, non-toxic level, 
thereby resulting in the activation of stress response, which in rum helps to prevent and 
repair the oxidative damage to cellular macromolecules. In addition, the increased 
lipolysis of neutral lipids under CR conditions results in significantly diminished amounts 
of free fatty acids and DAG in the cytosol, thus preventing cell death by necrosis. The 
cumulative effect of these age-related changes in cellular processes extends the 
chronological life span of non-CR yeast. 
10.5 Conclusions 
My quantitative proteomics analysis, along with the data obtained from metabolomic and 
functional analyses carried out in Dr. Titorenko's laboratory, provides evidence that, in 
contrast to non-CR yeast that produce the bulk of ATP by glycolytic oxidation of the 
glycogen- and trehalose-derived glucose, chronologically aging CR yeast generate the 
majority of their ATP in mitochondria by oxidizing the pool of acetyl-CoA generated in 
peroxisomes via p-oxidation of free fatty acids. In order to validate this model of life-
span extension through a specific remodeling of metabolism in CR yeast, I evaluated the 
contribution of mitochondrial and peroxisomal processes to the beneficial effect of CR on 
longevity by comparing the age-related dynamics of changes in the proteomes of 
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mitochondria of wild-type strain and the short-lived mutant pex5A, which is impaired in 
peroxisomal p-oxidation of fatty acids. 
11 The comparative analysis of mitochondrial proteomes of wild-type and the 
short-lived pexSA mutant strains placed on the CR diet 
11.1 Introduction 
Most eukaryotic cells contain mitochondria, the double membrane-bound organelles of 
the prokaryotic origin that generate cellular energy in the form of ATP via oxidative 
phosphorylation. As mentioned previously, mitochondrial activity is responsible for over 
90% of total intracellularily produced ROS known to play a major role in the biological 
aging of yeasts, worms, flies, mice and mammals. Numerous studies in evolutionary 
distant organisms suggest that the aging is regulated, in part, by an intrinsically induced, 
mitochondria-controlled apoptotic cell death mechanism [192, 196, 197, 200, 203, 204]. 
According to the data from Dr. Titorenko's laboratory, the age-dependent, mitochondria-
controlled apoptotic death in yeast is regulated by the extent of fatty acid oxidation in 
peroxisomes, suggesting that peroxisomal fatty acid oxidation plays a key role in 
longevity regulation by modulating mitochondria-controlled apoptosis. One of the crucial 
evidence for the link between peroxisomes and mitochondria in longevity regulation 
came from findings in Dr. Titorenko's laboratory showing that Pex5p, a cytosolic 
shuttling receptor for peroxisomal import of PTS1-containing proteins, modulates the rate 
of chronological aging by regulating the intrinsic, mitochondria-dependent apoptotic cell 
death mechanism. Dr. Titorenko's laboratory also demonstrated that the short-lived 
pex5A mutant is highly sensitive to the exogenously induced apoptosis and does not 
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survive a long-term exposure to various stresses (Figure 11.1). It should be stressed that 
the CR diet greatly increases the detrimental effects of the pex5A mutation on the life 
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Figure 11.1. The pex5A mutation alters the morphology of mitochondria and impairs 
their function in S. cerevisiae cells grown under CR conditions. 
The availability of the short-lived pexSA mutant, whose defect in peroxisomal 
oxidation of free fatty acids greatly affects the morphology of mitochondria and impairs 
their function (Figures 11.1), allowed me to identify mitochondrial proteins that, in 
response to signals emanating from the peroxisome, control the rate of chronological 
aging of CR yeast. These proteins, whose levels in highly purified mitochondria of the 
short-lived pex5A mutant strain were significantly altered (as compared to those of wild-
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type strain), were identified and quantitated using mass spectrometry as described 
previously (section 10.2, "Materials and methods"). 
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Figure 11.2. The pexSA mutation dramatically shortens chronological life span of S. 
cerevisiae under CR conditions. 
11.2 Materials and methods 
Strains, media, reagents and solutions 
The wild-type strain Saccharomyces cerevisiae BY4742 (MATa his3Al leulAO lys2A0 
ura3A0) and mutant strain pex5A (MATa his3Al leu2A0 lys2A0 ura3A0 pex5A::kanMX4) 
were used in this study. The components of YEPD (0.2% glucose) medium were as 
follows: 1% yeast extract, 2% peptone and 0.2% glucose. 
Isolation of the crude mitochondria] fraction 
Yeast cells were pelleted at 3,000 x g for 5 min at room temperature, washed twice with 
distilled water, resuspended in DTT buffer (100 mM Tris-H2S04, pH 9.4, 10 mM 
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dithiothreitol [DTT]), and incubated for 20 min at 30°C to weaken the cell wall. The cells 
were then washed with Zymolyase buffer (1.2 M sorbitol, 20 mM potassium phosphate, 
pH 7.4), centrifuged at 3,000 x g for 5 min at room temperature, and incubated with 3 
mg/g (wet wt) of Zymolyase-100T in 7 ml/g (wet wt) Zymolyase buffer for 45 min at 
30°C. Following an 8-min centrifugation at 2,200 x g at 4°C, the isolated spheroplasts 
were washed in ice-cold homogenization buffer (5 ml/g) (0.6 M sorbitol, 10 mM Tris-
HC1, pH7.4, 1 mM EDTA, 0.2% (w/v) BSA) and then centrifuged at 2,200 x g for 8 min 
at 4°C. Washed spheroplasts were homogenized in ice-cold homogenization buffer using 
15 strokes. The cell debris was removed by centrifuging the resulting homogenates at 
1,500 x g for 5 min at 4°C. The supernatant was further centrifuged at 3,000 x g for 5 min 
at 4°C to remove residual cell debris. The resulting supernatant was then centrifuged at 
12,000 x g for 15 min at 4°C to pellet mitochondria. The remnant cell debris was 
removed by centrifuging the mitochondrial fraction at 3,000 x g for 5 min at 4°C. The 
resulting supernatant was then centrifuged at 12,000 x g for 15 min at 4°C to obtain the 
crude mitochondrial pellet, which was then resuspended in 3 ml of SEM Buffer (250 mM 
sucrose, 1 mM EDTA, 10 mM MOPS, pH 7.2) and used for the purification of 
mitochondria as described below. 
Purification of mitochondria devoid of microsomal and cytosolic contaminations 
A sucrose gradient was made by carefully overlaying 1.5 ml of 60% sucrose with 4 ml of 
32% sucrose, 1.5 ml of 23% sucrose, and then 1.5 ml of 15% sucrose (all in EM buffer; 1 
mM EDTA, 10 mM MOPS, pH 7.2). Finally, a 3-ml aliquot of the crude mitochondrial 
fraction in SEM buffer was applied to the gradient and centrifuged at 134,000 x g (33,000 
145 
rpm) overnight at 2°C in vacuum (Rotor SW50Ti, Beckman). The purified mitochondria 
found at the 60%/32% sucrose interface were carefully removed and stored at - 80°C. 
Protein precipitation, SDS-PAGE and silver staining of gels 
Protein concentration was determined using the RC DC protein assay kit (Bio-Rad) 
according to the manufacturer's instructions. Proteins were then precipitated using TCA 
as described previously (section "Materials and methods" in chapter 5.2) and resuspended 
in the SDS-PAGE sample buffer to a final concentration of 1 mg/ml. Proteins were then 
resolved on 7.5%, 10%, 12.5% or 16% SDS-PAGE gels as described previously (section 
"Materials and methods" in chapter 5.2). The Bio-Rad unstained molecular marker and a 
0.1 mg/ml solution of BSA in the SDS-PAGE sample buffer were also subjected to SDS-
PAGE. The proteins were then visualized by silver staining as described previously 
(section "Materials and methods" in chapter 5.2). 
Protein identification by mass spectrometry 
Selected protein bands were excised from a silver-stained gel and prepared for the mass-
spectrometric peptide mapping as described previously (section "Materials and methods" 
in chapter 5.2). My modifications to the standard procedure included supplementing the 
excised protein bands with a band containing 2 pg of bovine serum albumin (BSA) 
protein, which was resolved in a different well of the same SDS-PAGE gel. Therefore, 
the samples were supplemented with double volumes (as compared to the standard 
volumes) of all reagents, including the trypsin buffer (100 ul/tube). Mass accuracy was 
further improved by performing the internal calibration of peptide mass spectra for each 
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sample using two intense peptide masses from BSA (1479.8 and 1639.9) and one intense 
peptide mass from trypsin (1045.5). The proteins were identified by the Mascot peptide 
mass fingerprinting method as described previously (see section "Materials and methods" 
in chapter 5.2). 
Calculating the relative level of a protein of interest using BSA 
For calculating the relative level of a protein of interest, the intensity of the monoisotopic 
peak of each peptide recovered from the band containing this protein was divided by the 
intensity of the monoisotopic peak of a BSA peptide with the monoisotopic mass closest 
to the mass of the peptide of interest. For evaluating relative levels of the protein of 
interest found in the samples to be compared, a ratio "the intensity of the monoisotopic 
peak of a peptide originated from the protein of interest/the intensity of the monoisotopic 
peak of a BSA peptide with the monoisotopic mass closest to the mass of the peptide of 
interest" was calculated for each peptide originated from the protein of interest. Based on 
these data, the average value for relative levels of the protein of interest found in the two 
compared samples was calculated. The method for evaluating relative levels of the 
protein of interest recovered in different samples was validated by calculating relative 
levels of several standard proteins in the samples supplemented with different quantities 
of each of these proteins. 
147 
11.3 Results 
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Figure 11.3. Protein spectra of purified mitochondria of wild-type and pexSA placed on 
CR diet. 
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11.3.2 The pex5 A mutation decreases the levels of components of the PDH complex 
and TCA cycle in mitochondria 
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Figure 11.4. Relative levels of protein components of the mitochondrial PDH complex 
and TCA cycle recovered from purified mitochondria of wild-type and pex5A S. 
cerevisiae cells that were grown under CR conditions and recovered for analysis upon 
reaching D phase. 
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11.3.3 The pex5A mutation decreases the levels of proteins involved in the 
mitochondrial ETC, heme synthesis and attachment, ATP synthesis, and 
ATP/ADP and P; transport across the membrane 
Day 2 (D phase) 
• • B I 3 E 3 Mirlp | P, earner 
• • B B S S Hem14p | Heme biosynthesis 
^ H H H i S l cyc3p | Heme attachment to cytochrome c 
wild pex5& 
type 
Figure 11.5. Relative levels of proteins involved in the mitochondrial ETC, heme 
synthesis and attachment, ATP synthesis, and of ATP/ADP and Pj carriers recovered 
from purified mitochondria of wild-type and pex5A S. cerevisiae cells that were grown 
under CR conditions and recovered for analysis upon reaching D phase. 
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11.3.4 The pex5A mutation significantly affects mitochondrial morphology by 
altering the levels of mitochondrial proteins involved in mitochondrial fission 
and fusion 






































Figure 11.6. Relative levels of proteins involved in mitochondrial fission and fusion 
recovered from purified mitochondria of wild-type and pex5A S. cerevisiae cells that 
were grown under CR conditions and recovered for analysis upon reaching D phase. 
11.3.5 The pex5A mutation significantly decreases the levels of proteins that 
detoxify ROS to protect mitochondrial macromolecules from oxidative 
damage 
Relative level<j^g^6^£J-PJ-2-5] f ^ Q ] -[111-1.5] Q.Q IQ +[1 -^^j^^^^^Pfl^*^. 
Day2(D phase) 
Sod2p | mitochondrial MnSOD (superoxide dismutase) that detoxifies superoxide radicals 
Prxlp | Mitochondrial peroxiredoxin with thioredoxin peroxidase activity that detoxifies hydroperoxides 
Ccplp [ Mitochondrial cytochrome-c peroxidase that detoxifies ROS 
wild pex5A 
type 
Figure 11.7. The pex5A mutation remodels protein team that protects mitochondrial 
macromolecules from oxidative damage. 
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11.3.6 The pexSA mutation increases the levels of some chaperone proteins that 
control the unfolding of proteins during their translocation into the 
mitochondrial matrix and/or protein folding/refolding in the mitochondrial 
matrix 
Relative level <-[3.0] -[2.6-3.Q]-[2.1-2.5]-[1.6-2.0]-[1.1-1.5] Q,Q m +[1.1-1.5]t[1.6-2.0]t[2.1-2.5]+[2.6-3.0] >+[3.0] 
Day2(D phase) 
Ssdp I Pre-protein unfolding on the cytosolic face of the mitochondrion & pre-protein translocation into the mitochondrial matrix 
Hsp60p 
Protein folding & refolding in the mitochondrial matrix 
Two subunits of the inner mitochondrial membrane chaperone that promotes folding of the newly synthesized 
membrane components of the ETC & stabilizes these components in the inner mitochondrial membrane 
wild pex i i 
type 
Figure 11.8. The pex5A mutation remodels protein machineries that control the unfolding 
of proteins during their translocation into the mitochondrial matrix and/or protein 
folding/refolding in the mitochondrial matrix. 
11.3.7 The pex5A mutation alters the levels of mitochondrial proteins involved in 
the biosynthesis of various amino acids and/or stabilization of mitochondrial 
DNA (mtDNA) 
Relative l e v e l l J j ? ^ ^ 2 3 ^ ^ M ! ^ ^ ^ L °-° i1-0 f^f.r.Vl-.^ ilM L1 •|^?T^PJ!^^lP£jJ!LLlE^L 
Day2(D phase) 
Abf2p | mtDNA-binding protein involved in mtDNA replication, recombination & maintenance 
Ilv5p | Protein involved in branched-chain amino acid biosynthesis & required for maintenance of mtDNA 
Ilv2p j 
Ilv3p | Proteins involved in branched-chain amino acid biosynthesis 
Batlp ! 
Idp1 p | Protein involved in qlutamate biosynthesis 
Shmlp | Protein involved in glycine biosynthesis 
wild pex5d 
type 
Figure 11.9. The pexSA mutation remodels protein machineries that control biosynthesis 
of various amino acids and/or stabilize mitochondrial DNA (mtDNA). 
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11.3.8 The long-lived mitochondrial mutants idhlA & idhlA have increased levels of 
cytosolic anti-stress chaperones and proteins that decompose ROS in the 
cytosol 
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Figure 11.10. Quantitative analysis of cellular proteomes of WT, idhlA & idhlA 
mutants revealed that both mutations elevate the levels of cytosolic anti-stress chaperones 
and proteins that decompose ROS in the cytosol, thereby protecting other proteins from 
oxidative damage. 
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11.3.9 The long-lived mitochondrial mutants idhlA and idh2A have increased levels 
of the mitochondrial proteins involved in the import of other proteins into 
the mitochondrial matrix, folding and refolding of mitochondrial proteins 
following stress exposure, decomposition of ROS, and protection of mtDNA 









Day 9 (ST phase); purified 
mitochondria 
•
| | a | | | M i 
S 3 TT? 
4fkWM| *&m»l 
•A 
wt idhU idhlA 
Day4(PD) Day 9 (ST) 
Protein import into 
mitochondria and 
folding/refolding of proteins 
in mitochondria 
Detoxification of ROS 
produced in mitochondria 
Mitochondrial DNA-
binding proteins 
wt idhUidh2A wt idhUidhlA 
Purified 
mitochondria 
Relative level (fold difference 
!*i>3"lS!w re!ativeto that for WT strain) 
Figure 11.11. The long-lived idhlA and idh2A mutants have elevated levels of 
mitochondrial enzymes involved in protein import into the mitochondrial matrix, protein 
folding and refolding following stress exposure, degradation of ROS and protection of 
mtDNA from oxidative damage. 
11.4 Discussion 
My quantitative proteomic analysis revealed numerous mitochondrial proteins whose 
levels have been altered in mitochondria of the short-lived pex5A mutant strain (as 
compared to those of wild-type strain) grown under CR conditions. These findings imply 
that the Pex5p-dependent assembly of peroxisomes plays an essential role in longevity 
regulating by modulating a distinct set of mitochondrial processes, as described below. 
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11.4.1 The pex5A mutation alters the mitochondrial PDH complex and impairs the 
TCA cycle in mitochondria 
According to my quantitative proteomic analysis, the pex5A mutation substantially 
decreases the levels of almost all protein subunits (except Pdxlp) of the mitochondrial 
PDH complex (Figure 11.4). The pyruvate dehydrogenase (PDH) multienzyme complex 
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Figure 11.12. The pyruvate dehydrogenase (PDH) multienzyme complex in the yeast S. 
cerevisiae. 
Acetyl-CoA formed by the PDH complex acts as a substrate for the citrate 
synthase-dependent reaction of the TCA cycle in mitochondria, whereas NADH provides 
reduced equivalents to drive the mitochondrial ETC. Thus, proper functioning of the 
PDH complex is crucial for the synthesis of ATP in mitochondria. The PDH complex 
consists of four enzyme subunits: the El subunit composed of Pdalp and Pdblp, the E2 
subunit Latlp, the E3 subunit (Lpdlp), and the X subunit Pdxlp (Figure 11.12). The 
observed in the pex5A mutant strain decrease in levels of the Pdalp, Pdblp and Latlp 
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(the El and E2 subunits of the PDH complex) greatly reduces acetyl-CoA formation and 
ATP production in the mitochondria (Figure 11.4). Furthermore, the pex5A mutation 
lowers the levels of Lpdlp (E3), thus also decreasing the rate of mitochondrial NADH 
formation (Figure 11.4). Of note, enzymatic activities of the PDH complex subunits 
appear to play a crucial role in regulation of the chronological aging of S. cerevisiae. In 
fact, recent work in Dr. Titorenko's laboratory demonstrated that the mutants lacking 
either El or E2 subunits of PDH are short-lived, whereas those lacking the X or E3 








\ \ P A. I K 
fc 
V [ N 
& 3 
-I^i 
* • = * 
A 
m g-
Data from Alex Goldberg 
0 5 10 15 20 25 30 
Days in culture 
• wild type <§• latiA 
~®-pdalA -OpdxlA 
-ArpdblA -i^tpdlA 
Figure 11.13. Lack of the Pdalp, Pdblp or Latlp components of the mitochondrial PDH 
complex shortens the chronological life span of S. cerevisiae grown under CR conditions, 
whereas the lack of Pdxlp and Lpdlp subunits extends its life span. 
Based on my proteomic data implicating mitochondrial PDH complex as a rate-
limiting factor in the aging process, and taking into account the research findings of my 
colleagues in Dr. Titorenko's laboratory on life span extension in S. cerevisiae mutants 
lacking either X or E3 subunits, I propose the following model for the integration of the 
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mitochondrial PDH complex into the cellular longevity network. Lack of either X 
(Pdxlp) or E3 (Lpdlp) subunits of the mitochondrial PDH complex prevents the NADH 
synthesis but does not impair the formation of acetyl-CoA, and thus does not 
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Electron transport chain ATP, ROS 
Figure 11.14. Remodeling of the PDH multienzyme complex in the long-lived pdxl A 
and IpdlA mutants of S. cerevisiae grown under CR conditions. 
However, the impairment of NADH synthesis by the PDH complex in the 
mitochondria of the pdxl A and IpdlA mutants slows down electron flow through the 
ETC, thus lowering the production of ROS and reducing amount of ROS-mediated 
oxidative damage to mitochondrial macromolecules. The anticipated decrease in the 
amount of ROS produced in mitochondria of the pdxl A and IpdlA mutants has been 
confirmed by Dr. Titorenko's laboratory, thus supporting my hypothesis that the 
reduction of ROS-mediated oxidative damage to mitochondrial macromolecules is the 
major cause in the chronological life span extension observed in these mutants. 
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On the contrary, lack of Pdalp, Pdblp or Latlp components of the PDH complex 
impairs the synthesis of both acetyl-CoA and NADH, thereby decelerating the TCA cycle 
as well as the mitochondrial ETC and, thus, lowering the synthesis of ATP (Figure 
11.15). The insufficient ATP production in mitochondria of pdalA, pdblA and latlA 
mutants could therefore explain their shorter lifespan (Figure 11.15). 
TCA cycle NADH,FADH2 
Electron transport chain ATP,R0S 
Lipoamide 
Figure 11.15. Remodeling of the PDH multienzyme complex in the short-lived pdalA, 
pdblA and latlA mutants of S. cerevisiae grown on CR diet. 
My quantitative proteomic analysis also revealed that the pex5A mutation decreases 
the levels of enzymes involved in the mitochondrial TCA cycle, such as Acolp, Kgdlp, 
Kgd2p, and Fumlp (Figure 11.4). In addition, the pex5A mutation lowers the levels of the 
Sdh2p subunit of the mitochondrial succinate dehydrogenase (SDH) complex, which also 
catalyzes one of the mandatory reactions in the TCA cycle (Figure 11.4). Of note, these 
four TCA cycle enzymes and the Sdh2p subunit of the SDH complex have no redundant 
protein counterparts, which do exist for several other enzymes involved in the TCA 
cycle. As a result, a mutant strain lacking any of these five mitochondrial proteins has a 
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partially impaired TCA cycle activity and generates insufficient amounts of ATP, which 
could account for the observed life span shortening in such mutants. Furthermore, my 
proteomic analysis also revealed that the pex5A mutation does not alter the levels of TCA 
cycle enzymes that have redundant subforms, such as Citlp and Cit3p, Idhlp and Idh2p, 
as well as Lsclp and Lsc2p (Figure 11.4). In fact, mutants lacking only one redundant 
subform of these TCA cycle enzymes live longer than wild-type strain and are more 
resistant to elevated temperature and oxidative stress, which is consistent with the 
elevated levels of numerous stress-protecting proteins observed in all these mutants 
(Figures 11.10, 11.11, 11.16 and 11.17). Moreover, consistent with my proteomic data, 
studies in Dr. Titorenko's laboratory also showed that the long-lived mutants idhlA or 
idh2A have lower frequencies of mtDNA mutations, which can explain their longer (as 
compared to wild-type strain) life span (Figure 11.18). 
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Figure 11.17. Chronologically aging CR yeast carrying the idhlA or idhlA mutation 
have increased resistance to elevated temperatures and oxidative stress, which is 
consistent with the elevated levels of numerous stress-protecting proteins observed in 
these mutants. 
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Figure 11.18. Chronologically aging CR yeast carrying the idhlA or idh2A mutation 
show decreased frequencies of mtDNA mutations, which is consistent with the elevated 
levels of numerous proteins that bind to mtDNA and protect it from oxidative damage. 
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Taken together, my proteomic data implicating certain components of the 
mitochondrial TCA cycle as the regulators of the chronological aging in S. cerevisiae, 
along with the recent findings from Dr. Titorenko's laboratory on the life span extension 
in mutants lacking a single redundant subform of several TCA cycle enzymes, strongly 
suggest the following scenario for the integration of the mitochondrial TCA cycle into the 
cellular longevity network. Lack of a single isoform of either the mitochondrial citrate 
synthase, NAD-dependent isocitrate dehydrogenase or succinyl-CoA ligase does not 
impair the ability of mitochondria to produce NADH and FADH2 and, thus, do not impair 
ATP synthesis. However, lack of a single isoform of each of these enzymes also 
decreases the amounts of NADH and FADH2 produced, thereby slowing down electron 
flow through the mitochondrial ETC, lowering the amount of ROS generated during this 
process and, consequently, reducing the extent of oxidative damage of mitochondrial 
macromolecules by ROS. The predicted by my hypothesis decreased ROS production in 
the citlp, cit3p, idhlp, idh2p, help and lsc2p mutants has been recently confirmed in Dr. 
Titorenko's laboratory and could satisfactorily explain the life span extension observed in 
these mutants. 
11.4.2 The pex5A mutation remodels the protein machineries regulating 
mitochondrial ETC, heme biosynthesis and attachment, ATP synthesis, and 
ATP/ADP exchange 
I also found that the pex5 A mutation decreases the levels of certain protein components of 
the mitochondrial ETC and ATP synthase, including the mitochondrial ETC complex I 
constituent Ndilp, the mitochondrial ETC complex II constituent Sdh2p (a subunit of the 
succinate dehydrogenase complex), the mitochondrial ETC complex III subunits Corlp 
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and Qcrlp, and the Atplp, Atp2p, Atp4p and Atp5p subunits of the ATP synthase Fl 
catalytic complex (Figure 11.5). In addition, lack of Pex5p substantially decreases the 
levels of the ATP/ADP carrier protein Pet9p and of the Pj carrier protein Mirlp in the 
mitochondrial membrane (Figure 11.5). These two proteins promote the synthesis of ATP 
by transporting the ADP and Pi substrates into the mitochondria from the cytosol and by 
coupling the import of ADP into mitochondria with the export of synthesized ATP into 
the cytosol (Figure 11.5). Furthermore, the pex5A mutation substantially lowers the 
amounts of the HemHp protein involved in the mitochondrial heme biosynthesis 
pathway and of the Cyc3p protein that promotes the attachment of mitochondrially 
synthesized heme to the subforms 1 and 7 of cytochrome c, a mobile component of the 
mitochondrial ETC (Figure 11.5). The observed decrease of multiple protein components 
of the ETC and ATP synthesis in mitochondria of the pex5A mutant, in turn, shortens its 
life span (Figure 11.2). Of note, lack of either complex I protein Ndilp or the complex II 
subunits Sdhlp or Sdh4p of the mitochondrial ETC extends the life span of S. cerevisiae 
cells grown under CR at 0.2% glucose (Figure 11.19). 
Taken together, recent findings from Dr. Titorenko's laboratory on life span 
extension in S. cerevisiae mutants lacking either complex I or complex II components of 
the mitochondrial ETC, along with my proteomic data identifying crucial protein 
components of the mitochondrial ETC and ATP synthesis teams involved in longevity 
regulation, suggest the following scenario for the integration of the protein components 
that function in the mitochondrial electron transport and ATP formation into the global 
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Figure 11.19. Lack of the Sdhlp, Sdh4p or Ndilp components of the mitochondrial ETC 
extends the chronological life span of yeast grown under CR conditions. 
cellular longevity network. Lack of either complex I or complex II components results in 
a reduced electron flow through the mitochondrial ETC but does not impair the 
mitochondrial ability to synthesize ATP. The reduced rate of the mitochondrial ETC in 
these mutants decreases the amount of mitochondrially produced ROS and therefore 
reduces the detrimental effect of ROS on mitochondrial macromolecules, ultimately 
resulting in life span extension. 
11.4.3 The pex5A mutation remodels mitochondrial morphology 
My quantitative proteomic analysis also revealed that the pex5A mutation remodels 
protein teams regulating mitochondrial morphology in the yeast S. cerevisiae (Figure 
11.6). Mitochondrial morphology in a cell depends on a delicate balance between the 
processes of mitochondrial fusion and fission [262-264]. Furthermore, the relative rates 
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of mitochondrial fusion and fission have a strong impact on the intrinsic pathway of the 
apoptotic cell death [190, 191, 205-208]. The fusion process helps to maintain 
mitochondria in a network configuration to allow the efficient transfer of the 
mitochondrial membrane potential among cellular regions with varying degree of 
oxygenation. The mitochondrial network also facilitates mtDNA repair, thus substantially 
reducing signaling through mitochondrial pro-apoptotic pathways and preventing 
intrinsically-induced cell death [190, 191, 205-208]. The mitochondrial membrane 
proteins Fzolp, Mgmlp, Ugolp, Rbdlp, Mdm30p, Mdm37p and Mdm39 promote the 
formation of the mitochondrial tubular network by fusion of individual mitochondria 
[262]. At the same time, the proper inheritance of mitochondria during cell division 
requires a break-down of the mitochondrial network by the fission process. Mitochondrial 
fission can also cause respiratory defects, eventual loss of mtDNA due to accumulated 
mtDNA mutations, and increased rate of intrinsically-induced apoptotic cell death [ 190, 
191, 205-208]. The mitochondria-associated proteins Dnmlp, Fislp, Mdvlp and 
Mdm33p promote mitochondrial fragmentation by facilitating the fission of individual 
mitochondria into a mitochondrial tubular network [262]. In addition, several other 
proteins have been implicated in the regulation of mitochondrial morphology in S. 
cerevisiae, although their exact functions in mitochondrial fusion and fission remain to be 
elucidated [262]. 
According to my quantitative proteomic analysis, the pex5A mutation substantially 
increases the amounts of two proteins involved in mitochondrial fission, Dnmlp and 
Mdvlp (Figure 11.6). In non-stressed cells and in cells undergoing exogenously induced 
apoptosis, both these proteins stimulate fragmentation of the mitochondrial tubular 
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network [262]. Such fragmentation results from the coordinated action of the 
mitochondrial fission and fusion protein machineries, which control the release of 
cytochrome c and several other pro-apoptotic proteins from the mitochondrial 
intermembrane space [265]. In fact, mitochondrial fragmentation has been shown to 
promote the release of cytochrome c, Aiflp and Nuclp (EndoG) from mitochondria to 
the cytosol in response to a short-term exposure of yeast to the pro-apoptotic stimuli 
hydrogen peroxide and acetic acid [266-268]. Furthermore, it has been also shown that 
once in the cytosol, cytochrome c activates yeast metacaspase 1, whereas both Aiflp and 
Nuclp (EndoG) are transported into the nucleus where they promote DNA cleavage [269, 
270]. My proteomic data provide evidence that the pexSA mutation decreases the levels 
of mitochondria-bound Fislp and Mdm33p proteins, both of which are known to promote 
the fragmentation of the mitochondrial tubular network only in non-stressed cells (Figure 
11.6) [262, 264]. However, lack of Fislp does not impair mitochondrial fission in aging 
CR yeast but, in contrast to what was expected, accelerates the fragmentation of their 
mitochondrial network and shortens their life spans (Figure 11.20) [271]. Therefore, the 
observed in the pex5A mutant decrease in the mitochondria-bound pools of Fislp and 
Mdm33p promotes the fragmentation of its mitochondrial tubular network and 
consequently shortens its life span (Figure 11.6). 
My quantitative proteomic analysis also indicates that the premature aging of the 
pex5A mutant coincides with the dramatic decrease in the mitochondria-bound pools of 
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Figure 11.20. Lack of proteins that promote mitochondrial fission (except Fislp) extends 
the lifespan of chronologically aging S. cerevisiae grown on CR diet. 
numerous proteins that promote mitochondrial fusion into a tubular network, such as 
Fzolp, Mgmlp, Rbdlp, Mdm37p, and Mdm39p (Figure 11.6). Therefore, my findings 
also suggest that the pex5A mutation promotes the fragmentation of the mitochondrial 
tubular network by down-regulating the synthesis and/or accelerating the degradation of 
several proteins promoting mitochondrial fusion. My hypothesis is supported by the 
recent data from Dr. Titorenko's laboratory showing that lack of several mitochondrial 
fusion-promoting proteins shortens the chronological life span of S. cerevisiae under CR 
conditions (Figure 11.21). 
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Figure 11.21. Lack of proteins that promote mitochondrial fusion shortens the 
chronological life span of 5. cerevisiae grown under CR conditions at 0.2% glucose. 
Altogether, my proteomic data and recent findings from Dr. Titorenko's laboratory 
strongly suggest that aging in yeast promotes mitochondrial fragmentation by stimulating 
the fission of the mitochondrial tubular network and inhibiting the fusion of individual 
mitochondria into the network. This, in turn, promotes the release of the pro-apoptotic 
proteins cytochrome c, Aiflp and Nuclp (EndoG) from mitochondria to the cytosol, 
thereby culminating the aging process by activating the programmed cell death. 
11.4.4 The pex5A mutation remodels protein teams that function in the response to 
stresses, stabilization of mitochondrial DNA (mtDNA) and biosynthesis of 
various amino acids 
My quantitative proteomic analysis revealed that the pex5A mutation leads to a 
significant decrease in the levels of proteins that protect mitochondrial macromolecules 
from ROS-induced oxidative damage (Figure 11.7). In fact, the levels of two crucial 
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ROS-scavenging proteins Sod2p and Ccplp are dramatically decreased in mitochondria 
of the pex5A mutant, as compared to those observed in wild-type strain (Figure 11.7). 
The decreased levels of these two proteins in the pex5A mutant result in the build-up of 
oxidatively-damaged mitochondrial macromolecules, thereby significantly reducing 
mitochondrial activity and function, stimulating mitochondrial fragmentation and the pro-
apoptotic mitochondrial signaling, and shortening its life span [265-270]. 
According to my proteomic data, the pex5A mutation also alters the levels of 
proteins controlling the unfolding of proteins during their translocation into the 
mitochondrial matrix and/or their folding/refolding in the mitochondrial matrix (Figure 
11.8). In fact, the levels of the molecular chaperones Ssclp, Hsp60p and Cpr3p were 
considerably higher in mitochondria of the pex5A mutant than those observed in 
mitochondria of wild-type strain (Figure 11.8). In addition, the pex5A mutation elevates 
the levels of mitochondrial proteins regulating the synthesis of branched amino-acids and 
maintenance of mtDNA, such as Ilv5p, Ilv2p, Ilv3p, Batlp, Idplp and Shmlp (Figure 
11.9). Of note, the levels of Abf2p, another protein involved in the stabilization of 
mtDNA, are significantly decreased by \h.tpex5A mutation (Figure 11.9). These findings 
suggest that the pex5A mutation not only impairs the peroxisomal function in yeast, but 
also significantly diminishes mitochondrial functional activity and lowers the efficiency 
of mtDNA repair and maintenance. The insufficient synthesis of ATP in mitochondria 
resulting from the impaired peroxisomal production of acetyl-CoA and low glucose 
concentration under CR conditions may activate the biosynthesis of various amino acids 
in mitochondria of pexSA mutant and their subsequent catabolism allowing to use these 
amino acids as an alternative, albeit weak, energy source for the mutant. Thus, the 
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insufficient energy production and activated mitochondrial pro-apoptotic signaling could 
be the major causes of the dramatic decrease in the chronological life span of the pex5A 
mutant under CR conditions. 
11.5 Conclusions 
Altogether, my proteomic data and the recent data of metabolomic and functional studies 
conducted in Dr. Titorenko's laboratory demonstrate that the extension of the 
chronological life span in CR yeast can only be achieved if the fatty acid oxidation 
pathway in the peroxisome is fully functional. In fact, the cytosolic shuttling receptor 
Pex5p, which is required for peroxisomal import of two major enzyme components of 
fatty acid |3-oxidation, plays a key role in longevity regulation of chronologically aging 
yeast under CR conditions by modulating the levels of proteins involved in such essential 
mitochondrial processes as the mitochondrial PDH complex, TCA cycle, ETC, heme 
biosynthesis and attachment, ATP synthesis, ATP/ADP exchange, as well as 
mitochondrial fusion and fission, mitochondrial pro-apoptotic signaling, maintenance of 
mtDNA, protein folding and unfolding, protein translocation into the mitochondrial 
matrix, and mitochondrial biosynthesis of various amino acids. In order to understand 
how defects in peroxisomal fatty acid oxidation process result in such profound effect on 
various mitochondrial functions, and to better define the contribution of lipid metabolism 
to longevity regulation in CR yeast, I explored the age-dependent dynamics of changes in 
the proteomes of the ER and lipid bodies taking place in wild-type and pex5 A cells grown 
under CR conditions. 
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12 Quantitative proteomic analysis of the ER and lipid bodies purified from 
wild-type and pexSA strains of the yeast S. cerevisiae that were aged 
chronologically under CR conditions 
12.1 Introduction 
As glucose becomes limited in the growth medium, yeast cells undergo a diauxic shift in 
energy metabolism from glycolysis to mitochondrial respiration. Recent evidence from 
Dr. Titorenko's laboratory shows that in wild-type strain of S. cerevisiae this metabolic 
transition is accompanied by a substantial shortening of the length of ER membranes, 
almost complete disappearance of lipid bodies (LB) and massive proliferation of 
mitochondria (Figure 12.1). 
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Figure 12.1. Electron micrographs illustrating a substantial shortening of the length of 
ER membranes and the disappearance of lipid bodies in the chronologically aging wild-
type strain of S. cerevisiae grown under Cr conditions at 0.2% glucose. In contrast, the 
short-lived pexSA mutant displays ER expansion and lipid body accumulation under these 
conditions. 
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In contrast, cells of the short-lived pex5A mutant recovered from D phase displayed 
greatly extended ER membranes that were closely apposed to abundant LBs present in 
these cells; in addition pex5A cells showed no proliferation of mitochondria (Figure 
12.1). As wild-type S. cerevisiae cells entered the PD growth phase, their mitochondria 
enlarged and increased in number, whereas PD-phase cells of the pex5A mutant showed 
no growth of the mitochondrial network and accumulate larger amounts of LBs as their 
ER membranes shorten (Figure 12.1). 
L D PD 
Figure 12.2. BODIPY staining showing the dynamics of lipid body consumption in 
chronologically aging wild-type and pex5A cells grown under CR conditions at 0.2% 
glucose. 
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Day 1 Day 3 Day 6 
L D PD 
Figure 12.3. The age-dependent dynamics of neutral lipid consumption in 
chronologically aging wild-type and pex5A cells grown under CR conditions at 0.2% 
glucose. 
In both wild-type and pex5A cells, LBs were found in close proximity to the ER (Figure 
12.1), which is consistent with the ER origin of LBs. In fact, LB are formed between the 
two leaflets of the ER membrane after the droplets of newly formed NL are enveloped by 
a monolayer of ER-derived phospholipids containing proteins that lack transmembrane 
domains [272, 273]. Altogether, these findings suggest that during L phase both wild-
type and pex5A cells under CR conditions generate energy by glycolysis and store the 
NL, FFA and phospholipids by forming LBs. Using electron and fluorescent 
microscopies, Dr. Titorenko's laboratory showed that wild-type and pex5A cells under 
CR conditions substantially differ in the age-dependent abundance and morphological 
appearance of their mitochondria, ER and LBs (Figures 12.1 and 12.2). In order to 
establish the roles of ER- and LBs-associated proteins in the aging process, I used mass 
spectrometry-based proteomics to analyze the proteomes of ER and LBs purified from 
wild-type andpex5A cells grown under CR conditions. 
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12.2 Materials and methods 
Reagents and solutions 
1. TSD reduction buffer: 0.1 M Tris/Sulfate (pH 9.4), 10 mM DTT 
2. HEPES lysis buffer: 20 mM HEPES/KOH, pH 6.8, 50 mM KC1, 200 mM 
sorbitol, 2 mM EDTA, 1 mM DTT 
3. Spheroplast medium A (pH 7.5): 0.67% yeast nitrogen base (w/o) amino acids, 2 
% (w/v) glucose, 1 M sorbitol, 20 mM Tris/HCl (pH 7.5) 
4. Spheroplast medium B: 0.67% yeast nitrogen base (w/o) amino acids, 2 % (w/v) 
glucose, 1 M sorbitol 
5. 1.2 M sucrose/ HEPES, 36% (w/w): 7.2 g sucrose + 12.8 ml HEPES lysis buffer 
6. 1.5 M sucrose/ HEPES, 43%(w/w): 8.6 g sucrose + 11.4 ml HEPES lysis buffer 
7. MES buffer 1 (MES breaking buffer): 10 mM MES/Tris (pH 6.9), 12 % (w/w) 
Ficoll 400, 0.2 mM EDTA 
8. MES buffer 2: 10 mM MES/Tris (pH 6.9), 8 % (w/w) Ficoll 400, 0.2 mM EDTA 
9. MES buffer 3: 10 mM MES/Tris (pH 6.9), 0.6 M sorbitol, 8 % (w/w) Ficoll 400, 
0.2 mM EDTA 
10. MES buffer 4: 10 mM MES/Tris (pH 6.9), 0.25 M sorbitol, 0.2 mM EDTA 
11. KPi buffer (pH 7.4): 20 mM KH2PO4/KOH (pH 7.4), 1.2 M sorbitol 
Purification of ER 
Wild-type and pex5A mutant cells were grown in YEPD (0.2% glucose) medium. 
Cultures were harvested at mid-exponential and diauxic phases, checked for 
contamination by bright-field microscopy and used to measure cell density at OD6oo- The 
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non-contaminated wild-type and mutant cells were pelleted at 4,000 x g for 5 min at room 
temperature. Cells were then resuspended at 10 OD600 units/ml in TSD reduction buffer, 
incubated for 10 min at room temperature, and centrifuged for 5 min at 4,000 x g at room 
temperature. Pelleted cells were then resuspended at 20 OD600 units/ml in Spheroplast 
medium A and supplemented with Zymolyase 100T at a concentration of 7.5 ug per 
OD600 units of cells. 10 ul of each cell suspension was then removed, diluted in 990 u,l of 
df^O and used to measure the ODeoo- The remaining cell suspensions were incubated at 
30°C for 30 min and the efficiency of cell wall removal was monitored by measuring the 
OD600. Cell wall digestion was allowed to proceed until the OD600 measurement of the 
diluted cell suspension became 5% of the original value, with the total digestion time not 
exceeding 1 hour. Spheroplasts were then harvested by centrifugation at 1,500 x g for 5 
min at room temperature, followed by resuspending at 1 to 5 OD600 units/ml in 
Spheroplast medium B by gentle swirling of the tube or gentle stirring with a glass rod. 
Spheroplasts were then harvested by centrifugation at 1,500 x g for 5 min at 4°C and then 
resuspended at a concentration of 1,000 OD6oo units/ml of ice-cold HEPES lysis buffer 
with freshly-added DTT. Spheroplasts were then homogenized using 20 strokes and 
resulting lysates were centrifuged at 1, 000 x g for 10 min at 4°C. The supernatants 
(Si000) were subjected to another round of centrifugation at 1, 000 x g for 10 min at 4°C, 
and resulting supernatants were further centrifuged at 27,000 x g for 10 min at 4°C. The 
pelleted membranes (P27,ooo) were resuspended in 1.0 ml of HEPES lysis buffer (5,000 
OD600 equivalents per ml) using a trimmed 1 -ml pipette tip and carefully layered on top 
of a sucrose gradient prepared in advance (2.1 ml of 1.5 M sucrose/HEPES solution was 
deposited to the bottom of a Beckman Ultra-Clear centrifuge tube for the Beckman MLS-
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50 rotor, and then overlaid with 2.1 ml of 1.2 M sucrose/HEPES solution). The gradient 
tubes were then placed in the pre-chilled swinging bucket Beckman MLS-50 rotor and 
centrifuged at 100,000 x g (36,000 rpm) for 1 hr at 4°C using the slow acceleration and 
deceleration setting to minimize disruption of gradients. 18 gradient fractions of 227 JJ.1 
each were then collected starting from the top of the sucrose gradient and stored at -20°C 
for further analyses. 
Purification of lipid bodies 
Wild-type and pex5A mutant cells were grown in YEPD (0.2% glucose) medium. 
Cultures were harvested at mid-exponential and diauxic phases, checked for 
contamination by bright-field microscopy and used to measure cell density at ODeoo- The 
non-contaminated wild-type and mutant cells were pelleted at 4,000 x g for 5 min at room 
temperature. The cells were then washed once with distilled water and resuspended in the 
TSD reduction buffer at 10 x OD600 units/ml. Following a 10-min incubation at room 
temperature, the cells were pelleted by centrifugation at 4,000 x g for 5min at room 
temperature and then washed once in Spheroplasts medium A. The cells were then 
resuspended in Spheroplasts medium A at 20 x OD600 units/ml, supplemented with 
Zymolyase 100T at a concentration of 2.5 ug per OD600 units of cells, and incubated at 
30°C for 45 min on a shaker set at 75 rpm. Spheroplasts were then pelleted by 5min 
centrifugation at 1,500 x g at room temperature, resuspended in the ice-cold Spheroplasts 
medium B at 5 x OD600 units/ml using pipettes with cut tips, and centrifuged for 5 min at 
1,500 x g at 4°C. Spheroplasts were then washed twice by resuspending the pellets in ice-
cold KPi buffer at a concentration of 5 OD60o units/ml followed by centrifugation for 5 
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min at 1,500 x g at 4°C. After the second wash and centrifugation step, clean spheroplasts 
were resuspended in ice-cold MES Buffer 1 at a concentration of 1,000 OD6oo units/ml 
using pipettes with non-cut tips. Spheroplasts were then lysed in a homogenizer using 20 
strokes at 4°C. Lysates were centrifuged for 5 min at 5,000 x g at 4°C and the resulting 
supernatants (85,000) were transferred to pre-chilled centrifuge tubes kept on ice. Lipid 
bodies were then purified by subjecting the spheroplast lysates to a series of flotation 
gradient centrifugations using a MLS 50 swinging bucket rotor (Beckman). The first 
flotation gradient was prepared by placing 2.5 ml of the Ss;ooo fraction to the bottom of a 
centrifuge tube (Ultra-Clear Beckman tubes for MLS 50 rotor) and overlaying it with 2.5 
ml of ice-cold MES Buffer 1. Following 1 hour centrifugation at 100,000 x g (36,000 
rpm) at 4°C, the floating layer from the top portions of the gradients was collected with a 
cut tip and transferred to the bottom of a new centrifuge tube, which was then 
supplemented with MES buffer 2 to a total volume of 2.5 ml and gently mixed by 
pipetting. Resulting suspension was overlaid with 2.5 ml of ice-cold MES buffer 2 and 
then centrifuged for 1 hr at 100,000 x g (36,000 rpm) at 4°C. The floating layer from the 
top portions of the gradients was again collected with a cut tip and transferred to the 
bottom of a new centrifuge tube, which was then supplemented with MES buffer 3 to a 
total volume of 2.5 ml and gently mixed by pipetting. Resulting suspension was overlaid 
with 2.5 ml of ice-cold MES buffer 4 and then centrifuged for 1 hr at 100,000 x g (36,000 
rpm) at 4°C. The floating layer from the top portions of the gradients was collected with a 
cut tip and purified lipid bodies were stored -20°C for further analyses. 
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Protein precipitation, SDS-PAGE and silver staining of gels 
Protein concentration was determined using the RC DC protein assay kit (Bio-Rad) 
according to the manufacturer's instructions. Proteins were then precipitated using TCA 
as described previously (section "Materials and methods" in chapter 5.2) and resuspended 
in the SDS-PAGE sample buffer to a final concentration of 1 mg/ml. Proteins were then 
resolved on 7.5%, 10%, 12.5% or 16% SDS-PAGE gels as described previously (section 
"Materials and methods" in chapter 5.2). The Bio-Rad unstained molecular marker and a 
0.1 mg/ml solution of BSA in the SDS-PAGE sample buffer were also subjected to SDS-
PAGE. The proteins were then visualized by silver staining as described previously 
(section "Materials and methods" in chapter 5.2). 
Protein identification by mass spectrometry 
Selected protein bands were excised from a silver-stained gel and prepared for the mass-
spectrometric peptide mapping as described previously (section "Materials and methods" 
in chapter 5.2). My modifications to the standard procedure included supplementing the 
excised protein bands with a band containing 2 jag of bovine serum albumin (BSA) 
protein, which was resolved in a different well of the same SDS-PAGE gel. Therefore, 
the samples were supplemented with double volumes (as compared to the standard 
volumes) of all reagents, including the trypsin buffer (100 ul/tube). Mass accuracy was 
further improved by performing the internal calibration of peptide mass spectra for each 
sample using two intense peptide masses from BSA (1479.8 and 1639.9) and one intense 
peptide mass from trypsin (1045.5). The proteins were identified by the Mascot peptide 
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mass fingerprinting method as described previously (see section "Materials and methods" 
in chapter 5.2). 
Calculating the relative level of a protein of interest using BSA 
For calculating the relative level of a protein of interest, the intensity of the monoisotopic 
peak of each peptide recovered from the band containing this protein was divided by the 
intensity of the monoisotopic peak of a BSA peptide with the monoisotopic mass closest 
to the mass of the peptide of interest. For evaluating relative levels of the protein of 
interest found in the samples to be compared, a ratio "the intensity of the monoisotopic 
peak of a peptide originated from the protein of interest/the intensity of the monoisotopic 
peak of a BSA peptide with the monoisotopic mass closest to the mass of the peptide of 
interest" was calculated for each peptide originated from the protein of interest. Based on 
these data, the average value for relative levels of the protein of interest found in the two 
compared samples was calculated. The method for evaluating relative levels of the 
protein of interest recovered in different samples was validated by calculating relative 
levels of several standard proteins in the samples supplemented with different quantities 
of each of these proteins. 
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12.3 Results 
12.3.1 The pexSA mutation alters the levels of numerous ER proteins early in 
yeast life span 
D> Depleted in pex5A: 
Mvdlp (ergosterol 
biosynthesis) 
Aiflp (homolog of mammalian 
Apoptosis-lnducing Factor) 
Glolp (glyoxalase I, a stress 
response protein) 
Gcn2p (protein kinase that 
phosphorylates the alpha-
subunit of translation initiation 
factor elF2 in response to 
starvation) 
Log phase Diauxic and post-diauxic phases 
*4 Enriched in pex5A 
Avo2p (component of a 
complex containing the Tor2p 
kinase) 
Cajlp (Hsp of the DnaJ family) 
Cct7p (a subunit of the 
chaperonin Cct ring complex) 
Figure 12.4. Silver-stained 12.5% SDS-PAGE gels of proteins recovered from the ER 
purified from wild-type and pex5A cells grown under CR conditions at 0.2% glucose. 
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12.3.2 The pex5A mutation alters the levels of numerous lipid body 
associated proteins early in yeast life span 
Day 1 (L) Day 2(D) Day 3 (D) 
pexSA pex5A pex5A 
Day4(PD) 
- - imm\ 
Day5(PD) 
pex5A pex5A 
Figure 12.5. Silver-stained 12.5% SDS-PAGE gels of proteins recovered from lipid 
bodies purified from wild-type and pex5A cells grown under CR conditions at 0.2% 
glucose. 
12.3.3 Early on in yeast life span, the pex5A mutation significantly elevates the 
levels of proteins involved in lipid biosynthesis and simultaneously decreases 
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Figure 12.6. Relative levels of proteins identified in lipid bodies purified from wild-type 
andpex5A cells grown under CR conditions at 0.2% glucose. 
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12.4.4 Discussion 
Using quantitative mass spectrometry, I compared the age-dependent dynamics of 
changes in the proteomes of ER and LBs purified from wild-type and prematurely aging 
pex5A cells. According to my proteomic data, the pex5A mutation altered the levels of 
numerous cytosolic, peroxisomal, ER and LB-associated proteins but only in aging cells 
that reached D and PD phases. In contrast, no significant differences were observed in the 
protein profiles of "young" wild-type and pex5A cells recovered from L phase (Figure 
12.4). Proteomic analysis of the ER purified from chronologically aging wild-type and 
pexSA cells revealed that the pex5A mutation decreased the levels of a distinct group of 
proteins, including 1) Mvdlp, an enzyme involved in ergosterol biosynthesis; 2) Aiflp, a 
homolog of mammalian apoptosis-inducing factor; 3) Glolp, a glyoxalase involved in 
stress response; and 4) Gcn2p protein kinase, which phosphorylates the a-subunit of eIF2 
translation initiation factor in response to starvation (Figure 12.4). At the same time, the 
levels of some of the ER proteins were elevated in the short-lived pex5A mutant, 
including those of 1) Avo2p, a subunit of a complex containing Tor2p kinase; 2) Cajlp, a 
heat shock protein of the DnaJ family; and 3) Cct7p, a subunit of the chaperonin cct ring 
complex (Figure 12.4). 
The data of my quantitative proteomic analysis suggest that the biogenesis of LBs 
in chronologically aging yeast progresses through several consecutive steps. Moreover, 
using this analysis, I was able to follow the age-related metabolic evolution of LBs 
during chronological aging. I found that throughout L, D and PD phases of life span, the 
pex5A mutation significantly elevated the levels of proteins involved in the biosynthesis 
of the neutral lipids TAG (Ayrlp, Dgalp, Slclp) and EE (Arelp, Are2p), as well as the 
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levels of LB-associated proteins required for the biosynthesis of ergosterol (Erg6p) and 
ethyl esters of FFA (Ehtlp). During L and D phases, the pex5A mutant also showed an 
increase in the levels of proteins composing the nuclear envelope and the ER, both of 
which are used as a template for LB formation. Some of these proteins are involved in the 
biosynthesis of ethyl esters of FA (Ehtlp), while the others function in ER protein import 
and folding (Kar2p), ER protein sorting and dolichol synthesis (Rer2p), ER-to-Golgi 
protein transport (Sarlp) and ER protein catabolism (Ssm4p). During late D (day 3) and 
early PD (day 4) phases, the pex5A mutation also substantially decreased the levels of 
LB-bound proteins involved in the degradation of neutral lipids (Tgl3p and Tgl4p) and of 
peroxisomal proteins required for fatty acid oxidation (Faalp, Fatlp and Foxlp). Faalp, 
Fatlp and Foxlp have been shown to associate with distinct peroxisomal extensions 
known as pexopodia that penetrate LBs to promote the degradation of neutral lipids and 
to oxidize their FFA derivatives [274]. During early PD phase (day 4), the pex5A mutant 
strain showed a significant decrease in the levels of normally cytosolic proteins 
regulating glycolysis, especially those involved in the conversion of glyceraldehyde-3-
phosphate to pyruvate (Enolp, Pgklp, Tdh3p and Tpilp) as well as proteins involved in 
the metabolism of ethanol (Adhlp and Adh2p), a final product of glucose fermentation. 
Finally, during late D (day 3) and early PD (day 4) phases, the pex5A mutation 
considerably increased the levels of the LB-associated protein PetlOp of unknown 
function, the Sirlp protein required for chromatin maintenance in the nucleus, and the 
nuclear/cytosolic chaperone Ssalp of the HSP70 protein family. In sum, my comparative 
proteomic analysis of LBs purified from wild-type and pex5A cells grown under CR 
conditions showed that several proteins were considerably elevated in LBs of pex5A 
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during L (day 1) and early PD (day 2) phases, whereas no significant differences in lipid 
body protein profiles were observed in wild-type and pexSA mutant during late D (day 3) 
and early PD (days 4 and 5) phases, although certain protein species were enriched or 
depleted in LBs purified from pex5A, as compared to those from wild-type cells (Figures 
12.5 and 12.6). 
Consistent with my proteomics data, studies in Dr. Titorenko's laboratory showed 
a similar dynamics of age-dependent consumption of TAG, EE, DAG and FFA in ER and 
LBs purified from wild-type andpex5A cells grown under CR conditions (Figure 12.7). 
Purified ER 
WT 5A WT 5A WT 5A 
Day 1 Day 2 Day 3 
Purified LB 
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Figure 12.7. Lipid analysis by TLC revealed the age-dependent consumption of TAG, 
EE, DAG and FFA in the ER and lipid bodies purified from wild-type and pex5A cells 
grown under CR conditions. 
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12.5 Conclusions 
My analysis of ER and LB proteomes, along with findings from Dr. Titorenko's 
laboratory on the effect of impaired degradation of storage lipids on longevity, provide 
evidence that peroxisomal compartmentalization of fatty acid oxidation is a crucial factor 
in regulating yeast longevity. Taken together, my proteomic analysis of the ER and LB 
purified from chronologically aging wild-type and pex5A cells and the data of functional 
and metabolomic analysis conducted in Dr. Titorenko's laboratory strongly suggest the 
following scenario for the biogenesis of LB during an early stage of the aging process. 
During e L phase, LB purified from both wild-type and pex5A cells are attached to their 
ER templates, which is consistent with my proteomics data showing that L-phase LBs 
contain several protein components of the nuclear envelope and ER (Figure 12.6). During 
early D phase (day 2), LBs of wild-type cells bud off from the ER, which would 
satisfactorily explain the association of these proteins with LBs (Figure 12.6). In contrast, 
LBs of the prematurely aging pex5A mutant strain remain associated with their ER 
template throughout the entire D phase (days 2 and 3), which is consistent with the 
proteomic data showing that substantial amounts of the ER and nuclear envelope proteins 
are still present in LBs purified from pex5A cells (Figure 12.6). It should be stressed that 
a significant deceleration of LB consumption observed in the pex5A mutant strain is 
supported by the results of my proteomic analysis, which revealed the elevated levels of 
proteins catalyzing neutral lipid biosynthesis and decreased levels of proteins catalyzing 
NL degradation in LBs of pex5A cells, as compared to those seen wild-type cells (Figures 
12.6 and 12.7). As my proteomic analysis revealed, during late D phase (day 3) and early 
PD phase (day 4), LBs in wild-type cells contain considerable amounts of peroxisomal 
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enzymes catalyzing oxidation of fatty acids, whereas none of these peroxisomal enzymes 
was detected in LBs purified from pex5A cells (Figures 12.6). Of note, peroxisomal 
oxidation of NL-derived FFA in wild-type cells is known to coincide with the formation 
of distinct peroxisomal extensions known as pexopodia, which penetrate LBs in order to 
promote the lipolysis of neutral lipids and the oxidation of free fatty acids formed during 
this process [274]. However, no pexopodia formation was observed in ihepex5A mutant 
strain [274]. Furthermore, my proteomic analysis revealed that LBs purified from wild-
type cells recovered from early PD phase (day 4) contained enzymes involved in ethanol 
biosynthesis and degradation (Adhlp and Adh2p) along with a group of normally 
cytosolic proteins catalyzing several glycolytic reactions, especially those involved in the 
formation of pyruvate from glyceraldehyde-3-phosphate (Figure 12.6). Notably, these 
proteins normally function in the formation of acetyl-CoA, which is then transported into 
mitochondria to be used for ATP production. In contrast, no such proteins were detected 
in the LBs purified from pex5A mutant cells (Figure 12.6). These findings strongly 
suggest that the age-dependent association of all acetyl-CoA-generating enzymes with 
LBs of wild-type cells may considerably improve the efficiency of acetyl-CoA formation 
in LBs during FFA oxidation as well as facilitate the transport of acetyl-CoA from LBs to 
mitochondria. 
Finally, my proteomic analysis of LBs purified from the short-lived pex5A mutant 
strain revealed a substantial increase in the levels of the following three proteins: 1) 
PetlOp, a protein of unknown function; 2) Sirlp, which is known to be involved in the 
maintenance of nuclear chromatin; and 3) the nuclear/cytosolic chaperone Ssalp of the 
HSP70 protein family (Figure 12.6). It remains to be elucidated, what role, if any, the 
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association of these proteins with LBs plays in the longevity-related 
compartmentalization of lipid metabolism in the short-lived pex5A mutant strain. 
13 A novel anti-aging molecule LA extends the chronological life span of the 
yeast S. cerevisiae 
13.1 Introduction 
Using a high-throughput assay for screening several combinatorial chemical libraries, Dr. 
Titorenko's laboratory in collaboration with Dr. David Thomas at McGill University has 
recently identified 22 compounds belonging to five chemically distinct groups that 
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Figure 13.1. A high-throughput screening of several combinatorial chemical libraries for 
anti-aging small molecules revealed 22 novel compounds that cause a 6- to 10-fold 
extension of life span in the short-lived pex5A mutant of the yeast S. cerevisiae under CR 
conditions. 
Of note, all of the anti-aging molecules identified by this assay are structurally 
different from another small anti-aging molecule, resveratrol, a constituent of red wine 
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that has been shown to extend the replicative life span of yeast and the chronological life 
spans of worms, flies and fishes through activation of the sirtuin family protein Sir2p 
[275-281]. Furthermore, the novel anti-aging compounds identified by Dr. Titorenko's 
laboratory are also structurally different from other molecules that, similar to resveratrol, 
delay aging and the onset of age-related diseases in rodent models by activating SIRT1 
sirtuin protein [282-284]. It is conceivable therefore that the novel anti-aging compounds 
identified by Dr. Titorenko's laboratory extend the chronological life span of yeast by 
targeting the longevity-related cellular processes that are not modulated by resveratrol 
and/or other known sirtuin activators. To gain insight into these processes, Dr. 
Titorenko's laboratory focused on studying the molecular mechanisms underlying the 
anti-aging action of one of the compounds identified in the high-throughput screen. This 
compound, which is further referred to as 'LA', causes significant life span extension in 
both wild-type and pex5A mutant strains of the yeast S. cerevisiae grown under CR 
conditions at 0.2% glucose (Figure 13.2). 
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Figure 13.2. LA significantly extends the chronological life span of wild-type strain of 
the yeast S. cerevisiae grown under CR conditions. 
In addition, a recent spot assay analysis conducted in Dr. Titorenko's laboratory 
using yeast cells exposed to exogenously added H2O2 demonstrated that LA increases the 
resistance of aging CR yeast to chronic oxidative stress (Figure 13.3). 
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Figure 13.3. A spot assay analysis of yeast cells treated with H2O2 shows that LA 
increases the resistance of aging yeast to chronic oxidative stress. 
To see if the beneficial effects of LA on yeast chronological life span results from a 
change in the steady-state levels of some key proteins involved in certain longevity 
regulation pathways, I used a mass spectrometry-based proteomic approach to identify 
proteins whose levels in yeast cells are altered in response to LA treatment and then to 
examine the age-dependent changes in their steady-state levels. 
13.2 Materials and methods 
Strains, media and growth conditions 
The wild-type strain Saccharomyces cerevisiae BY4742 (MATa his3Al leu2A0 lys2A0 
ura3A0) was used in this experimental set-up. Contents of the YEPD (0.2% glucose) 
growth medium were as follows: 1% yeast extract, 2% peptone and 0.2% glucose. At the 
inoculation, yeast cultures were treated with either DMSO only, 25 \xM 'LA' in DMSO 
or 50 \xM 'LA' in DMSO. 
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Preparation of total cell lysates 
Aliquots of yeast cells cultured in the presence or absence of LA were taken for 
proteomic analyses on days 1,6, 10, 15 and 20. Total lysates of yeast cells were prepared 
as described in section 10.2 "Materials and methods". 
Protein precipitation by TCA, SDS-PAGE and silver-staining 
Proteins were precipitated from total cell lysates by the TCA method, resolved by SDS-
PAGE and visualized by silver staining as described previously (section 5.2 "Materials 
and methods"). All modifications to the standard procedures of TCA precipitation and 
SDS-PAGE are described in section 10.2 "Materials and methods" of this thesis. 
Protein identification and quantitation by mass spectrometry 
Protein bands whose intensities differed from that in total lysates of CR yeast exposed to 
25 or 50 uM LA, as compared to those of the untreated CR yeast, were excised from the 
gel and subjected to mass spectrometry-based protein identification and quantitation as 
described previously (see sections 5.2 and 10.2, "Materials and methods"). All 
modifications to the standard procedures of protein identification and quantitation by 
mass spectrometry are described in section 10.2 "Materials and methods" of this thesis. 
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13.3 Results 
13.3.1 LA alters the levels of a limited group of proteins throughout yeast life span 
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Figure 13.4. Silver-stained SDS-PAGE gels showing protein profiles of total lysates of 
yeast cells cultured in the presence or absence of LA taken at L (Day 1), PD (Day 6) or 
stationary (Days 10, 15 and 20) phase. 
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13.3.2 In aging CR yeast, LA increases the levels of proteins involved in stress 
response, detoxification of ROS, glycogen degradation, biosynthesis of 
neutral lipids, glycolysis, biosynthesis of acetyl-CoA, mitochondrial PDH 
complex, TCA cycle and mitochondrial synthesis of ATP; at the same time, 
LA decreases the levels of proteins operating in glyoxylate cycle, degradation 
of neutral lipids, mitochondrial division, and proteins with currently 
unknown functions 
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Figure 13.5. Dynamics of age-dependent changes in the levels of proteins recovered in 
total lysates of yeast cells cultured in the presence or absence of LA. 
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13.3.3 LA causes a significant increase in the levels of the chaperone protein Ssa2p, 
which mediates stress response in the cytosol 
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Figure 13.6. Dynamics of age-dependent changes in the steady-state levels of Ssa2p in 
LA-treated and untreated wild-type yeast cells grown under CR conditions. 
13.3.4 LA causes a significant increase in the levels of the chaperone protein Ssa4p, 
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Figure 13.7. Dynamics of age-dependent changes in the steady-state levels of Ssa4p in 
LA-treated and untreated wild-type yeast cells grown under CR conditions. 
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13.3.5 LA causes a significant increase in the levels of the chaperone protein 
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Figure 13.8. Dynamics of age-dependent changes in the steady-state levels of Hsp26p in 
LA-treated and untreated wild-type yeast cells grown under CR conditions. 
13.3.6 LA causes a significant increase in the levels of the ROS scavenger protein 
Tsalp, which detoxifies ROS in the cytosol 
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Figure 13.9. Dynamics of age-dependent changes in the steady-state levels of Tsalp in 
LA-treated and untreated wild-type yeast cells grown under CR conditions. 
195 
13.3.7 LA causes a significant increase in the levels of the chaperone protein Ssclp, 
which mediates stress response in mitochondria 
- L A 
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Figure 13.10. Dynamics of age-dependent changes in the steady-state levels of Ssclp in 
LA-treated and untreated wild-type yeast cells grown under CR conditions. 
13.4 Discussion 
According to my proteomic data, the exposure of the yeast S. cerevisiae to La under CR 
conditions led to a significant increase in the steady-state levels of several molecular 
chaperone proteins, such as Ssa2p, Ssa4p, Ssclp and Hsp26p, as well as proteins that 
protect cellular components from oxidative damage, such as Tsalp (Figures 13.6, 13.7, 
13.8, 13.9, and 13.10). The Ssa2p and Ssa4p proteins belong to the HSP70 subfamily of 
cytosolic chaperones that bind newly-translated proteins and assist in their proper folding, 
as well as prevent the aggregation of oxidatively or otherwise damaged proteins in the 
cytosol [285-288]. Of note, Ssa4p also protects yeast cells expressing human a-synuclein, 
a protein responsible for amyloid fiber formation in Parkinson's, from undergoing 
apoptosis [289]. Hsp26p is another cytosolic chaperone that belongs to the small heat 
shock protein family of molecular chaperones and, similar to Ssa2p and Ssa4p, also binds 
196 
damaged proteins and prevents their aggregation in the cytosol [290, 291]. According to 
my proteomic data, the steady-state level of Ssa2p substantially increased in LA-treated 
yeast cells by Day 6, which corresponds to the end of PD growth phase and an entry point 
into stationary phase, when the cell senescence process begins (Figures 13.5 and 13.6). 
The level of Ssa2p continued to elevate during stationary phase of in LA-treated yeast 
cells, reaching a maximum by day 10, at which point it began to decrease gradually, but 
yet remained high in comparison to that seen in untreated cells (Figures 13.5 and 13.6). 
The steady-state levels of Ssa4p and Hsp26p had undergone very similar age-dependent 
changes in LA-treated yeast cells (Figures 13.5, 13.7 and 13.8). Based on these findings 
and the fact that Ssa2p, Ssa4p and Hsp26p participate in the protein folding and stress 
response, it seems likely that the anti-aging effect of LA is partly due to its ability to 
increase the levels of these cytosolic chaperones, thus preventing the aggregation of 
damaged proteins, which accumulate in aging yeast due the progressive build-up of ROS. 
This hypothesis is indirectly supported by recent findings from Dr. Titorenko's 
laboratory, which showed that LA increased the resistance of yeast cells to chronic 
oxidative stress imposed by their long-term exposure to hydrogen peroxide (Figure 13.3). 
It should be stressed that my proteomic data support this hypothesis further by 
demonstrating that LA significantly elevates the steady-state level of Tsalp in aging yeast 
(Figures 13.5 and 13.9). Tsalp is a thioredoxin peroxidase that, under conditions of 
oxidative stress, can act as a potent ribosome-associated or cytosolic antioxidant by 
forming a high-molecular weight chaperone complex from association with its own 
proteins [292-294]. Similar to the levels of Ssa2p, Ssa4p and Hsp26p, the level of Tsalp 
also significantly increased in LA-treated yeast cells by day 6, when yeast cells entered 
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stationary phase and became senescent (Figures 13.5 and 13.9). After Tsalp levels 
peaked at day 10, they began to decline in LA-treated senescent yeast cells, while still 
remaining higher than those seen in untreated cells (Figures 13.5 and 13.9). 
My proteomic data also demonstrate that LA significantly increases the steady-
state levels of Ssclp in aging yeast (Figures 13.5 and 13.10). Ssclp is a mitochondrial 
chaperone protein of the HSP70 family that, in addition to being involved in proper 
protein folding and preventing aggregation of damaged proteins in the mitochondria, also 
facilitates the import of proteins into the mitochondrion and further assists in their folding 
process [286, 287, 294-296]. Of note, age-dependent dynamics of changes in the level of 
Ssclp in LA-treated yeast cells differed from that observed for Ssa2p, Ssa4p, Hsp26p and 
Tsalp. In fact, the level of Ssclp in LA-treated yeast reached its maximum at the L and 
PD growth phases and then significantly decreased as yeast entered stationary phase and 
became senescent (Figures 13.5, 13.6, 13.7, 13.8 and 13.9). Taken together, the 
knowledge of the mitochondria-related functions of Ssclp and the observed pattern of 
age-dependent changes in its steady state levels induced by LA (Figures 13.5 and 13.10), 
suggest that the longevity-promoting properties of LA are partially due to its ability to 
increase the levels of Ssclp, which would have a beneficial effect on longevity as a 
result of: 1) Ssclp acting to prevent the aggregation of damaged proteins that accumulate 
in the mitochondria due to a dramatic increase in the amount of mitochondrial production 
of ROS observed in aging CR yeast, and 2) Ssclp assisting mitochondria in maintaining 
its oxidation-reduction processes that, according to recent experimental evidence from 
Dr. Titorenko's laboratory, are required for the anti-aging effect of LA. 
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My quantitative proteomic analysis also revealed that, in addition to significantly 
amplifying the response, LA remodeled carbohydrate metabolism in yeast by increasing 
the levels of proteins involved in glycogen degradation (Gphlp), glycolysis (Glklp, 
Hxklp, Fbalp and Pyk2p) and biosynthesis of Acetyl-CoA in the cytosol (Acslp) (Figure 
13.5), as well as by decreasing the levels of proteins involved in the glyoxylate cycle in 
the mitochondrion and cytosol (Icllp, Mlslp, Pcklp, Mdh2p, Fbplp and Pyclp). 
Furthermore, LA remodeled lipid metabolism of chronologically aging yeast by elevating 
the level of Dgalp protein that catalyzes the biosynthesis of TAG and by decreasing the 
level of Tgl4p protein that catalyzes TAG breakdown (Figure 13.5). LA also significantly 
increased mitochondrial activity by elevating the levels of several mitochondrial proteins 
functioning in the PDH complex (Latlp, Lpdlp), TCA cycle (Acolp) and ATP synthesis 
(Atplp). Moreover, LA altered mitochondrial morphology by decreasing the levels of 
Caf4p protein involved in mitochondrial division (Figure 13.5). 
Of note, recent data from Dr. Titorenko's laboratory provided evidence that in 
"young", non-treated yeast cells grown under CR conditions, there is an intense spike in 
the level of mitochondrially produced ROS (Figure 13.11). The level of ROS then 
progressively declines throughout yeast life span (Figure 13.11). In fact, the levels of 
ROS observed in yeast cells that have not been exposed to LA and reached D phase are 
high enough to inflict a significant oxidative damage to their mitochondrial 
macromolecules. At the same time, considerably lowered levels of ROS during later 
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Figure 13.11. LA decreases the amplitude of the spike in ROS early (L and PD phases) 
and prevents the sharp decline in ROS levels during stationary phase, maintaining it at a 
steady-state level. 
stages of the life span of these yeast are insufficient for the activation of the stress 
response, anti-aging pathways in chronologically aging CR yeast. In contrast, the 
treatment of yeast cells with LA significantly reduces the initial spike in ROS levels, 
thereby preventing the excessive oxidative damage to mitochondrial macromolecules 
(Figure 13.11). Moreover, LA appears to enable aging yeast cells to maintain their ROS 
production at an optimal level that prevents the excessive oxidative damage, while 
simultaneously activating their stress response. In fact, recent data from Dr. Titorenko's 
laboratory showed that LA-treated cells had similar patterns of age-dependent changes in 
their oxygen consumption and mitochondrial membrane potential (Figures 13.12 and 
13.13). 
200 
L D PD ST 
J£ 6 0 ^ 
u 
Z- 2 0 
M 
o 
W T - LA 
WT + 5 0 ||M LA 
Data from C'luis Gregg 
ami Svetlsma Milijevic 
5 10 15 
Days in culture 
Figure 13.12. LA decreases the amplitude of the spike in O2 consumption early (L and 
PD phases), and prevents the sharp decline in O2 consumption later in stationary (ST) 
phase, maintaining it at a steady-state level. 
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Figure 13.13. LA decreases the amplitude of the spike in the mitochondrial membrane 
potential C¥A) early (L and PD phase), and prevents the sharp decline in ^A later in 
stationary (ST) phase, maintaining it at a steady-state level. 
Taken together, my proteomic analysis of the LA-induced, age-dependent changes 
in the steady-state levels of proteins and recent findings from Dr. Titorenko's laboratory 
strongly suggest the following model of lifespan extension by LA (Figure 13.14). 
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Figure 13.14. A model for life span extension due to a specific remodeling of various 
cellular processes by LA (red arrows represent processes accelerated by LA, while green 
arrows show processes that are decelerated by LA). 
In this model, LA promotes the conversion of glycogen-derived glucose into 
pyruvate, which then enters mitochondria and is used by the PDH complex as a substrate 
to enter the TCA cycle, thereby boosting the synthesis of ATP in mitochondria. As a 
result, certain optimal levels of ROS are generated in mitochondria. These levels of ROS 
do not exceed the cytotoxic threshold but are sufficient to activate the stress response, 
anti-aging pathways without causing the excessive damage to mitochondrial 
macromolecules. At the same time, the sustained activity of mitochondria decreases 
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mitochondrial fragmentation, thereby delaying mitochondria-controlled apoptosis. 
Furthermore, by decreasing the lipolysis of neutral lipids deposited in LBs, LA lowers the 
levels of intracellular DAG, thereby down-regulating the DAG-dependent activation of 
necrotic cell death. These findings strongly suggest that the level of ROS generated in 
mitochondria appears is the major determinant of the rate of chronological aging in CR 
yeast. An optimal level of ROS that is sustained throughout the life span of yeast exposed 
to LA activates a variety of cellular repair and damage control pathways, which helps to 
maintain cellular fitness and, thus, to extend life span. 
13.5 Conclusions 
Altogether, my proteomic analysis of age-dependent changes in the steady-state levels of 
proteins in yeast treated with a novel anti-aging molecule LA strongly suggest that the 
beneficial effect of LA on longevity may be partly due to its ability to increase the levels 
of a distinct group of proteins (such as Ssa2p, Ssa4p, Ssclp, Hsp26p and Tsalp), which 
are involved in stress response and protection against oxidative damage. Therefore, by 
increasing the steady-state levels of these proteins in an age-dependent fashion, LA can 
extend yeast life span, in part, by helping to prevent the aggregation of oxidatively 
damaged proteins that accumulate in the cytosol and mitochondria of aging yeast due to 
the progressive build-up of ROS. In addition to attenuating the stress response, LA 
remodels carbohydrate metabolism in CR yeast by increasing glycogen degradation, 
glycolysis and biosynthesis of acetyl-CoA in the cytosol, while simultaneously 
decreasing the activity of the glyoxylate cycle in the mitochondrion and cytosol. 
Furthermore, LA remodels yeast lipid metabolism by promoting the biosynthesis of 
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neutral lipid TAG and preventing its breakdown to DAG and FFA, thereby significantly 
delaying DAG-activated necrotic cell death. The most profound effect of LA, however, is 
on the mitochondrial function and morphology. In fact, LA significantly increases 
activities of the mitochondrial PDH complex, TCA cycle and synthesis of ATP, while 
decreasing the rate of mitochondrial fission. As a result of increased ATP production in 
mitochondria, higher levels of ROS (which are maintained at a threshold, non-cytotoxic 
level) activate the stress response, anti-aging pathways. In fact, LA maintains the 
mitochondrial production of ROS at a level that is not sufficient to cause a significant 
oxidative damage to mitochondrial macromolecules but is sufficiently high to induce a 
potent stress response. Finally, sustained mitochondrial activity in yeast exposed to LA 
and the observed LA-induced decrease in mitochondrial division help to maintain the 
mitochondrial network, thereby delaying the mitochondria-controlled, age-dependent cell 
form of cell death. Taken together, these findings strongly suggest that the LA-induced 
life span extension in yeast is primarily a result of the effect of LA on mitochondrial ROS 
production, mitochondrial morphology and mitochondrially-induced apoptosis. 
14 Aging mechanisms: summary and suggestions for future work 
14.1 CR extends yeast life span by remodeling a distinct set of the key cellular 
processes 
My quantitative proteomic analysis, along with the data of metabolomic and functional 
analyses from Dr. Titorenko's laboratory, implies that during L and D phases, "young" 
non-CR yeast meet their metabolic requirement by producing the bulk of ATP through 
glycolysis. In contrast, "young" CR yeast remodel their carbohydrate metabolism by 
shifting from glycolysis to gluconeogenesis, thereby producing the majority of their ATP 
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through mitochondrial oxidation of acetyl-CoA (Figure 14.1). 
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Figure 14.1. CR remodels carbohydrate and lipid metabolism early in the life span of 
chronologically aging yeast. 
Considerable quantities of mitochondrial ROS generated during ATP production in CR 
yeast are then decomposed through the antioxidant reactions catalyzed by superoxide 
dismutase Sod2p and peroxiredoxin Prxlp, whose activities are promoted by the CR diet. 
In addition, the CR diet greatly accelerates the depletion of ethanol from yeast cells by 
altering the levels of enzymes involved in ethanol biosynthesis and degradation, thus 
greatly reducing the negative effect of ethanol on longevity. In contrast, no increase in the 
mitochondrial activity is observed in young non-CR yeast that synthesize ATP primarily 
via glycolysis, thereby generating substantial amounts of ethanol and actively 
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synthesizing neutral lipids that are deposited in LBs (Figure 14.1). The lowered 
mitochondrial activity in non-CR yeast decreases the mitochondrial membrane potential, 
eventually {i.e., later in the aging process) causing the fragmentation of the mitochondrial 
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Figure 14.2. A CR-induced remodeling of cellular processes continues during PD growth 
phase in a diet-dependent fashion. 
During PD phase, CR promotes the accumulation of glycogen and trehalose, two 
major glucose storage compounds, by activating the synthesis of enzymes catalyzing their 
biosynthesis and suppressing the synthesis of enzymes required for their degradation 
(Figure 14.2). In addition, CR remodels yeast lipid metabolism by accelerating the 
lipolytic consumption of LB-deposited neutral lipids TAG and EE (Figure 14.2). The 
206 
substantial amounts of FFA generated by such lipolytic degradation of neutral lipids are 
rapidly converted to FA-CoA. FA-CoA is first imported into peroxisomes and then 
converted to acetyl-CoA via the peroxisomal P-oxidation pathway (whose activity is also 
greatly accelerated by the CR diet) and then transported into mitochondria to be used for 
ATP synthesis (Figure 14.2). The elevated mitochondrial activity in chronologically 
aging CR yeast promotes mitochondrial fusion, thereby preventing the fragmentation of 
mitochondrial network observed in non-CR yeast (Figure 14.2). In contrast, 
chronologically aging yeast grown under non-CR conditions are unable to consume their 
neutral lipids deposited in LBs due to the inhibition of the peroxisomal p-oxidation 
pathway by ethanol, which results in the build-up of TAG in their LBs and also 
decelerate the exit of TAG from the ER (Figure 14.2). The accumulation of TAG in the 
ER of non-CR yeast, in turn, slows down its biosynthesis from FFA-CoA and DAG, 
leading to the build-up of DAG within the ER and thereby promoting necrotic cell death 
(Figure 14.3). As a result of being unable to delay the mitochondria-controlled apoptosis 
promoted by mitochondrial fragmentation and due to the accelerated cell death by 
necrosis resulting from the accumulation of DAG and FFA, chronologically aging non-
CR yeast die faster then their CR counterparts (Figure 14.3). 
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Figure 14.3. CR extends yeast life span by enhancing stress response and preventing the 
activation of both mitochondria-controlled apoptosis and necrotic cell death. 
The early metabolic remodeling allows aging CR yeast to enjoy their "retirement" 
in the stationary phase by increasing their stress response, promoting the chaperone 
activity of trehalose in protein folding, and elevating the levels of ROS-scavenging 
enzymes as well as proteins helping to repair and protect mtDNA from oxidative damage 
(Figure 14.3). 
14.2 Modular longevity network and its remodeling in CR yeast 
My quantitative proteomic analysis, along with the data of metabolomic and functional 
analyses from Dr. Titorenko's laboratory, suggest that the rate of aging in yeast is 
controlled by what we call a "modular longevity network", which is established in a diet-
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and genotype-specific fashion and undergoes remodeling throughout the aging process. 
Furthermore, the analysis of the spatiotemporal dynamics of the modular longevity 
network revealed that it integrates several processes and metabolic pathways, which we 
call "modules" and which regulate 1) trehalose and glycogen metabolism; 2) glycolysis, 
glucose fermentation to ethanol, and gluconeogenesis; 3) lipid metabolism in the ER, LBs 
and peroxisomes; 4) interorganellar metabolic flow; 5) oxidation-reduction reactions in 
mitochondria; 6) maintenance of ROS homeostasis; 7) protection of mtDNA from 
oxidative damage; 8) maintenance of a tubular mitochondrial network; and 9) 
mitochondria-controlled apoptosis (Figure 14.4). Based on my findings and on the 
extensive functional and metabolomic studies conducted in Dr. Titorenko's laboratory on 
how the individual modules of the network influence yeast life span, I propose a model 
for the integration of various key cellular processes into a modular longevity network and 
for the spatiotemporal dynamics of this network in chronologically aging yeast (Figure 
14.5). In this model, before entering a non-proliferative state, yeast design a diet- and 
genotype-specific configuration of the network by establishing the rates of the processes 
taking place within each of its individual modules. Different configurations of the 
network established prior to entry into a non-proliferative state set different aging rates 
following such entry. Thus, by designing a specific configuration of the modular 
longevity network prior to reproductive maturation, yeast define their chronological life 
span. Taken together, my findings and data from Dr. Titorenko's laboratory provide 
evidence that yeast establish a diet- and genotype-specific configuration of the longevity 
network by setting up the rates of the processes within each of its modules prior to entry 
into non-proliferative stage. Furthermore, my model predicts that different configurations 
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of this network established early in yeast life result in different rates of chronological 
aging upon entry of yeast cells into a non-proliferative stage. 
Figure 14.4. Numerous key cellular processes are merged as modules into a longevity 
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Figure 14.5. Different configurations of the modular longevity network are designed in a 
diet- and genotype-specific manner prior to entry of yeast cells into non-proliferative 
state (i.e., stationary phase). 
14.3 Longevity regulation by a novel anti-aging drug LA 
It seems that the extension of yeast life span by a novel anti-aging molecule LA results to 
a significant extent from the effect that this compound has on mitochondrial morphology 
and function. According to my proteomic data and extensive metabolic and functional 
studies in Dr. Titorenko's laboratory, LA promotes mitochondrial fusion and help to 
maintain mitochondrial activity, thereby generating an "optimal" level of ROS that is 
sufficiently high to cause the activation of efficient stress response but is too low to lead 
to any significant oxidative damage of cellular macromolecules. These findings strongly 
suggest that the level of ROS generated in mitochondria is one of the major determinants 
of the rate of chronological aging in yeast (Figure 13.15). This "optimal" level of ROS, 
which is sustained throughout the entire life span, activates a variety of cellular repair and 
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Figure 14.6. The extension of yeast lifespan by LA is due to a ROS-mediated 
"mitohormetic" signaling. 
The novel anti-aging small molecules identified by Dr. Titorenko's laboratory can 
be used as pharmaceutical agents for aging and age-related disorders. In fact, recent 
evidence from Dr. Titorenko's laboratory demonstrated that, in addition to promoting 
mitochondrial fusion in yeast, LA also assists in the fusion of human mitochondria in 
vitro. Thus, one of the potential applications of LA may be as a drug to treat 
mitochondrial morphology disorders, all of which are neurological disorders. 
Furthermore, the LA-induced life span extension of CR yeast can be used as a model to 
study the molecular mechanisms by which age-dependent changes in mitochondrial ROS, 
mitochondrial morphology and mitochondrially induced apoptosis regulate longevity. 
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